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ABSTRACT 
Introduction 
Stump healing is essential in patients with a lower limb amputation in order for them to 
mobilize again. Little research has been being done on factors affecting stump healing. The 
aim of this paper is to explore the effect of haematological makers as well as patient 
characteristics on stump healing after patients have undergone an amputation procedure. In 
addition, a practical model regarding factors that affect stump healing was developed. 
Methods 
Patients who underwent a major lower limb amputation (above knee and below knee) at the 
Royal Infirmary of Edinburgh from the period of 2006 to 2009 were included in this study. A 
prognostic model utilizing backward stepwise logistical regression was developed to measure 
the probability of lower limb stump healing. The relationship between the dependent and 
independent variables was identified using univariate and multivariate logistic regression. 
Hosmer and Lemeshow goodness of fit test and Receiver Operating Curve (ROC) was used in 
order to measure the effectiveness of the model. The model was validated with the prospective 
data of 100 patients that had undergone major lower limb amputation from the year 2010 and 
2011 in Royal Infirmary of Edinburgh prospectively.  
Results 
In this study healing of the stump as defined was achieved in sixty three percent (63%) of 
patients. Univariate analysis found seven variables to be associated with lower limb stump 
healing (type of amputation, gender, hypertension, smoking, serum sodium, serum creatinine 
and serum High Density Lipid cholesterol (HDL)). A further four variables (age, diabetes 
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mellitus, white cell count and Prothrombin Time) were added to the model secondary to their 
strong clinical association with the stump healing. Three variables, namely serum sodium, 
serum creatinine and serum High Density Lipid cholesterol were identified which influenced 
stump healing. Patients with normal serum sodium were 75% more likely to have lower limb 
stump healing compared to that of patients with abnormal serum sodium (odds ratio [OR] 
1.756; 95% confidence interval [CI] 1.048-2.942). Patients with normal serum creatinine were 
66% more likely to have their stump healed (OR 1.664; 95% CI 0.94 to 2.946). The healing 
rate of patients with a normal level of serum High Density Lipid cholesterol was 75%, in 
contrast to patients with an aberrant level of serum High Density Lipids cholesterol (OR 1.753; 
95% CI 1.061 to 2.895). The effectiveness of the retrospective stump-healing model was 
demonstrated by the area under the Receiver Operator Curve (0.612), which was supported by 
the Hosmer and Lemeshow goodness-of-fit test (p=0.879). In the prospective study, the model’s 
discriminatory power was verified by the area under the Receiver Operator Curve (0.584) and 
Hosmer and Lemeshow goodness-of-fit test (p>0.05).  
Conclusion 
Serum sodium, serum High Density Lipid cholesterol and serum creatinine have a strong 
correlation with lower limb stump healing. However, serum sodium and serum High Density 
Lipid cholesterol secondary to multiple co-morbidities in this cohort group could be altered 
secondary to disease pathology itself. Further clinical research is necessary to evaluate the 
association of the risk factors with lower limb stump healing.
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1.1 Lower limb amputation 
Lower limb amputation is one of the oldest surgical procedures and is performed frequently. 
Though lower limb revascularisation techniques have vastly improved, an amputation is still 
commonly performed secondary to advanced peripheral arterial disease (Allie et al. 2005). 
In contrast to patients without diabetes mellitus, patients with diabetes mellitus are twice as 
likely to develop several complications which affect the lower limbs, such as peripheral 
vascular disease, peripheral neuropathy, ulceration and amputation (Gregg et al. 2004). 
According to Mountford et al. (2007) the risk of lower limb amputation alone is almost 30 
times higher in patients with diabetes mellitus than in the normal population.  
According to Kazmers et al. (2000), the mortality rate in the first month following amputation 
showed a significant variation, from 8% to 23%.  High peri and post-operative mortality and 
morbidity rates among patients suffering from peripheral vascular disease, who underwent a 
lower limb amputation were also noted by Aulivola et al. (2004). Subramaniam et al. (2005) 
argued that the higher the location of the amputation, the higher is the mortality rate in the 
period immediately after the amputation surgery, potentially indicating the severity of advanced 
vascular disease.  
Hospital admissions for foot ulceration have increased over the past decade as about 15% of 
the people with diabetes mellitus go on to develop foot ulceration (Frykberg et al. 2006). In the 
United Kingdom, the 56% prevalence of leg amputation as a result of vascular complication in 
1998/99 increased to 74% in 2011-12 (United National Institute for Prosthetics & Orthotics 
Development annual report. 2012). The number of people who have undergone lower limb 
amputation in the United Kingdom is approximately 5000 in 2011-12 and out of which 50% of 
referrals to prosthetic devices have had a below knee amputations as reported by the Limbless 
                            Chapter 1 
2 
 
Society formally known as the Amputee Statistical Database for United Kingdom (United 
National Institute for Prosthetics & Orthotics Development Annual Report. 2012). According 
to National Diabetes Audit (2011/12), dysvascularity was the most common indication 
accounting for 75% of all lower limb amputation, half of which were secondary to diabetes 
mellitus. Though the report largely reflected the entire population in the United Kingdom, 
major geographical differences in lower limb amputation rates have been noted, possibly 
depicting differences in decision making due to local clinical guidelines and policies and their 
delivery, although ethnic factors may also contribute (National Amputee Statistical Database 
for the United Kingdom. 2007).  
1.2 Stump healing in lower limb amputation 
The process of stump healing of an amputee is important because it enables the patient to regain 
limb function with the use of a prosthesis. In addition to the type of treatment administered, the 
stump healing process is also influenced by the characteristics of the wound and the condition 
of the patient. There is a major variation in the healing rates of amputations, depending on the 
level where they were performed (National Amputee Statistical Database for the United 
Kingdom. 2006). Above-knee amputations have been attributed a 70%-90% healing rate, whilst 
below-knee amputations have a healing rate of 30%-92%, with a 30% likelihood for additional 
amputation procedures (Dormandy et al. 1999). The variation in healing rates may be due to 
lack of evidence based guidelines and lack of patient selection for the right. Many clinicians 
agree that the ultimate goal of caring for a patient with a diseased lower extremity is to 
maximize their quality of life by preserving their independence via their ability to ambulate 
(Pell et al. 1993). Multiple studies have documented the increased rehabilitation rate in below-
knee amputation (BKA) vs above-knee amputation (AKA) patients, with more than 65% of 
below knee amputation patients ambulating with prostheses (Aulivola et al. 2004). In contrast, 
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less than one third of patients with above-knee amputation are likely to rehabilitate with the 
use of a prosthesis. However, it could be argued that the outcomes regarding quality of life 
improvement could be related to other factors including pain sensation, prosthetic factors, and 
psychosocial well-being (adaptation to amputation, prosthesis and body image). But in a survey 
of 44 patients with lower limb amputation investigating prosthesis satisfaction, body image, 
and phantom pain, Murray et al. (2002) found that higher levels of prosthesis satisfaction were 
significantly correlated with lower levels of body image disturbance. But with a below-knee 
amputation procedure however, there is a greater risk of non-healing of the stump resulting in 
a further procedure either at the same or higher level. Patient selection, given this variability in 
outcomes, therefore becomes important. This thesis provides new evidence to facilitate with 
patient selection and aid clinicians in decision making with regards to when it is best to proceed 
with a below-knee amputation and achieve a decreased risk complication and where a 
successful outcome is more likely. 
Izumi et al. (2006) emphasized that the success of an amputation depends on wound treatment 
as well as patient awareness of the implications of such a surgical procedure. According to the 
studies conducted by Canavan et al. (2008) the prevalence of leg amputations can be reduced 
by up to 78% by employing an adequate multidisciplinary diabetes mellitus treatment. To 
obtain the best results after an amputation, a meticulous approach to the preoperative 
assessment and surgical technique is necessary. 
1.3 Research problem and aims of the study  
1.3.1 Rationale of the study 
Lower Extremity Amputations (LEA) is a major source of morbidity and mortality in patients 
with diabetes mellitus (Hambleton et al. 2009). According to estimates, every half a minute a 
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patient with diabetes mellitus loses a leg due to an amputation (Boulton et al. 2005). The life 
expectancy rate among individuals who have been subjected to major amputation procedures 
is low and can be compared to survival rates in cancer patients (5-year mortality rates up to 
55% vs 73% in colon cancer vs lower limb amputation) (Armstrong et al. 2005). According to 
Schofield et al. (2006), people with diabetes mellitus also had a 55% greater risk of death than 
those without the disease. Diabetes foot disease requires patients to spend a considerable period 
of time in hospital, which contributes to 25% of the hospital expenditure for diabetes mellitus 
(Canavan et al. 2008). There is a growing necessity for interdisciplinary treatment for 
amputations secondary to diabetes mellitus, as the number of people with diabetes mellitus 
continues to increase. 
The proportion of the elderly in the population of the United Kingdom is considerable, 
signifying that an increasing number of patients with diabetes mellitus of advanced age will go 
on to require some form of lower limb amputation surgery (National Amputee Statistical 
Database for the United Kingdom. 2006). This poses questions about the viability of subjecting 
older patients to surgical procedures, given the reduced healing and the co-existence of multiple 
conditions such as diabetes mellitus and peripheral vascular disease. Most patients in the 
United Kingdom referred for an amputation procedure are 75 years of age or older (United 
National Institute for Prosthetics & Orthotics Development annual report. 2011). The increased 
age of this group increases the risk of developing amputation-related complications and 
demands the creation of more efficient treatment to ensure the survival of these patients. 
Healthcare professionals are faced with the challenge of assessing the different risk factors and 
deciding which one of them have a greater influence on the stump healing rate. There are 
currently an insufficient number of studies regarding factors effecting lower limb amputation. 
The available studies exhibit wide variation in structure and outcome. In addition, the related 
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literature shows discrepancies regarding methods of patient selection, surgical procedures and 
post-operative implications. The variation exhibited by such studies makes it difficult to reach 
a conclusion about the way stump healing affects limb rehabilitation. It is imperative that 
further studies are conducted to enable the creation of a set of guidelines regarding factors 
contributing to the healing of the stumps following leg amputation (Nawijn et al. 2005).   
The biomarkers used in this study were chosen because they were readily available given the 
scope of the study.  A good biomarker is one that is relevant to the study, is cost effective, easily 
reproducible, has a high sensitivity, specificity and validity proven towards that disease and 
least prone to measurement errors and bias. The markers used in this study are factors that play 
a role in healing of a diabetic foot ulcer as noted in several studies and play a role in the 
pathophysiological pathways of peripheral vascular disease and diabetes which are the main 
causes for a lower limb amputation surgery.  These biomarkers are easy to use, readily available 
for a surgeon/physician on a day to day basis for decision making, are cost effective and do not 
require any equipment or any expertise to use or interpret. The blood markers used are readily 
available via the laboratory in any hospital setting almost daily for any inpatient who has 
regular blood check for his illness.   
1.3.2 Research question 
What are the important blood markers and patient factors that can be helpful in determining 
lower limb stump healing before surgery? 
1.3.3 Aims of the study 
The aim of the present study was to conduct an evaluation of the potential predictive factors of 
the healing process of lower limb amputation in people with diabetes mellitus suffering from 
advanced atherosclerosis. The identification of such factors will not only enhance the quality 
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of life of the patients but will also be economically and clinically beneficial, as it could enable 
an efficient management of the healthcare budget.  
1.3.4 Objectives 
 To retrospectively explore the potential influence of blood markers and patient factors 
(risk factors, kidney function profile, coagulation profile, lipid profile and infection 
markers) on stump healing of patients with diabetes mellitus who have undergone lower 
extremity amputation surgery at the Royal Infirmary of Edinburgh. 
 To prospectively explore the influence of blood markers and factors, as classified by 
kidney function tests, coagulation profile and lipid profile, risk factors, and infection 
markers on healing of the stump of patients who have undergone lower limb amputation 
surgery at the Royal Infirmary of Edinburgh and to develop and validate a prognostic 
model for the prediction of lower limb stump healing. 
1.3.5 Outline of the thesis 
1.3.5.1 Chapter 2 (Literature Review)  
This chapter provides up-to-date evidence on aetiology, predisposing factors, classification of 
diabetes mellitus and its complications. It discusses risk factors and pathogenesis of people 
with Diabetic foot ulcer as a pre-amputation state. It also discusses the etiopathogenesis and 
latest trends in lower limb amputation. Finally, relationship of patients’ factors, blood markers 
and stump healing post major lower limb amputation is discussed. 
1.3.5.2 Chapter 3 (Methods) 
This chapter provides information about the retrospective and prospective part of the study. In 
addition, information about the research procedures including recruitment, inclusion/exclusion 
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criteria and details of blood markers is mentioned.  Data collection and the statistical method 
adopted is presented. 
1.3.5.3 Chapter 4 (Results) 
In this chapter, results are presented for both development and validation phases of the study. 
Data analysis on patient’s demographics, univariate and multivariate analysis are reported. 
1.3.5.4 Chapter 5 (Discussion) 
This chapter presents the results of the developed model and relates them to the context of the 
literature and current practice. 
1.3.5.5 Chapter 6 (Conclusion)  
The key findings of this thesis are brought together in this final chapter. The summary presents 
the strengths, limitations and clinical implications of the research, whilst emphasising the 
potential offered by the model for lower limb stump healing prior to surgery. 
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2. Amputation 
2.1 Introduction  
Amputation is a common procedure in which a part of the body or a portion of a body part is 
surgically removed (Marcovitch, 2005). Despite the significant advances that have been made 
with regards to this surgical intervention, it is still responsible for a great number of deaths, 
especially among older patients. In general, widespread trauma, vascular disease and tumours 
are the key determinants in decision-making regarding amputation. Of these three 
determinants, vascular disease is currently the most widely invoked reason for amputation 
(Dillingham et al. 2002). Limbs often have to be amputated in the case of individuals suffering 
from severe limb ischaemia for whom vascular reconstruction has failed or is untenable and in 
patients with diabetes mellitus with severe foot infection. Seventy percent of all amputations 
performed worldwide are caused by Peripheral Vascular Disease (NASDAB, 2005). According 
to Eardley et al. (2010) because patients undergoing an amputation surgery have a high 
mortality due to their complex comorbidities, it is important that the patients who undergo 
amputation are well-informed about the procedure and its outcomes in order to obtain the best 
results.  
2.2 Types of amputation 
 
According to International Working Group on the Diabetic Foot, (1999) a major amputation 
refers to any amputation above the mid-tarsal level. "Major" limb loss is defined as amputation 
above the elbow, below the elbow, above the knee, below the knee, or the foot. "Minor" limb 
loss is defined as amputation of the hand or digits (fingers or toes) (Tseng et al. 2007). Lower 
limb amputations are much more frequent than upper limb and are most commonly the result 
of disease followed by trauma. 
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2.3 Upper limb amputation 
 
Upper limb amputations are performed infrequently and are mostly indicated by severe 
traumatic injuries. The location of the injury will determine the level of amputation. 
Preservation of extremity length is often a goal. The amputation site will have important 
implications on the functional status of the patient and options for prosthetic reconstruction.  
 
 Levels for Upper Limb Amputations, according to Braddom (1996) distal to proximal are,  
 
1. Amputation of individual digits- the thumb is the most commonly amputated digit. 
 
2. Multiple digit amputation- when more than one digits are lost.  
 
3. Metacarpal amputation- this type of amputation involves loss of the entire hand but the 
wrist is still intact. 
 
4. Wrist disarticulation- involves the loss of the hand, but at the level of the wrist joint. 
 
5. Forearm (transradial) amputation- this type of amputation is classified by the length of 
the remaining stump.  
 
6. Elbow disarticulation- this type of amputation involves the removal of the entire 
forearm at the elbow.  
 
7. Shoulder disarticulation- in this type of amputation, the shoulder blade remains. The 
collarbone may or may not be removed.   
 
8. Forequarter amputation- includes removal of the shoulder blade and collarbone.  
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Figure 1: Levels for Amputation 
 
 Source: Braddom R.L. Physical Medicine and Rehabilitation, Philadelphia W.B. Saunders, 
1996 
 
 
 
 
 
2.4 Lower limb amputation  
2.4.1 Introduction 
Among amputation surgery, lower limb amputation is the most frequently performed 
procedure. Of all the complications of diabetes mellitus, lower limb amputation is perhaps the 
most debilitating, and is often associated with a high mortality rate and the likelihood of further 
re-amputation (Reiber, 2001).  
Limb amputation has been performed since antiquity, Hippocrates being the first to have 
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established the stages of this surgical procedure (Murdoch et al. 1997). These have remained 
largely unchanged up to the present day, except for a number of additional developments, such 
as haemostasis, anaesthesia and a safer surgical environment. 
The frequency of lower extremity amputations surpasses that of upper extremity amputations, 
being usually caused by disease and trauma. In the UK, the number of people who have 
undergone leg amputations has been estimated by the National Amputee Statistical Database 
Annual Report (2005-06) to be approximately 52,000. Ninety two percent of the referrals for 
prosthetic implants in the United Kingdom are individuals with leg amputations. With the 
prevalence of diabetes mellitus on the rise, its complications including vascular complications 
like lower limb amputations are also increasing. In the United Kingdom, the 56% prevalence 
of leg amputation as a result of vascular complications or ischaemia in 1998/99 increased to 
75% in 2004/05 (NASDAB 2005). In the US, it has been estimated that the number of annual 
leg amputation procedures will increase to 58,000 by 2030 (Fletcher et al. 2002). 
2.4.2 Types of lower limb amputation  
According to Seymour (2002), the types of Lower Extremity Amputations organized by 
anatomical location, distal to proximal are: 
 
1. Toe Amputation:  
 
2. Transphalangeal Amputation (Toe Disarticulation) 
 
3. Transmetatarsal Amputation 
 
4. Lisfranc Amputation: Performed at the tarsometatarsal joint and involves disarticulation of 
all five metatarsals and digits. 
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5. Chopart Amputation: At the talonavicular and calcaneocuboid joints, it involves 
disarticulation through the midtarsal joint leaving only the calcaneus and talus. 
 
6. Syme Amputation: Ankle disarticulation in which the heel pad is kept for good weight-
bearing. 
 
7. Transtibial Amputation (BKA) 
 
8. Transfemoral Amputation (AKA) 
 
 
Figure 2: Common levels of lower limb amputation 
 
Source: Marcovitch H, editor. Black's Medical Dictionary. London: A&C Black Publishers, 
2005. 
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2.4.2.1 Transtibial Amputation (BKA) 
Transtibial amputations make up most of all lower-limb amputations and the healing rates of 
below knee amputation are the benchmark to compare other amputation success including 
above knee amputation. This level is used primarily when the proximity of the disease process 
precludes a partial foot or ankle amputation. 
Many techniques of transtibial amputation have been described, but the most commonly used 
is the long posterior flap. Burgess advocated the long posterior flap as the main advantage of 
transtibial amputations (Burgess, 1969). The primary goal of flap selection is to allow adequate 
soft tissue coverage for a tension-free closure, provide a soft tissue envelope for later prosthetic 
fitting, and avoid scar adhesion to the underlying bone. In this technique, the transverse anterior 
incision begins at the junction of the proximal two-thirds and distal one-third of the leg. Sharp 
corners are avoided to prevent the formation of “dog ears.” All major peripheral nerves are 
identified and transected under tension to allow for retraction to prevent painful neuromas. The 
other technique used is the skew flap which is the medial flap technique. The figure below 
explains the process involved in selecting the level of the amputation as well as that of flap 
harvesting. Step A explains the general anatomy of the proposed site of the surgery. Step B 
explains the amputation technique. Step C illustrates the preparation of the stump. 
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Figure 3: Below knee amputation surgery-Level of bone section and skin flaps 
Source: Canale, S. T. and Beaty, J. H. 2013. Campbell’s Operative Orthopaedics, 12th Ed. 
Elsevier 
 
 
2.4.2.2 Transfemoral amputation (AKA) 
More than a third of patients in the UK that are referred to prosthetics have had trans-femoral 
amputations (NASDAB, 2005). It is one of the common surgical procedures performed today 
especially with the growing prevalence of diabetes mellitus. Nowadays, this procedure is 
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mostly used on patients who suffer from advanced vascular disease and diabetes mellitus, who 
are considered to have a low healing rate for lower-level amputations. The figure below 
explains the process involved in selecting the level of the amputation as well as the different 
flap during the process of above knee amputation. 
 
Figure 4: Above Knee Amputation surgery-Level of bone section and skin flaps 
 
Source: Canale, S. T. and Beaty, J. H. 2013. Campbell’s Operative Orthopaedics, 12th Ed. 
Elsevier 
 
 
 
In trans-femoral amputations, a tourniquet is only used if there is a special requirement for it, 
and is positioned at the highest possible level on the femur and removed before setting muscle 
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tension. Before the operation begins, the skin flaps are carefully traced, the ones at the front 
being longer than the flaps at the back of the leg to ensure that the suture line will be on the 
dorsal side. In addition, a long flap situated on the lateral inside part of the leg can also be used, 
as can any form of flap which will increase possible length preservation. 
There are 2 approaches to managing the muscle in the limb during amputation: myodesis and 
myoplasty. With a myodesis, the muscles and fasciae are sutured directly to the distal residual 
bone through drill holes. However, myodesis is contraindicated in patients with severe 
peripheral vascular disease, because the blood supply to the muscle may be compromised. 
Myoplasty requires the surgeon to suture the opposing muscles in the residual limb to each 
other and to the periosteum or to the distal end of the cut bone. Myoplasty has been suggested 
as a method of anchoring the muscles; however, it does not re-establish normal tension in the 
muscles and it does not enable proper muscle control of the thigh, diminishing muscle strength 
in the affected limb. Myoplasty entails the conjoining of the agonist and antagonist muscle 
groups over the epiphysis of the bone. This generates muscle instability and pain as a result of 
the movement of the femur in the muscle casing.  Furthermore, the muscle casing around the 
end of the amputated stump can hinder the attachment of the prosthetic limb (Gottschalk, 
2002).  
2.5 Burden of amputation on the NHS 
Despite a reduction in amputation rates worldwide, the cost implications continue to be a high 
for healthcare systems. This has resulted in increased diabetic foot disease often leads to serious 
long-term complications, putting significant socio-economic pressure on resources and health 
care. In the UK, the National Health Service is under enormous financial strain because of 
diabetic foot complications, reflected in greater outpatient costs, bed occupancy, and extended 
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hospitalisation. The cost of diabetic foot care alone to the UK National Health Service during 
2010-2011 was £639-662 million. A proportion of 10% of the NHS budget is taken up by 
diabetes and diabetes-related complications account for 80% of the total cost. Li et al. (2010) 
estimated that, taking into consideration modifications in demography and the increasing rate 
of obesity, in the coming two decades, diabetes mellitus will come to represent 17% of the 
whole NHS budget, if the current cost of diabetes treatment remains unchanged (Kerr et al. 
2012). These figures do not take account of the indirect costs to patients such as the effect on 
physical, psychological and social wellbeing. Social care will also require additional funding 
because individuals who undergo amputations require assistance in daily activities and in 
caring for themselves. Hence, diabetes mellitus will place an even greater strain on the health 
and social care system. What is more, diabetics also have significantly lower work productivity 
due to poor health, the cost of which has been approximated at around £9 million, though 
further research is needed to with corroborate this. The International Diabetes Federation has 
estimated that around 50% of direct healthcare costs are due to loss of work productivity in the 
United States (Yang et al. 2012). 
2.6 Aetiology of lower limb amputation 
The indication for performing a lower limb amputation is often multi-factorial. The 
International Classification of Diseases (9th Revision) has suggested a categorization of the 
diseases which determine leg amputation (Stroke Unit Trialists' Collaboration, 2002). 
According to the Amputee Coalition of America (2010), the main cause of leg amputation is 
vascular disease, with a rate of eight times higher than that of the second important cause of 
amputation which is trauma. The diseases which can lead to leg amputation are presented in 
Table 1. Some of the common causes include diabetes mellitus, chronic osteomyelitis and 
trauma. 
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Table 1: Aetiology of lower limb amputation 
Source: International Classification of Diseases. (9th Revision) 2010-11. 
 
Disease 
 
 
Types 
  
Chronic Osteomyelitis Chronic osteomyelitis of pelvic region and thigh, lower leg, 
ankle, and foot. 
 
Congenital Deformity 
 
 
Device Infection 
 
 
Diabetes mellitus 
 
Local Significant 
Infection 
 
 
 
Lower Extremity Cancer 
 
 
 
Previous Amputation 
Complication 
Transverse deficiency of lower limb, longitudinal deficiency 
of lower limb. 
Vascular device, internal orthopaedic device, tissue graft, joint 
prosthesis 
Diabetes mellitus type I with and without manifestations, 
diabetes mellitus type II with and without manifestations. 
Gangrene, actinomycotic infections, cellulitis, pyogenic 
arthritis, infective myositis, necrotizing fasciitis. 
 
Malignant neoplasm of pelvic bones, sacrum, coccyx, long 
and short bones of lower limb, connective tissues of lower 
limb including hip, skin of lower limb including hip. 
 
Non-resolving infected amputation stump. 
 
 Atherosclerosis, aortic aneurysm, venous thrombosis, arterial 
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Problems with Peripheral 
Circulation 
 
 
Skin Breakdown 
 
Systemic Sepsis 
 
Trauma 
stricture or stricture of graft, circulatory disease, venous 
insufficiency, organ or tissue replaced by blood vessel, 
gangrene, vascular complications of other vessels. 
 
Non-healing ulcer or decubitus ulcer of lower extremity. 
Septicaemia, gram negative septicaemia 
 
Acute osteomyelitis, closed or open fractures to lower 
extremities, fracture of one or more phalanges of foot, trauma 
to AKA or BKA, open wound to lower limb, burns of lower 
limb, fracture of lower limb, open wound of lower limb, late 
effects of injuries, poisonings, toxic effects, and other external 
causes, crushing injury of lower limb. 
  
  
 
According to Donohue et al. (2001), peripheral vascular disease is the cause of 70-80% of leg 
amputations performed worldwide, followed by diabetic foot ulceration infections. The table 
below summarizes the causes of lower limb amputation in percentages with vascular 
insufficiency accounting for most cases (75%). In the vascular insufficiency group, nearly half 
were patients with diabetes mellitus. This highlights the burden of patients with diabetes 
mellitus with regards to lower limb amputation (Table 2). 
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Table 2: Conditions that contribute to lower limb amputation in percentages 
Source: National Amputee Statistical Database. National Amputee Statistical Database Annual 
Report, 2005-2006 
 
 
Cause of lower limb amputation 
 
Percentage 
 
Vascular insufficiency 
 
75 
 
Neoplasia 
 
2 
 
Neurological disorder  
 
2 
  
Infection 
 
Trauma 
 
Other 
 
No cause provided 
7 
 
9 
 
3 
 
2 
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 The vascular insufficiency group can be broken down as follows:  
 
Cause of lower limb amputation 
 
Percentage 
 
Diabetes mellitus 
 
42 
 
Non-diabetic arteriosclerosis 29 
 
Patients for whom no additional detail was 
available 
 
 
24 
Other vascular insufficiency 5 
  
  
 
 
2.6.1 Vascular insufficiency 
Peripheral arterial disease (PAD) is a vascular condition typified by the presence of 
atherosclerotic plaques that occludes the vasculature in the lower limbs. PAD increases the risk 
for lower-limb amputations, but it also raises the risk of cardiovascular and cerebrovascular 
disease; furthermore, PAD can indicate the presence of atherosclerotic plaques elsewhere in 
the vasculature. According to the findings of the Framingham Heart Study, of those patients 
who were symptomatic for PAD, 20% co-presented with diabetes. However, since many PAD 
sufferers are asymptomatic, its prevalence is likely to be considerably greater than determined 
by the number of symptomatic patients. Indeed, more than half of those identified as having 
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PAD are either asymptomatic or present with atypical symptoms; approximately 30% 
experience pain or cramp in the legs due to claudication. The disease is present in severe form 
in the remaining 20% (Hiatt, 2001). 
2.6.2 Diabetes mellitus 
Diabetes mellitus is a well-known cause of lower limb amputation. It is discussed in further 
detail in the subsequent chapters. 
2.6.3 Neoplasm   
Amputations due to cancers of the lower limb are rare and account for under 2% of the total 
lower limb amputations. Tumours could be primary tumours of the lower limb or 
secondary/metastasis from other organs. Surgical intervention to excise growth is needed to 
resolve primary malignant tumours of the limbs. Excision can be localised to the tumour and 
sufficient margin around the site that is clear of malignancy but in some instances, may require 
removing the compartment in entirety. In recent years, there has been little difference between 
the interventions in terms of survival and disease-free states, with patients enjoying higher post-
operative health and survival rates, aided by chemotherapy and/or radiotherapy (Ragnarsson et 
al. 2003). 
2.6.4 Trauma 
Worldwide, limb trauma is the most common reason for young, working-age people to undergo 
an amputation. More than 65% of trauma-related limb amputations occur in youths and adults 
under 45 years old. The prevalence of limb loss that is secondary to trauma is 15%. This differs 
significantly to the approximate 64% of amputations for adults of 65 years or more, which are 
attributed to vascular disease (Ebskov, 1992). 
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2.7 Vascular insufficiency 
2.7.1 Introduction 
PAD is a vascular condition typified by the presence of atherosclerotic plaques that occlude the 
vasculature in the lower limbs. The morbidity associated with atherosclerosis is high with the 
greatest burden arising from coronary artery disease and stroke, closely followed by PAD of 
the lower extremities. Nonetheless, the worldwide burden of PAD is considerable, as it is 
associated with high levels of non-fatal cardiovascular ischaemic events (heart attack, stroke 
and other thromboembolic events), reduced quality of life and increased mortality. 
2.7.2 Epidemiology  
The findings of natural history and epidemiology studies indicate that PAD affects about 30% 
of older individuals and increases a patient’s risk of non-fatal and fatal cardiovascular 
ischaemia. Selvin et al. (2004) report that based upon the epidemiological research, the total 
prevalence of PAD ranges between 3–10%, rising to 15–20% in people 70 years or more.  
The risk of needing lower-limb amputation is significant for diabetic patients who co-present 
with PAD. Although asymptomatic PAD patients are free of symptoms, they are not free of 
risk, with the disease increasing their vulnerability to coronary, cerebral and renal events, which 
in turn raise the risk of heart attacks, strokes and death. Despite being a major contributor to 
the mortality of patients, PAD is frequently underdiagnosed. Hirsch et al. (2006) conducted a 
conducted a multi-centre, cross-sectional study conducted at 350 primary care practices 
throughout the United States in 1999 with 6979 patients aged 70 years or older or aged 50 
through 69 years with history of cigarette smoking or diabetes with an ankle-brachial index 
(ABI) of 0.90 or less as a part of PAD Awareness, Risk, and Treatment: New Resources for 
Survival (PARTNERS) programme, reported that about 35% of the patients were undiagnosed 
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despite having risk factors.  (Hirsch et al. 2006). 
2.7.3 Age and Gender predilection 
Various studies have shown that PAD is a disease with a predilection for men (Aronow et al. 
1994). However, other studies have noted that PAD was as common in women especially in 
those who are aged without CVD.  
Albeit slight, there are gender differences in the prevalence of PAD. Whether asymptomatic or 
not, more men than women present with PAD; this is most noticeable in younger patients. The 
ratio of men to women experiencing intermittent claudication is between 1:1 and 2:1, though 
in severe disease states, for example, chronic limb ischaemia, the ratio has been found to rise 
to 3:1 (Norgren et al. 2007). 
The Edinburgh Artery Study, which was a random sample survey of the general population, 
found that the occurrence of claudication in males in the 50–59 year age bracket was 2.2%, 
which rose to 7.7% in the 70–74 year age group (Fowkes et al. 1991). Most of surveys, similar 
trend of PAD prevalence being greater in males than females was noted, though the gap 
decreased with increasing age.  
2.7.4 Pathophysiology of atherosclerosis 
Atherosclerosis is a complex condition that has both genetic and environmental elements; it is 
the leading cause of disability and death in the developed world. The disease is typified as an 
accumulation of cholesterol, connective tissue, macrophage infiltration, over-production of 
smooth muscle cells and the development of thrombi (Turumen et al. 1999). The predisposition 
to developing atherosclerosis is dependent upon a number of systemic and general factors, but 
plaques most often develop at particular sites in the circulatory system; these include branching 
                            Chapter 2 
27 
 
points, and in small vessels, places where the artery curves (Smedby, 1996).  
Atherosclerotic plaques are categorised into six categories dependent upon histological factors 
(Stary et al. 1995). Type I, which is present at birth in most people, contains mononuclear 
leukocytes and atherogenic lipoproteins; this typically presents with a thickening of the intima 
of the vascular wall. In type II, foam cells or macrophages and smooth muscle cells (SMCs) 
infiltrate the intima from the media. The whole plaque is described as a fatty streak, which is 
specific to atherosclerosis. Type III is an intermediate stage in which coarse lipid particles 
disturb the natural arrangement of SMCs. Type IV plaques have a large extracellular lipid core 
and grow outward into the arterial wall. Type V lesions are sub-categorised into types Vb and 
Vc. In type Vb, the lesions are generally calcified but still have a large extracellular lipid core, 
whereas in type Vc there is a clear increase in the accumulation of collagen and SMCs, making 
the lesion fibrous; type Vc lesions contain little lipid and do not show signs of calcification. 
Type VI plaques are those that have ruptured leading to the formation of fissures of haematomas 
in the lumen of the vessel. As a consequence of the rupture, the exposure of the lipid core to 
blood initiates platelets to aggregate, resulting in a thrombus. 
2.7.5 Evolution of an atheroma 
The endothelium becomes more permeable to the lipoproteins that transport lipids, such as 
cholesterol and triglycerides, enabling these transport proteins to bind to components of the 
extracellular matrix, known as proteoglycans. The affinity of heparin sulphate proteoglycan 
molecules for lipoproteins is strong, enabling the latter to be chemically modified. 
Hydroperoxides, lysophopholipids and oxysterols are products of lipid oxidation, as are 
aldehyde products from free fatty acids. Not only do proteoglycans make a considerable 
contribution to atherosclerosis, it also inhibits the proliferation of SMC (Pillarisetti, 2000). 
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There are no less than five different means by which lipoproteins undergo modification in the 
wall of the artery. The most important of these are ROS oxidation, non-oxidative glycation in 
diabetes mellitus and chronic uraemia. The atherogenicity of those lipoproteins that are 
modified by oxidation (oxLDL) exceeds that of native LDL, resulting in macrophages being 
recruited to the lesion. Atherosclerosis is therefore, considered an autoimmune disease as the 
oxLDL in the intima of the artery are determined by the immune system to be an exogenous 
invasion, leading to the recruitment of leukocytes to the site. Macrophages engulf the oxLDL 
to become foam cells. In due course, macrophages undergo apoptosis, but the engulfed lipid 
core persists in the intima, which then develops into the atherosclerotic plaque. 
2.7.6 Role of Endothelial dysfunction 
Vascular endothelium which performs multiple key functions is strategically positioned 
between the blood and the arterial wall. Being an endocrine organ, the endothelium regulates 
a number of processes, including the adhesion and migration of blood cells, coagulation, 
fibrinolysis, formation of NO, prostacyclins and ETs, permeation of lipoproteins and plasma 
proteins, proliferation of SMC, regulation of the sub-endothelial matrix and vascular tone. 
Furchgott and Zawadzki (1980) demonstrated that endothelium-derived NO caused 
vasorelaxation under the influence of acetylcholine. The endothelium also generates 
prostacyclin and tissue-type plasminogen, which are also effective vasodilators. Endothelium 
exposed to shear stress arising from blood flow turbulence and vascular stretching, such as 
vertebral arteries promotes its likelihood of prematurely developing atherosclerosis 
(Ravensbergen et al. 1998). The risk of atherosclerosis is promoted by ROS production in 
response to stimuli such as smoking, anaerobic metabolism, radiation damage and stressful 
conditions. In diabetes mellitus and chronic uraemia, the oxidative stress caused by ROS results 
in an accumulation of ‘advanced glycation end products’ (AGEPs). These AGEP peptides 
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initiate the activation of inflammatory cytokines and the modification of apolipoprotein B 
leading to a vicious cycle of atherogenesis. 
The secretion of factors such as ET-1 results in increased vasoconstriction. In response to ET-
1, surface adhesion molecules, such as integrins, selectins and immunoglobulins are expressed, 
which are ligands for the leukocytes and platelets that are chemotactically recruited to the area. 
Cellular adhesion molecules abundantly expressed on the surface of macrophages and 
endothelial are markers for atherosclerosis. Examples of these molecules that enable 
monocytes to adhere to the surface of the endothelium include intercellular adhesion molecule-
1 (ICAM-1), P selectin and vascular cell adhesion molecule-1 (VCAM-1). Monocytes then 
migrate from the surface into the intima. ET-1 also triggers the mitosis of SMC and initiates 
vasoconstriction, which leads to the production of inflammatory cytokines and free radicals, 
which are released into the circulation. Furthermore, leukocyte adhesion and activation are 
enhanced by proinflammatory cytokines IL-1 and TNF-α at sites where the endothelium 
becomes inflamed or damaged. Neutrophils, granulocyte macrophage colony stimulating 
factor, IL-8 and plasminogen-activating factor are also generated and these in turn lead to the 
activation of extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase/stress 
activated protein kinase and p38 mitogen-activated protein kinase (MAPK). All three of these 
MAPK subtypes transduce growth factor and stress agent messages. Endothelial damage 
arising from ROS is promoted by activated neutrophils; their activation is greatly enhanced by 
the granulocyte macrophage colony stimulating factor and plasminogen-activating factor 
which are generated by cytokine-activated endothelial cells. The inflammatory process is 
exacerbated by the damage to the endothelial cells’ reduced expression of plasminogen-
activating factors and marked antithrombotic activities (Shoenfeld et al. 2000). 
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2.7.6.1 Role of inflammation 
The premise that atherosclerosis is an autoimmune disease is further enhanced by the 
observation that lipoproteins that have undergone oxidative modification stimulate 
haemoadhesive molecules, immunoregulatory molecules, inflammatory mediators and T-
lymphocytes. However, atherosclerosis can also be categorised as an inflammatory condition 
because the leukocyte migration is determined by the state of the endothelium. Given the 
multifactorial nature of atherosclerosis, Ross (2006) proposed that the pathogenesis behind 
atherosclerotic plaques arises from the combined activity of the immune and inflammatory 
systems. The migration of leukocytes occurs in response to accumulating and modified 
lipoproteins as well as part of the inflammatory response. 
The presence of ICAM-1, P selectin and VCAM-1 enhances the recruitment of leukocytes to 
the plaque growing on the endothelial surface of the artery. These adhesion molecules are 
further promoted by the presence of inflammatory cytokines, such as IL-1 and TNF-α (Mach, 
2001). 
2.7.6.2 Role of smooth muscles 
Cytokines and growth factors are also synthesised by macrophages recruited to digest the 
modified lipoproteins; these proinflammatory factors attract more macrophages to the lesion 
as well as SMC. Plaque formation is mediated by PDGF and FGF, which are products of IL-1 
and TNF-α stimulation. In response to PDGF released by activated endothelial cells, SMC 
migrate from the media to the intima. The secretion of matrix metalloproteinases (MMP) and 
MMP9 in particular, are considered to be important in SMC successfully migrating and 
proliferation, as the MMP degrade the elasticity of the lamina in cerebral arteries and the 
abdominal aorta. SMC proliferation is enhanced by the endothelial secretion of lipoprotein 
lipase; through the activation of protein kinase-C and the lipase enzyme binding to SMC 
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proteoglycan, gene expression for contractile proteins is turned off and other genes are 
activated. The result is the SMC synthesis of extracellular matrix, which contributes to the 
development and stabilisation of the plaque. TGF-β promotes the production of collagen and 
in common with interferon-γ, inhibits SMC proliferation. These factors acting together 
generate fibro-fatty lesions (Gawaz et al. 2000). 
Development of lesions also involves neovascularisation of the vasa vasorum of the adventitia. 
The hormone, leptin, which is a product of the Ob-R gene, promotes angiogenesis. Elevated 
concentrations of leptin in both the plaque and the vasa vasorum stimulate inflammatory 
neovascularisation as well as functionally upregulating vascular endothelial growth factor 
(VEGF). Angiogenic growth is stimulated by the endothelial Ob-R gene generating a growth 
signal that activates tyrosine kinase-dependent intracellular pathways. OxLDL also contributes 
to atherosclerosis by inducing VEGF in macrophages. The matrix, thrombus and SMC 
proliferations associated with primary lesions in atherosclerosis are also implicated in the re-
narrowing of arteries following angioplasty and stents (Glover et al. 2000). 
2.7.7 Risk factors for atherosclerosis 
The biggest risk factors for PAD are diabetes and smoking, though advanced age, 
hyperlipidaemia and hypertension are other recognised risk factors (Lee et al. 2009). 
2.7.7.1 Hypertension 
One of the challenges of studying hypertension as a PAD risk factor is that it is hard to establish 
whether rises in blood pressure are consequential or causal to PAD. Compared to healthy 
controls, the mean blood pressure and prevalence of hypertension in hospitalised vascular cases 
is generally higher. Studies of intermittent claudication in the general population show the 
phenomenon is related to raised systolic and diastolic pressures (Bulpitt, 1991), though most 
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commonly it is associated with raised systolic pressure. Fowkes et al. (1992) notes that in the 
Edinburgh Artery Study, individuals with symptomatic and asymptomatic PAD exhibited 
higher systolic blood pressure compared to non-PAD participants. This finding also supports 
the Framingham study, which at a 26-year follow-up, found there was a three-fold increase in 
intermittent claudication in hypertensive patients (Kannel et al. 1985). 
In a study by Hirst et al. (2001), compared to controls, patients with PAD presented a greater 
incidence of hypertension (P<0.001). The control patients were also treated for hypertension 
less frequently than were patients with PAD (P<0.001). The researchers noted that patients with 
CVD received more intensive hypertension treatment than those patients who had newly 
diagnosed or prior PAD only (P<0.001).  
2.7.7.2 Smoking 
The contribution that tobacco makes to PAD pathogenesis is well recognised. PAD patients can 
reduce their risk of mortality and disease progression by stopping smoking (Jonason et al. 
1987). Compared to patients with CVD only, the popularity of smoking was greater in patients 
with prior PAD (P<0.001) (Hirst et al. 2001). 
Smoking cigarettes is a prime risk factor for PAD; this was the conclusion in 1965 when more 
than 90% of vascular patients attending hospital had a history of being a smoker, either 
currently or recently (Lord, 1965). The estimation is that almost half of the cases of PAD is 
attributable to smoking (Fowkes, 1988), which indicates that it is a key risk factor. This is borne 
out by the reduction in IC that is associated with the cessation of smoking. The Edinburgh 
Artery Study found that the relative risk of IC in smokers was 3.7 whereas in those who had 
ceased smoking for less than 5 years the relative risk was 3.0 (Fowkes, 1992). 
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2.7.7.3 Diabetes 
Diabetes mellitus is a recognized risk factor for critical limb ischaemia and is related to the 
occurrence of milder forms of PAD. This has been discussed in further detail in the subsequent 
sections. 
2.7.7.4 Inflammation 
Persistent low-grade inflammation has been linked to asymptomatic PAD. In these patients 
who went on to develop PAD within the next 5 years, the levels of C-reactive protein (CRP) 
were higher than the levels in age-matched controls, who remained asymptomatic. The risk to 
those in the highest quartile of baseline CRP was more than double that of those in the lowest 
quartile (Ridker et al. 2001). 
2.7.8 Investigation for detection of vascular insufficiency 
2.7.8.1 Physical examination and history 
The evidence indicates that the presence or absence of symptoms is unrelated to the progression 
of PAD. Hirsch et al. (2001) suggest that the presence or absence of intermittent claudication 
however, determines whether there is local deterioration and progression to critical limb 
ischaemia (CLI). 
Intermittent claudication is the most common PAD symptom, which presents as pain, ache or 
cramp in the buttocks, thighs or calves when walking and resolves at rest. However, in extreme 
PAD, pain can occur at rest and can also include gangrene and loss of tissue. CLI describes 
these severe, limb-threatening presentations of PAD. 
Classic claudication was present in 8.7% of the PAD-only group in Hirst et al.’s study (2001), 
though it was less prevalent in patients newly diagnosed with PAD compared to those with 
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prior PAD (5.5% c.f. 12.6%; P<0.001); it was appreciably lower in patients without 
atherosclerosis (1.7%; P <0.001). Using duplex scanning, the Edinburgh Artery Study found 
blockages in a lower limb artery in one third of asymptomatic PAD patients (Fowkes et al. 
1991). In these asymptomatic patients, diagnosis was most likely to be determined through ABI 
measurement, as typically clinicians use claudication history to establish a PAD diagnosis, 
thereby missing between 85–90% of PAD diagnoses (Newman et al. 1997). 
An initial clinical assessment of PAD typically includes a history and physical examination. 
Using intermittent claudication to identify PAD can be useful, but as indicated, it grossly 
underestimates PAD’s actual prevalence. Examinations that use palpable pedal pulses, may 
eliminate diagnoses with a negative predictive value of more than 90%; on the other hand, 
using pulse abnormalities, such as absent or diminished beats, overestimates the prevalence of 
PAD. These results indicate the need to use objective measures to determine PAD in patients. 
Ankle brachial index (ABI) is the main non-invasive PAD screening test. 
2.7.8.2 Investigations 
2.7.8.2.1 Bedside investigation 
2.7.8.2.1.1 Ankle Brachial Pressure Index  
In the general population, the prevalence of asymptomatic PAD in lower limbs can only be 
estimated with non-invasive measurements; but where PAD is suspected, ABI can be 
administered at the bedside to identify PAD. Using a 10–12 cm sphygmomanometer with the 
cuff located just above the ankle to measure ankle artery pressures and a Doppler instrument 
to measure the systolic pressure of the posterior tibial and dorsalis pedis arteries in each leg. 
The ABI is derived from normalising these pressures to that of the higher brachial pressure of 
either arm. The leg with the lower ABI is usually defined as the index leg. 
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A haemodynamic definition of PAD is often defined by a resting ABI of ≤ 0.90, which is 
attributed to haemodynamically significant arterial stenosis. This method that uses an ABI ≤ 
0.90 reliably identifies 95% of symptomatic arteriogram-positive PAD individuals and almost 
100% of healthy controls (Norgren et al. 2007). 
2.7.8.2.2 Imaging tests 
Not all lesions are suitable for revascularisation, but imaging is an effective means of 
identifying those arterial lesions that may be suitable by using open surgery or endovascular 
techniques. Revascularisation should be determined based upon the extent of a patient’s 
walking ability, and the functional limitations imposed by the state of the vasculature. This 
includes claudication distance and the extent to which it affects a patient’s day-to-day life, their 
independence and self-care capacity. So long as there are no contraindications that would 
preclude endovascular or surgical intervention, imaging and revascularisation are essential for 
CLI cases. 
At present, imagining options include angiography, computed tomographic angiography 
(CTA), duplex ultrasound and magnetic resonance angiography (MRA). When selecting the 
imaging modality, contraindications and potential side effects need to be considered. 
2.7.8.2.2.1 Angiography 
Although angiography is expensive and is not risk free, it is the ‘gold standard’ imaging test. 
Approximately 0.1% of patients who undergo this test have a severe reaction to the contrast 
medium. The technique also carries a 0.16% risk of mortality. Atheroembolism, arterial 
dissection, access-site complications, including haematoma and renal failure arising from the 
contrast medium are included among the complications of angiography. Technological 
advancements have ameliorated several of these issues, such as using digital subtraction 
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angiography, intra-arterial pressure measurements across the stenosis (with and without a 
vasodilator) non-ionic contrast agents, and superior image projection and storage. Also, instead 
of traditional contrast media, magnetic resonance contrast agents such as gadolinium can be 
used. In patients who are vulnerable to renal impairment, partial studies that reduce the amount 
of contrast medium used and amount of time required, are more suitable than imaging the entire 
infrarenal arterial tree, as the risks are lowered. Nonetheless, full angiography that enables all 
arteries between the kidneys and feet to be viewed using digital subtraction angiography (DSA) 
is preferable for most instances.   
2.7.8.2.2.2 Duplex ultrasound 
An alternative to angiography is colour-assisted duplex imaging. This technology is much 
cheaper and safer than angioplasty; a skilled practitioner can extract key anatomic data 
including functional information, such as velocity gradients across stenoses. Visualisation of 
the lower extremity arterial tree can be achieved and include an accurate assessment of the 
extent and severity of lesions. A disadvantage of the technique is that it can take longer to 
conduct, and the results are influenced by the practitioner’s skill. 
2.7.8.2.2.3 Multidetector computed tomography angiography 
The level of morbidity and costs are considerably reduced with duplex scanning compared to 
other non-invasive techniques. CTA and MRA provide non-invasive imaging capable of 
evaluating the state of the lesions prior to invasive angioplasty; they can be applied to numerous 
situations. Frequently, PAD is being diagnosed using multi-detector computed tomography 
angiography (MDCTA), which is also used to determine appropriate treatment options. 
Familiarity with CT technology and the ease of using fast MDCTA multi-slice systems in the 
community have promoted the popularity of this technology. 
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2.7.8.2.2.4 Magnetic resonance angiography 
MRA is the preferred choice of technology to diagnose and plan treatment of PAD patients in 
many health centres. In part, this reflects the safety of the technology, as well as its ability to 
generate high-resolution 3D images. MRA can successfully image the whole abdomen, lower 
extremities and pelvis in one session. 3D images have the advantage of being rotated across an 
infinite number of planes, giving full visual perspectives. The technique is appropriate for 
evaluating lesions for their suitability for endovascular intervention. Using MRA prior to a 
procedure may reduce radiation exposure and the use of iodinated contrast media. 
2.7.9 Management of Vascular insufficiency 
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Figure 5: Overall treatment strategy for peripheral arterial disease 
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BP – blood pressure; HbA1c – hemoglobin A1c; LDL – low density lipoprotein; MRA – 
magnetic resonance angiography; CTA – computed tomographic angiography. Reproduced 
with permission from Hiatt WR. N Engl J Med 2001; 344:1608–1621. 
 
To manage the disease state of a PAD patient, treatment needs to take into account the 
epidemiology and natural history of the disease as well as systemic disease risk factors that can 
be modified and those that adversely influence limb circulation. 
2.7.9.1 Medical management 
Claudication, which is reversible muscle ischaemia during walking, manifests as cramp or pain 
in the muscles involved in walking. The effect of the symptoms can be significant, greatly 
curtailing the amount of walking and exercise a sufferer can undertake. Consequently, patients 
with claudication are to varying extents, disabled and treatments aim to ameliorate symptoms 
and promote functional walking/exercising ability. Structured exercise ought to be the initial 
means to treat the symptoms, though some patients may be directed to pharmacological 
interventions to reduce claudication during exercise. For example, antiplatelet therapy and 
modification of risk factors may be required to minimise the risk of cardiovascular events and 
promote survival). Escalation to limb revascularisation is likely to be considered if structured 
exercise and/or pharmacology fail to make the desired improvements. 
2.7.9.1.1 Antiplatelets 
Hirst et al. (2001) report that 34% of the control group received antiplatelet drug therapy, which 
is lower than the number of patients who had already been diagnosed with atherosclerotic 
syndromes (P<0 .001). In PAD-only patients, those who were recently diagnosed received less 
antiplatelet therapy than those who had a longer-standing diagnosis (P< 0.001). Antiplatelet 
therapy was more likely to be administered to CVD-only patients than those with PAD-only 
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(P<0 .001).  
2.7.9.1.2 Statins 
Statins play an important role in managing patients with atherosclerosis. However, as majority 
of patient with PAD are underdiagnosed, they are not prescribed commonly. According to a 
cross sectional study by Hirst et al. (2001), the levels of LDL cholesterol had been obtained 
from only 63% of newly diagnosed and 65% of previously diagnosed PAD-only patients; in 
contrast, the LDL levels were identified in 73% of CVD-only patients (P<0.01 for prior PAD 
only c.f. CVD-only). The difference in the prevalence of hyperlipidaemia in the PAD and 
control groups was statistically significant (P<0.001). Those patients who had recently been 
diagnosed with PAD received less intense hyperlipidaemia treatment, which was comparable 
to the control group, compared to those who had been diagnosed previously (P < 0.006). Of all 
groups, the CVD-only patients received the most intensive therapy for hyperlipidaemia 
(P<0.001). 
2.7.9.2 Surgical management 
Acute limb ischaemia is a surgical emergency. For patients who have a profoundly ischaemic 
limb and have undergone severe loss of motor and sensory capability in a short period of time, 
immediate revascularisation may be indicated. However, the extent of success is largely 
determined by the speed at which revascularisation is performed after onset. The window is 
likely to be measurable in hours, with marked recovery possible if the procedure is completed 
very quickly. But as the window closes, significant neuromuscular damage is almost certain. 
Whether revascularisation is endovascular or open surgery largely depends on the location of 
the blockage. In the past, surgery was the treatment of choice for urgent treatment, but with as 
endovascular management has progressed and greater understanding about the importance of 
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circulation significantly promoting patency, where endovascular services are available, the 
time window for immediate revascularisation has been widened (TASC, 2000). 
2.7.9.2.1 Angioplasty 
The success of percutaneous transluminal angioplasty (PTA), as determined by patency, tends 
to be highest in the common iliac artery, with literature reporting technical and clinical 
successes exceeding 90%. PTA resolves almost 100% of focal iliac lesions. The technical 
success rate of revascularisation of long segment iliac occlusions is 80%–85% with or without 
additional fibrinolysis. The technical success of revascularisation has benefitted from device 
developments aimed at treating entire blockages. PTA is progressively less effective for lesions 
in distal arteries (Saket et al. 2004). 
Tetteroo et al. (1998) conducted a prospective, randomised, multicentre study into the outcome 
of primary stents compared to PTA with provisional stenting. They found that the intervention 
rate of 7% of the latter technique was comparable to the 4% of primary stents (not significant). 
A similar pattern was observed at 5 years (mean 5.6 years ± 1.3) after treatment, with 82% of 
PTA and provisional stenting and 80% of primary stents not requiring further revascularisation 
of the iliac artery segments (Klein et al. 2004). 
2.7.9.2.3 Bypass 
Where there is diffuse disease throughout the aortoiliac segment, bilateral bypass surgery from 
the infra-renal abdominal aorta to both femoral arteries is usually recommended. The interest 
in endarterectomy has recently undergone a bit of a renaissance, though its technical challenges 
make it less commonly practised than bypass grafts. In a report by Rothwell et al. (2004) 
exploring primary patency rates 5-years after intervention, the researchers found a considerable 
variation (60–94%), which was attributed to the skill of the professional performing the 
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endarterectomy. 
There is limited randomised trial data comparing bypass surgery and PTA for infrainguinal 
arterial obstructive disease. This can in part be accounted for by bypass surgery typically being 
performed in disease states with long lesions and CLI. In contrast, PTA is used more often 
where the disease is less extensive, obstructions are short and IC. One prospective, randomised, 
multicentre trial included 262 men with obstructions in the iliac, femoral or popliteal artery. 
Patients were randomly allocated to bypass surgery or PTA intervention; a 4-year median 
follow-up that evaluated patency, limb salvage and survival found no significant difference 
between interventions. Primary patency a further year on was 43% in 56 PTA patients, and 82% 
in bypass surgery patients. This indicates that surgery is superior to PTA where there are long 
superficial femoral artery (SFA) stenosis or blockages. Adams et al. (2005) found in their 
randomised study of 452 patients that there was no survival difference at 6 months in patients 
who had not undergone amputation. However, surgery is a more expensive option. 
2.8 Diabetes 
 
2.8.1 Introduction 
 
Diabetes mellitus is defined as a group of metabolic diseases characterized by hyperglycaemia 
resulting from defects in insulin secretion, insulin action, or both. In the long-term, various 
organs including eyes, kidneys, nerves, heart, and blood vessels become damaged because of 
chronic hyperglycaemia associated with diabetes mellitus (American Diabetes Association, 
2013). According to Wild et al. (2004) in 2000, the number of people globally suffering from 
diabetes mellitus was 171 million; by 2030, this figure is expected to rise to 366 million. The 
disease is responsible for increased morbidity and mortality because of microvascular 
complications, as well as a higher risk of macrovascular complications, including ischaemic 
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heart disease, stroke and peripheral vascular disease, and thereby resulting in reduced quality 
of life (World Health Organisation, 2011). 
During the period 2006-2011, there has been a 25% increase in the number of people that were 
diagnosed with diabetes mellitus in the United Kingdom, rising from 1.9 million to 2.5 million 
(Quality Outcome Framework Prevalence Data, 2012). Furthermore, the number of people with 
undiagnosed diabetes mellitus is thought to be around 850,000. Concomitantly, diabetes 
mellitus-related complications are also on the increase. At present, amputations, strokes, 
blindness and end-stage kidney failure occur primarily due to diabetes mellitus. Based on the 
existing trends, it is expected that the number of people in the United Kingdom suffering from 
diabetes mellitus will reach 5 million by 2025. Type 2 diabetes mellitus is the most common 
form of the disease, with 90% prevalence, while type 1 diabetes mellitus occurs in a proportion 
of 10% (Diabetes UK, 2011). 
Hex et al. (2012) reported that the treatment of diabetes mellitus takes up approximately 10% 
of the budget of the National Health Service (NHS). A report by Diabetes UK (2011), 
confirmed this and reported that in 2011, the treatment of diabetes mellitus accounted for 10% 
of the NHS budget, amounting to £10 billion. A proportion of 80% of these costs were 
associated with the treatment of preventable complications, such as diabetic foot ulcers. 
Together with indirect costs, which pertain to mortality rates, sickness, possible reduction in 
productivity among people in employment, and informal care, these direct costs amounted to 
£23.7 billion for 2010-2011 and the figure is predicted to increase to £39.8 billion by 2035-
2036 (Hex et al. 2012).  
2.8.2 Vascular complications of diabetes mellitus  
 
Chronic vascular complications may be further classified into macrovascular and 
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microvascular complications).  Vascular complications of diabetes mellitus shorten life 
expectancy on average by 16 to 20 years in type 1 diabetes mellitus patients and by 4 to 6 years 
in those with type 2 diabetes mellitus (Trento et al. 2013).  
One of the commonest complication which results from diabetic neuropathy and macrovascular 
complications of diabetes mellitus like peripheral vascular disease is diabetic foot disease. A 
diabetic foot ulcer is in most cases the first sign of lower limb amputation. 
2.8.3 Epidemiology of vascular complications of diabetes mellitus affecting amputation 
 
The available data for the global prevalence rate of amputation in numerous countries is poor, 
though the 5-year mortality rate is noted to be very high (up to78%) (Aleccia, 2010). In 2005, 
a number of about 664,000 of successful cases of major amputation and nearly a million cases 
of minor amputation were recorded globally (Ziegler-Graham et al. 2008). Moxey et al. (2010) 
further reported that, from 2003-2008, five out of every 100,000 individuals had a major 
amputation surgery, although considerable regional variation was noted. Vascular insufficiency 
and severe trauma account for 54% and 45%, respectively, of the approximately 5,000 
amputations performed each year in the UK (Aleccia, 2010). Furthermore, foot ulcers have 
been estimated to be developed by about 61,000 individuals who account for around 2.5% of 
the population of diabetics in the UK. According to the statistics of the National Diabetes Audit 
(2010), in 2009-2010, 7 and 13 out of every 10,000 individuals had major and minor 
amputation, respectively, of a lower limb.  Another study noted that, during the period 2007-
2010, for every 10,000 diabetics there were 25 major amputations of lower limb (Holman et 
al. 2012).  
2.8.4 Cost implications of diabetic mellitus related amputations 
Diabetic foot disease often leads to serious long-term complications, putting significant socio-
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economic pressure on resources and health care. The National Health Service is under 
enormous financial strain as a result of diabetic foot complications, reflected in greater 
outpatient costs, bed occupancy, and extended hospitalisation. The cost of diabetic foot care to 
the UK National Health Service during 2010-2011 was £639-662 million. A proportion of 10% 
of the NHS budget is taken up by diabetes and diabetes-related complications account for 80% 
of the total cost. Li et al. (2010) estimated that, taking into consideration modifications in 
demography and the increasing rate of obesity, in the coming two decades, diabetes mellitus 
will come to represent 17% of the whole NHS budget, if the current cost of diabetes treatment 
remains unchanged (Kerr et al. 2012). These figures do not take account of the indirect costs 
to patients such as the effect on physical, psychological and social wellbeing (Singh et al. 
2005). Social care will also require additional funding because individuals who undergo 
amputations require assistance in daily activities and in caring for themselves. Hence, diabetes 
mellitus will place an even greater strain on the health and social care system. What is more, 
diabetics also have significantly lower work productivity due to poor health, the cost of which 
has been approximated at around £9 million, though further research is needed with to 
corroborate this (Hex et al. 2012). The International Diabetes Federation has estimated that 
around 50% of direct healthcare costs are due to loss of work productivity in the United States 
(Yang et al. 2012). 
2.8.5 Macrovascular complications of diabetes mellitus and their role in amputation 
Diabetes mellitus is often accompanied by macrovascular complications. The morbidity and 
mortality rates among patients with diabetes mellitus are significantly increased by vascular 
disease, which, together with diabetes mellitus, is responsible for the greatest number of deaths 
on a global level (Nuzum and Merz, 2009). 
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2.8.5.1 Peripheral arterial disease and amputation  
As explained by Ross (1986), peripheral arterial disease is often associated with diabetes 
mellitus and is characterised by progressive decrease in blood flow to at least one extremity 
because of atherosclerosis. This has been discussed in further detail in the previous sections. 
2.8.5.2 Hypertension and amputation 
A diagnosis of hypertension is established when the average of at least two measurements of 
diastolic blood pressure (BP) on two or more visits is equal to or higher than 90 mmHg or when 
the average of several measurements of systolic blood pressure on at least two visits is 
constantly equal to or higher than 140 mmHg. The correlation between lower limb amputation 
and hypertension as well as between lower limb amputation and peripheral vascular disease 
led Lehto et al. (1996) to conclude that vascular aetiology is the cause of lower extremity 
amputation in numerous cases. Isolated systolic hypertension is identified when the systolic 
and diastolic BPs are respectively equal to or higher than 140 mmHg and lower than 90 mmHg. 
High blood pressure has also been implicated as a risk factor for lower limb amputation 
Hamalainen et al. (1999). According to Moss at el. (1999) who evaluated the risk factors for 
lower limb amputation looking at a cumulative 14-year incidence noted that lower limb 
amputation was related to higher diastolic blood pressure (OR for 10 mmHg 1.58 [1.20-2.07]) 
in the multivariate analysis.  
2.8.6 Microvascular complications and their role in amputation 
2.8.6.1 Diabetic retinopathy and amputation 
Diabetic retinopathy is a part of the microvascular complications of diabetes mellitus. It has 
been noted to be a marker for atherosclerosis and a risk factor for lower limb amputation in 
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patients with diabetes mellitus. The condition of the vascular system can be inferred from the 
condition of the retina and the changes in the retinal arterioles may signal a deterioration 
occurring elsewhere (Wong et al. 2001). Retinal arterioles, which can be observed without 
invasive procedures, are similar to the cerebral and coronary circulations in terms of their 
anatomy and physiology (Singerman et al. 1991). According to some studies, apart from 
hypertension, inflammation and endothelial dysfunction, the narrowing of retinal arterioles 
may also be a marker of coronary heart disease (Klein et al. 2002). The correlation between 
changes in retinal arterioles and the rate of lower extremity amputation was investigated by 
Moss et al. (2003) based on a sample of 996 individuals who developed diabetes mellitus at a 
younger age, with follow-up over a period of two decades. Their findings suggested that, 
compared to patients without generalised arteriolar narrowing, those with it were more likely 
to have a lower limb amputated (15.7% vs 5.7%; OR 3.08; 95% CI 1.60-4.68); likewise, the 
risk of lower limb amputation was also high among patients with focal narrowing (33.1% vs 
6.8%; OR 5.59; 95% CI 3.27-9.54).   
2.8.6.2 Diabetic nephropathy and amputation 
Diabetic nephropathy is a common complication of diabetes mellitus. About half of patients 
with type 1 diabetes mellitus with overt nephropathy develop End Stage Renal Disease within 
a decade, while over 75% develop it within two decades if they do not undergo treatment (Chen 
et al. 2004). In comparison to individuals with type 1 diabetes mellitus, a larger number of 
individuals with type 2 diabetes mellitus develop microalbuminuria or overt nephropathy at the 
time of or immediately after being diagnosed with diabetes mellitus. As noted by Waanders et 
al. (2013), the reason for this may be that the disease was present long before it was diagnosed. 
Within a decade, 20-40% of patients with diabetes mellitus related microalbuminuria develop 
overt nephropathy, of which 20% develop End Stage Renal Disease within two decades (Amin 
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et al. 2013). Worsening renal function due to diabetic nephropathy is a well-known factor for 
poor healing in patients with PAD resulting in higher risk of an amputation. 
2.8.6.3 Diabetic peripheral neuropathy and amputation 
 Diabetic peripheral neuropathy is one of the most common complications of diabetes mellitus. 
According to Aszmann et al. (2004), the prevalence of peripheral neuropathy is more than 50% 
in those who have been diabetic for 20 years. A recent definition of diabetic peripheral 
neuropathy put forth by Vinik et al. (2013) refers to it as a symmetric, length-dependent 
sensorimotor peripheral neuropathy caused by metabolic and microvascular abnormalities 
arising from chronic hyperglycaemia exposure due to diabetes mellitus and cardiovascular risk 
covariates. Both types of diabetes mellitus, as well as different forms of acquired diabetes 
mellitus, are associated with diabetic peripheral neuropathy (Dyck et al. 1993). Foot ulceration 
is the condition most commonly related to somatic peripheral neuropathy, often leading to 
gangrene and limb amputation. The risk of amputation is increased by peripheral neuropathy 
1.7-fold, 12-fold in the case of deformity, which is caused by peripheral neuropathy and 36-
fold if the patient has a history of earlier ulceration (Vinik et al. 2013). 
Independent from large-vessel disease, sensory loss may result in an ulcer development and 
sometimes amputation as well (Akbari et al. 1998). Ulcer development has an annual incidence 
rate of 2.5%, with one in six diabetics experiencing it at some point in their life (Frykberg et 
al. 2006).   
2.8.7 Pathophysiology of vascular complication of diabetes mellitus related to lower limb 
amputation 
There are a lot of factors that play a role which result in a lower limb amputation, diabetes 
mellitus being the most common. As indicated by Chaturvedi et al. (2001), in more than 50% 
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of all cases, leg amputation is carried out as a direct consequence of diabetes mellitus and its 
complications. Furthermore, in conjunction with peripheral neuropathy, diabetes mellitus is 
responsible for the occurrence of foot ulcers; with approximately 3% of patients with diabetes 
mellitus developing foot ulcers annually. Foot ulcers which do not heal determine leg 
amputations in 85% of cases of individuals suffering from diabetes mellitus (Boulton et al. 
2004). The ulcers generally develop in areas under extreme pressure, such as the distal ends of 
the first and fifth metatarsals, the calcaneum, and other areas which are prone to recurrent 
trauma like the extremities of the phalanges (Ledermann et al. 2002).  
Peripheral neuropathy and ischaemia represent the two major risk factors for foot ulcerations 
and subsequent lower limb amputation. Studies have shown that 30% to 50% of patients with 
type 1 as well as type 2 diabetes mellitus are likely to develop peripheral neuropathy and 
ischaemia (Bowering, 2001). 
2.8.7.1 Role of peripheral arterial disease in lower limb amputation 
PAD is one of the important causes of lower limb amputation. This has been discussed in the 
earlier section. 
2.8.7.2 Role of hyperglycaemia in lower limb amputation 
Individuals with diabetic foot disease are more likely to undergo amputation if diabetes mellitus 
is inadequately managed which leads to vascular and neuropathic complications. Brownlee 
(2005) reported that amputation is directly correlated with high glycaemic levels. 
Parillo et al. (2004) highlighted that atherosclerosis, cerebrovascular disease, and peripheral 
vascular disease all have a greater probability of development in the case of individuals with 
diabetes mellitus. Diabetes mellitus disrupts normal nutrient metabolism and leads to an 
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increase in inflammatory mediators, thus interfering with wound healing and increasing the 
risk of infection and foot ulcers. The most prevalent foot injury that may cause a lower limb 
amputation is diabetic lower limb ischaemia due to arterial blockage (Armstrong et al. 1998). 
Chronic hyperglycaemia is accompanied by a number of microvascular complications, 
including peripheral neuropathy and can undermine endothelial permeability, which can 
degenerate into endothelial dysfunction (Dang et al. 2005). Figure 6 and 7 illustrate the process 
which despite the high concentrations of plasma glucose present in all cells affected by diabetes 
mellitus, only the cell types which cannot control the transport of glucose into the cells, such 
as endothelial cells, are affected by hyperglycaemic disruption, causing intracellular 
hyperglycaemia (Brownlee, 2005). It also explains that there is genetic susceptibility as well 
as environmental factors at play which contribute to glucose related cell damage in patients 
with diabetes mellitus. 
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Figure 6: General features of hyperglycemia-induced tissue damage 
Source: Brownlee M. 2005. Diabetes; 54:16 15-1625 
 
As noted by Brownlee (2005), in the initial phases of diabetes mellitus, intracellular 
hyperglycaemia manifests as increased circulation, vascular permeability and intra-capillary 
pressure. These complications are caused by the reduced function of vasodilators, such as nitric 
oxide and the accelerated function of vasoconstrictors, such as angiotensin II and endothelin-1 
(Schmieder et al. 2009). As a result, there is an increased drainage of capillaries in certain 
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organs. In a study on diabetic animals, Brownlee (2001) observed that there was an over-
expression of the Connective Tissue Growth Factor (CTGF), implying that it contributes to the 
development of microvascular and macrovascular diabetic complications. 
Hyperglycaemia also results in mitochondrial Reactive Oxygen Species generation (mROS) 
(Brownlee, 2005), producing oxidative stress through a number of mediums, such as 
diacylglycerol/protein kinase C (DAG/PKC) and hexosamine that subsequently cause 
endothelial dysfunction and microvascular complications, including peripheral neuropathy, 
thereby leading to poor healing (Zhang and Gutterman, 2007). The Nuclear Factor-kappa B 
(NF-kappa B) family which comprises DNA-binding protein factors that are required for the 
transcription of most proinflammatory molecules. Various studies performed in a variety of cell 
and animal based experimental systems suggested that Nuclear Factor-kappa B activation was 
a key event early in the pathobiology of diabetes mellitus (Patel et al. 2009). Studies including 
Lupachyk et al. (2011) have highlighted the important role of poly (ADP-ribose) polymerase 
(PARP) activation in systemic oxidative stress in diabetic peripheral neuropathy. 
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Figure 7: The unifying mechanism of hyperglycemia-induced cellular damage 
Source: Brownlee M 2005. Diabetes; 54:1615-1625 
 
 
 
Abbreviations: ROS- Reactive Oxygen Species; DAG/PKC- diacylglycerol/protein kinase C; 
AGEs- Advanced glycation end products; GAPDH- glyceraldehyde-3-phosphate 
dehydrogenase; PARP- poly(ADP-ribose) polymerase; NFkB- Nuclear Factor kB 
 
The wound healing process is frequently delayed in patients with diabetes mellitus. Endothelial 
progenitor cells (EPCs) which are produced by the bone marrow, have an important role in the 
creation of blood vessels and wound healing. In their study on diabetic mice, Velazquez et al. 
(2007) noted in mouse models that diabetes mellitus is related to a reduction in the amount of 
Endothelial progenitor cells in the blood flow and in the area surrounding a wound. According 
to the researchers, the wound healing process in patients with diabetes mellitus is hampered by 
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the impaired endothelial Nitric Oxide Synthetase (eNOS) activation, which stimulates nitric 
oxide production, and by the reduced concentration of chemokine Stromal cells Derived Factor 
1 alpha (SDF-1alpha). Disruptions in the production or function of growth factors, angiogenic 
reaction, macrophages, collagen accumulation, epidermal barrier, amount of granulation tissue, 
keratinocytes and fibroblasts, could also contribute to inefficient wound healing in patients 
with diabetes mellitus (Maruyama et al. 2007)  
2.8.7.3 Endothelial dysfunction and lower limb amputation 
As mentioned in the previous two sections, patients with diabetes mellitus have 
hyperglycaemia related endothelial damage. This is compounded by the deceased vascularity 
due to pre-existing arterial insufficiency and infection. This results in further cell damage at 
the cellular level. The pathogenesis of diabetic vascular complications frequently arises in 
response to endothelial dysfunction, which is associated with the upregulation of inflammatory 
mediators and increased expression of Cell Adhesion Molecules (CAMs) (Nyström et al. 
2006). The over-expression of Cell Adhesion Molecules promotes leukocyte-endothelial 
interactions, which further stimulates the inflammation response leading to tissue damage. The 
levels of plasma soluble adhesion molecules have been found to be elevated in type 2 diabetes 
mellitus patients. Studies by Sármán et al. (1998), found that Endothelin-1, a potent 
vasoconstrictor with mitogenic capability, promotes proliferation of vascular smooth muscle 
cells, which contributes to the development of atherosclerosis.  
The release of endothelins contributes to the endothelial dysfunction that is commonly found 
in patients with diabetes mellitus. Sánchez et al. (2001) found a correlation between patients 
with poor glycaemic control and higher plasma levels of Endothelin-1. Indeed, the levels were 
even greater in patients with diabetes mellitus suffering from vascular disease complications. 
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This may be modulated by pharmacological intervention, as Schneider et al. (2002) noted that 
diabetic patients taking Angiotensin Converting Enzyme (ACE) inhibitors exhibited lower 
Endothelin-1 levels than those not taking Angiotensin Converting Enzyme inhibitors. Various 
studies have found that plasma Endothelin-1 concentrations were abnormally high in patients 
with conditions associated with endothelial cell injury, as well as in those with hypertension 
(Hiramoto et al. 2009), congestive heart failure (Kinugawa et al. 2003), coronary artery disease 
(Sánchez et al. 2001), and uraemia (Deray et al. 1992).  
In addition to Endothelin-1, Nitric Oxide (NO) is important in regulating the homeostasis of 
vascular tissue. Nitric Oxide is an endogenous vasodilator, synthesized by endothelial cells 
(Brownlee, 2005); it protects vascular tissue by countering the abnormal proliferation of 
vascular smooth muscle cells that occurs after vascular interventions, for example a bypass 
graft (Vural et al.  2001). Nitric Oxide has also been implicated in reducing monocyte adhesion 
and inhibiting platelet aggregation (Marin et al. 1997). An interesting observation was reported 
by Hattori et al. (1991) in which the release of Nitric Oxide and the response to it was reduced 
at the onset of diabetes mellitus. In summation, Endothelin-1 and Nitric Oxide are important 
mediators in maintaining vascular function. 
C-reactive protein (CRP) is a marker of inflammation, which is elevated in patients with 
Diabetic Mellitus with peripheral arterial disease. The level of C-reactive protein correlates to 
the severity of the arterial disease. Endothelial cells manufacture various proteins, including 
Intercellular Adhesion Molecule-1 (ICAM-1) and Vascular Adhesion Molecule-1 (VCAM-1). 
According to Bevilacqua (1985) and Karaduman et al. (2006) their expressions increase after 
stimulation by proinflammatory cytokines and the tissue Intercellular Adhesion molecule-1 
levels were positively correlated with blood glucose levels. Adhesive interactions between 
leukocytes and endothelial cells are involved in inflammatory or immunologic response 
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mechanisms. The adhesion molecules present on the surface of endothelial cells bind to the 
CD11a and CD11b/CD18 integrins on the surface of leukocytes; these integrins, which are 
abundant on polymorphonuclear leukocytes, are only expressed by White Blood Cells 
(Henderson et al. 2001).  According to DiPiro et al. (1997) lymphocyte CD11a/CD18 play an 
important role in determining the response to infection influencing the type of immunity and 
the inflammatory response to infection. CD11b/CD18 expressed by neutrophils is key in 
binding the neutrophil to the surface of vascular endothelial cells (Diamond et al. 1991). 
Jaeschke et al. (1991) reported that the expression of CD11b/CD18 on neutrophils correlates 
with microvascular dysfunction and is elevated in patients with infections. 
2.8.7.4 Role of hypertension in endothelial dysfunction and lower limb amputation 
The association between hypertension and endothelial dysfunction is well recognized (Panza 
et al. 1995). Based upon data collected from the Framingham offspring cohort study, there is a 
positive correlation between the severity of hypertension and the extent of endothelial 
dysfunction (Benjamin et al. 2004). Several studies have drawn a link between the increases in 
systemic oxidative stress and vascular inflammation associated with hypertension (Harrison et 
al. 2009). Sources of oxidative stress associated with hypertension include mitochondria and 
Nicotinamide Adenine Dinucleotide Phosphate (NADPH) oxidase (Widder et al. 2009). 
Studies by Vecchione et al. (2009) performed in animals concluded that isolated carotid arteries 
from mice when exposed to increasing intraluminal pressure showed a concomitant decrease 
in endothelium-dependent vasodilation to acetylcholine, increased vascular superoxide 
production, and increased Nicotinamide Adenine Dinucleotide Phosphate oxidase activity. 
Hypertension induced Reactive Oxygen Species (ROS) derived from mitochondria and 
Nicotinamide Adenine Dinucleotide Phosphate oxidase contributes to endothelial dysfunction 
(Doughan et al. 2008). 
                            Chapter 2 
57 
 
 
2.8.7.5 Role of obesity in endothelial dysfunction and lower limb amputation 
Obesity is a disorder of complex aetiology determined by genetic as well as environmental 
factors. As a consequence of the development of obesity, a large proportion of individuals 
develop the insulin resistance syndrome, which is characterized by several metabolic 
abnormalities such as hyperinsulinemia, diabetes mellitus, dyslipidemia and hypertension 
(Lobato et al. 2012).  
In recent years, the significance of adipose tissue in regulating metabolism and inflammation, 
as well as adipokines (cell signaling proteins) has been recognized by clinicians and researchers 
(Lobato et al. 2011). In obese patients, inflamed adipose tissue is linked to poor endothelial 
function (Dantas et al. 2004). Adipose tissue inflammation studies have explored the influence 
of perivascular adipose tissue on vascular homeostasis in hypertension. In studies using 
hypertensive rats, contrary to normal rats, adipose tissue was found to be inadequate in 
suppressing phenylephrine-induced vasoconstriction (Serpillon et al. 2009). In addition, 
hypertensive, obese rats with perivascular inflammation demonstrated greater endothelial 
dysfunction compared to normal rats (Akamine et al. 2006). Together, the data indicated that 
inflamed adipose tissue and perivascular adipose tissue make a significant contribution to 
regulating vascular homeostasis at local and systemic levels. 
2.8.7.6 Role of distal peripheral neuropathy and lower limb amputation 
This has been discussed in the earlier section. 
 2.9 Predisposing factors of lower limb amputation 
There are numerous risk factors for leg amputation in the case of patients with diabetes mellitus, 
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as indicated by different studies. In their study of 202 patients, Nather et al. (2008) specified a 
number of risk factors for amputation, including older age (over 60 years), ischaemic cardiac 
disease, nephropathy, peripheral vascular disease, sensory peripheral neuropathy, glycosylated 
haemoglobin, ankle brachial pressure index lower than 0.8, gangrene, infection and pathogen 
invasion, such as methicillin-resistant Staphylococcus aureus. According to Younes et al. 
(2004), the most common risk factors for foot ulceration, which most commonly leads to lower 
limb amputation are: diabetic peripheral neuropathy, anatomical deformity of foot, and 
peripheral vascular disease. Santos et al. (2006) also identified a combination of factors which 
heightens the likelihood of amputation, namely, older patients with diabetic foot infection, 
long-term diabetes mellitus, advanced lymphangitis, wounds in the calcaneum area and grade 
5 injuries in Wagner’s classification. Other risk factors are discussed in the following section.  
2.9.1 Diabetes and lower limb amputation 
Patients with diabetes mellitus account for 42% of the referrals made for prosthesis fitting. In 
the past eight years, there has been a substantial increase in the number of referrals for lower 
limb amputation, with diabetes mellitus being identified as the main cause (NASDAB, 2005). 
Among all the complications of diabetes mellitus, limb loss is perhaps the most distressing for 
the patient. Amputation has an extensive effect on the lifestyle of the patients, as well as on the 
healthcare budget (van Houtum et al. 2004). Dillingham et al. (2005), who looked at 12-month 
re-amputation and mortality rates in 3565 patients, concluded that diabetic amputees were 
younger by about seven years than the patients without diabetes mellitus (48 deaths in patients 
with diabetes mellitus with less than 75 years of age vs 24 in the non-diabetic group). In 
addition, diabetic amputees were generally of male sex, suffered from co-morbidities, and the 
first amputation they had been subjected to, was carried out at a younger age than in the case 
of patients without diabetes mellitus. Furthermore, they also observed that the age at death of 
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the patients with diabetes mellitus who had undergone amputation was also lower than that of 
those without diabetes mellitus.  
2.9.2 Peripheral vascular disease and lower limb amputation 
Peripheral vascular disease develops in the peripheral arteries usually of the lower limbs 
(Hirsch et al. 2006) and is a common cause for lower limb amputation. This has been discussed 
in further detail in earlier sections. 
2.9.3 Diabetes and peripheral vascular disease  
The prevalence of peripheral vascular disease is around 10% in patients with diabetes mellitus, 
whereas 2.6% of people who do not suffer from diabetes mellitus develop peripheral vascular 
disease (Gregg et al. 2004). Peripheral vascular disease has been indicated by the United 
Kingdom Prospective Diabetes Study (UKPDS) to occur more frequently in patients with type 
2 diabetes mellitus, in contrast to the non-diabetic population. It is considered a risk factor for 
foot ulceration and amputation in patients with diabetes mellitus (Adler et al. 1999; Boyko et 
al. 1999). Approximately 75-85% of lower extremity amputations are as a result of peripheral 
vascular disease, of which up to 42% have coexisting diabetes mellitus (Donohue et al. 2001). 
Peripheral vascular disease in patients with diabetes mellitus increases the risk for lower 
extremity amputation and mortality.   
2.9.4 Diabetic peripheral neuropathy and lower limb amputation 
Diabetic peripheral neuropathy plays a major role in lower limb amputation. This has been 
discussed in further detail in an earlier section. 
2.9.5 Renal disease and lower limb amputation 
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Patients with End Stage Renal Disease often develop diabetic peripheral neuropathy and 
peripheral arterial disease, which are prominent causes of leg amputation, thereby making 
patients with End Stage Renal Disease more prone for an amputation (Papanas et al. 2007). 
Hill et al. (1996) noted that End Stage Renal Disease patients have a 25% chance of developing 
diabetic foot complications, in contrast to diabetic patients not undergoing renal replacement 
therapy, who only had a 10% chance. There is a strong relation between deranged kidney 
function and unsuccessful healing of amputated stumps, as well as between albuminuria and 
risk of amputation (Ghanassia et al. 2008). 
As pointed out by various researchers (Wolf et al. 2009), there is an almost eight-fold increase 
in lower limb amputation among patients suffering from peripheral vascular disease and severe 
chronic kidney disease, than among healthy patients. In their studies, Nather et al. (2008) and 
Broumand (2007) have argued that in the case of patients with diabetes mellitus, nephropathy 
and haemodialysis increase the likelihood of leg amputation. Patients with End Stage Renal 
Disease who have had a minor amputation in order to preserve a limb are at a higher risk of 
having a major amputation in comparison to patients who do not have End Stage Renal Disease 
(Sheahan et al. 2005).  
2.9.6 Past medical history of amputation as a risk factor for lower limb amputation 
Individuals who have undergone amputations in the past are more likely to be subjected to the 
procedure again (Adler et al. 1999), particularly if the amputation level was not selected 
correctly, which can have a negative impact on the healing rate (Izumi et al. 2006). Diabetics 
subjected to primary digit amputation for sepsis are more predisposed to develop repeated 
infections, which can lead to additional amputations (Nehler et al. 1999). This has been 
corroborated by the results obtained by Dalla-Paola et al. (2003), who noted that 10% of 
                            Chapter 2 
61 
 
patients with diabetes mellitus with first digit amputations had been subjected to a further 
higher amputation after less than a year and a half of the original amputation. Similarly, 
Murdoch et al. (1997) observed that 51% of patients had undergone a higher amputation in the 
same leg less than a year after their initial first digit amputation. Sheahan et al. (2005) estimated 
that the first six months following an amputation represented a high-risk period for an 
additional ipsilateral amputation. About to re-amputations of the contralateral limb, 23-30% of 
them occurred after three years of the initial amputation and 51% after five years (Braddeley, 
1965).  Larsson et al. (1998) indicated that the probability rates of re-amputation were 14%, 
30% and 49% at one, three and five years, respectively. As major amputations are usually 
determined by Peripheral Arterial Disease which is progressive in nature in most cases, it 
follows that peripheral arterial disease extended to the healthy areas of the limbs, causing re-
amputation of the opposite side to the initial amputation (Izumi et al. 2006).  
2.9.7 Failed revascularization and lower limb amputation 
Revascularisation techniques are used to prevent/delay lower limb amputations. Popliteal to 
plantar arch vein graft bypasses had a high success rate of about 80%, thus promoting the 
application of vascular reconstruction whenever possible as a method of avoiding amputation 
(Fichelle, 2011). However, in some cases, it has been possible to prevent limb loss in patients 
with diabetes mellitus by improving peripheral blood circulation in the affected tibial or 
peroneal arteries through distal revascularization surgical procedures (Verhelst et al. 1997). 
Nevertheless, as indicated by Shaehan et al. (2005), the rate of limb loss was considerably high 
among patients who had undergone vascular reconstruction prior to amputation.  It has been 
described that critical limb ischaemia has a three-year limb loss rate of 40% with conservative 
therapy including revascularization techniques (Albers et al. 1992). In the majority of the cases, 
the three-year bypass rates of calf arteries varied from 40% for prosthetic bypasses to 85% for 
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saphenous bypasses (Vraux et al. 2006). However, there are many limiting factors to bypass 
grafts success including the occurrence of infection around the area targeted for intervention 
and failure of revascularization techniques itself prompting the patient to undergo a lower limb 
amputation. 
2.9.8 Nutritional status and lower limb amputation 
Adequate nutrition should be integrated into the injury treatment as it is vital for the proper 
healing of the wounds. Healing may be slowed down, or the wound can relapse and the whole 
wound treatment can be put in jeopardy if nutrition is inadequate (Vaneau et al. 2007). Improper 
nutrition can affect the generation of fibroblasts, damage neo-vascularisation, and reduce 
cellular and humoral immunity. The metabolic requirements in the healing process are high and 
patients with malnutrition are unable to cope with this (Harding et al. 2002). For an amputation 
to heal, the patient should have an acceptable nutritional status, including a serum albumin 
level of at least 2.5 g/dL (Pinzur et al. 2008). 
2.9.9 Infection and lower limb amputation 
Diabetics have a 25% chance of developing foot ulcers during their lifetime (Singh, 2005) and 
more than 50% of patients with diabetes mellitus develop infections (Lipsky, 2004). In 
particular, infections caused by diabetic foot ulcers sometimes determine amputation 
(Bowering, 2001). Infection can also develop as secondary to autonomic peripheral neuropathy 
resulting in the malfunctioning of the sweat glands; consequently, the skin becomes dry and 
cracked, enabling bacterial invasion (Clayton et al. 2009). However, amputation is only used 
as a last resort when the infected ulcers are life threatening or are resistant to any other types 
of treatment (Philbin, 2006). 
As noted by Thomas-Ramoutar et al. (2010), osteomyelitis – the infection of the bone tissue – 
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is usually the final stage, leaving no other option except an amputation of the limb in the 
majority of cases (Lavery et al. 2006). Osteomyelitis is a significant risk factor for leg 
amputation as it has a high prevalence rate among patients with diabetic foot disease (Centres 
for Disease Control and Prevention, 2005). The strain generated by the high morbidity and 
mortality rates of leg injuries in patients with diabetes mellitus, as well as their high treatment 
cost, is further increased by the implications of amputations carried out as a result of 
osteomyelitis (Thomas-Ramoutar et al. 2010). 
2.9.10 Leg ulcers and lower limb amputation 
History of ulceration in the lower limb increases the risk of amputation (Adler et al. 1999). 
Newly formed ulcers can rapidly expand, increasing the risk of limb loss. It has been shown 
that there is a direct causal relationship between formation of diabetic ulcers and amputation 
in almost 85% of cases (Reiber et al. 1999). Deep ulceration with uncontrolled infection in 
patients with diabetes mellitus complicated by peripheral vascular disease generally results in 
a lower-limb amputation (Pino et al. 2011).  
A high-grade leg ulcer of Wagner classification (grades 3) significantly multiplies the chances 
of a lower limb amputation (Sun et al. 2011). According to Boulton (2001), the Wagner grade 
is directly proportional to the probability of an amputation. However, several researchers have 
criticized the system, citing that it fails to take into account the influence of ischaemia or 
infection and instead puts too much emphasis on injury depth and tissue condition (Frykberg. 
2002; Boulton et al. 2008). 
2.9.10.1 Diabetic foot ulcer 
2.9.10.2 Introduction 
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Diabetic foot ulcer is a widespread and debilitating complication of diabetes mellitus, which 
often results in limb loss. Moreover, it is also associated with a high mortality rate as well as 
recurrence of unhealed ulcers. In the United Kingdom, majority of patients with diabetes 
mellitus undergo amputation due to diabetic foot ulcers, which constitute the main reason for 
non-traumatic limb amputation. The procedure is usually carried out above the ankle or within 
the foot. As stressed by Reiber et al. (1999), left undiagnosed or untreated, diabetic foot 
problems lead to a higher morbidity and mortality. 
2.9.10.3 Predisposing factors for diabetic foot ulcer 
Diabetic foot ulcer is mainly brought about by the three major factors of vasculopathy, 
peripheral neuropathy and predisposition to infection, but additional risk factors also contribute 
to its development (Frykberg, 1991; Sanders et al. 2010). To successfully manage diabetic foot 
problems and amputation prevention, it is necessary to detect these risk factors early on. 
Some of the risk factors for a diabetic foot ulcer include diabetic peripheral neuropathy, 
ischaemia due to PAD, duration of diabetes mellitus, control of diabetes mellitus and foot ulcer, 
past history of foot ulceration. 
2.9.10.4 Natural history of diabetic foot 
The treatment of diabetic foot ulcers requires knowledge of the natural history of the diabetic 
foot. Although all aspects of foot disease are considered, the central event is the development 
of the foot ulcer in stage 3, which calls for immediate and aggressive treatment. The 
management of diabetic foot lesions requires a multidisciplinary effort in order to effectively 
deal with the mechanical, wound, microbiological, vascular, metabolic and educational 
elements. The natural history of diabetic foot comprises five stages (Edmonds, 2008): 
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Stage 1 - Normal foot 
Stage 2 - High risk foot 
Stage 3 - Ulcerated foot  
Stage 4 - Infected foot  
Stage 5 - Necrotic foot  
2.9.10.4.1 Normal foot 
It is imperative for individuals with diabetes mellitus to undergo annual screening for the 
detection of risk factors for foot ulcer, such as peripheral neuropathy, ischaemia, deformity, 
callus and swelling. If these are present, then the foot is at risk, otherwise it is normal. 
2.9.10.4.2 Diabetic foot at risk 
According to NICE guidelines 2015, when examining the feet of a person with diabetes 
mellitus, the following risk factors should be looked out for: peripheral neuropathy (use a 10-
g monofilament as part of a foot sensory examination), limb ischaemia, ulceration, callus, 
infection and/or inflammation, deformity and gangrene. 
The NICE guideline (2015) classifies the foot in three categories based on the number of risk 
factors, namely; 
 Low risk: no risk factors present except callus alone. 
 Moderate risk: with one risk factor present. 
 High risk: with more than one risk factor present or history of previous ulceration or 
previous amputation or on renal replacement therapy 
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The active foot problems that should be checked include ulceration, spreading infection, critical 
limb ischaemia, gangrene, possibility of acute Charcot arthropathy, or unaccountable increased 
foot warmth, redness and swelling accompanied or unaccompanied by pain. 
2.9.10.4.3 Ulcerated diabetic foot 
The development of diabetic foot ulcer is life changing for a diabetic patient because it signals 
an increase in disease severity and occurrence of comorbidities. The wound can worsen quickly 
if it is not treatment early and effectively, and could lead to an amputation of the affected limb 
(Kerr, 2012). 
Two types of diabetic foot ulcers have been identified by Edmonds (2006), namely, neuropathic 
ulcers associated with neuropathic feet, and neuroischaemic ulcers occurring in feet with 
ischaemia often related to peripheral neuropathy. Ulcers secondary to ischaemia only occur in 
up to 15 % of cases (International Diabetes Federation Clinical Guidelines, 2012). 
The neuropathic foot is characterised by warmth and good perfusion with palpable pulses, 
which reduces sweating, causing the skin to become dry and likely to crack. The plantar side 
of the foot, beneath the heads of the metatarsals, and the plantar side of the toes are the primary 
locations for the development of neuropathic ulcers. As noted by Frykberg et al. (2006), 
ulceration is mainly caused by repetitive gait mechanical forces, which lead to the formation 
of the major lesions preceding neuropathic foot ulcers, namely, calluses. If it reaches excessive 
thickness, the callus will put pressure on the underlying soft tissues, leading to ulceration.  
The neuroischaemic foot lacks warmth and pulses, whereas the skin is thin, lustrous and 
hairless. The subcutaneous tissue becomes atrophic, while peripheral neuropathy may avert 
periodic claudication and rest pain. The foot edges are the main location of occurrence of 
neuroischaemic ulcers, particularly the medial surface of the first metatarsophalangeal joint 
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and over the lateral part of the fifth metatarsophalangeal joint (Edmonds, 2006). Furthermore, 
the tips of toes and underneath excessively thick toenails are also commonly noted areas of 
development of ulcers. Almost half of all the foot ulcers are ischaemic ulcers (Prompers et al. 
2007). 
2.9.10.4.4 Infected diabetic foot  
A crucial stage of evaluation is the detection of infection in individuals suffering from diabetic 
foot ulcers, although this is far from being an easy task. The importance of this cannot be 
emphasised enough, enabling the treatment of a minor infection before it degenerates into a 
severe one that frequently requires amputation (Lipsky et al. 2012). According to the statistics 
gathered by Wu et al. (2007), infection develops in around 56% of cases of diabetic foot ulcers, 
while amputation is necessary in around 20% of cases of diabetes mellitus associated with foot 
infection. However, almost 50% of patients do not exhibit the common symptoms of infection 
and inflammation (e.g. redness, heat and swelling), because arterial insufficiency often occurs 
alongside peripheral neuropathy. Consequently, as suggested by Edmonds et al. (2004), less 
apparent, ‘secondary’ indicators of infection, such as friable granulation tissue, wound 
undermining, bad smells, and wound exudates, should be looked out for. 
2.9.10.4.5 Necrotic diabetic foot 
Developing because of infection, ischaemia or both, necrosis can have severe consequences 
and can lead to limb loss (Ricco et al. 2013). Necrosis is managed differently, according to 
whether it is wet or dry. In the neuropathic foot, necrosis starts off as wet and in most cases, it 
is caused by septic arteritis that accompanies soft tissue infection, a complication of a digital 
or metatarsal ulcer. A septic thrombus frequently blocks the arterial lumen. In the 
neuroischaemic foot, by contrast, necrosis can be either wet or dry (Lepäntalo et al. 2011). Dry 
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necrosis in the neuroischaemic foot occurs in association with a significant decrease in arterial 
perfusion (Edmonds et al. 2008). Septic arteritis, underpinned by large vessel disease in the 
lower extremity, is also a widely encountered cause of a black toe (Cooney et al. 2011).  
2.9.10.5 Management of non-infected diabetic foot ulcer  
2.9.10.5.1 Conservative management 
2.9.10.5.2 Offloading 
The development of ulcerations is promoted by minor trauma, including recurrent stress and 
footwear-applied pressure (Frykberg et al. 2000). As noted by Armstrong et al. (2001), peak 
plantar pressures are not as high in the rear foot and medial arch as they are in the forefoot. To 
increase treatment efficiency, the pressure that is applied to the wound, particularly in the 
forefoot, must be kept to a minimum. However, the pressure on the plantar foot surface can be 
increased by irregular biomechanics arising from restricted joint movement and/or structural 
foot deformity (Cavanagh et al. 2010). Wound healing may be retarded by even light pressure 
(Millington et al. 2000). In addition to deterring healing, pressure that is not relieved enhances 
the likelihood of complications. Known as the offloading “gold standard”, Total Contact 
Casting (TCC) is the most efficient and widely used offloading method employed in 
neuropathic wound care (Armstrong et al. 2001). 
2.9.10.6 Management of an infected foot ulcer  
2.9.10.6.1 General management 
Armstrong et al. (2004) have advocated that wound cleansing after surgical debridement of 
dead tissue is not only complementary to systemic antibiotics, but also minimises the risk of 
recurrent infection. However, the lack of adequate randomised control trials means that no 
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single solution has been agreed upon as being of utmost efficiency with surgeons having a free 
choice about irrigant selection.  
2.9.10.6.2 Role of topical antimicrobials  
Treating heightened wound burden with topical antimicrobial strategies has intensified since 
bacteria have become increasingly resistant to antibiotics (e.g. Staphylococcus aureus exhibits 
resistance to methicillin) or due to other complications (e.g. infection with Clostridium 
difficile) (Chadwick, 2013). As explained by Lipsky et al. (2009), the reason for this 
intensification is that resistance is not promoted by antimicrobial agents applied topically as 
they only offer high local concentrations, without permeating unbroken skin or deeper soft 
tissue. 
2.9.10.6.3 Deep tissue infection  
Broad-spectrum antimicrobial agents should be used to treat deep tissue infection (e.g. 
cellulitis, lymphangitis, septic arthritis, fasciitis) as soon as it is detected, and alternative 
antimicrobial agents should be used if treatment appears to be ineffective, according to 
microbiological results (Scottish Intercollegiate Guidelines Network, 2010). Lipsky et al. 
(2012) recommended parenteral administration of antibiotics for all serious and certain 
moderate infections, while improvement of infection permits switching to oral administration. 
In most cases 1–3 weeks of therapy is sufficient for soft tissue infections. There is no pre-
defined duration of antibiotic therapy, as this is dictated by how severe the infection is and by 
treatment response (Richards et al. 2011). 
2.9.10.7 Osteomyelitis 
Osteomyelitis is the dreaded complication of diabetic foot ulcer and involves deep seated 
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infection affecting the underlying bone (Lipsky et al. 2006). Individuals suffering from 
moderate to severe diabetic foot infection often develop osteomyelitis. The diagnosis of this 
condition during the early phases is not easy to achieve, but its detection and adequate treatment 
is essential for the healing of the wound (Frykberg, 2002). Chronic, extensive and deep wounds 
are susceptible to infection from the underlying bone. Osteomyelitis is signalled by the 
existence of a ‘sausage toe’ or visible bone. Osteomyelitis can be clinically assessed by 
introducing a sterile, blunt metal probe into the ulcer to inspect the hard, gritty feel of the bone 
(Lozano et al. 2010). A high or low probability is respectively indicative of the presence or 
absence of osteomyelitis depending on the results of the probe-to-bone test. 
2.9.10.8 Management of a necrotic diabetic foot ulcer 
Wet necrosis in the neuropathic foot is managed in most cases through surgical debridement, 
since the arterial circulation is generally good (Heikkinen et al. 2007). With regards to the 
neuroischaemic foot, Tannenbaum et al. (1992) recommended the removal of wet necrosis 
when it occurs in conjunction with extensive sepsis, regardless of the existence of pus. If there 
is no immediate threat to the limb and necrosis is contained to one or two toes, intravenous 
antibiotics may be administered to achieve infection control, prior to urgent revascularisation 
associated with digital or ray amputation, which has good chances of healing. However, as 
Schaper (2011) points out, not all patients may be adequate candidates for revascularisation. 
Furthermore, Edmonds et al. (2008) propose that antibiotics should be used to transform wet 
necrosis into dry necrosis, which subsequently may auto-amputate. 
2.10 Criteria for selection of the level of amputation 
After taking the decision to perform the amputation procedure, an appropriate amputation level 
has to be established and the surgical techniques have to be verified for accuracy (Pino et al. 
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2011). It is of the utmost importance to establish the most suitable amputation level for each 
patient as it influences the functioning of the prosthetic limb. To ensure that the patient enjoys 
as independent a lifestyle as possible, the options of bypass surgery vs primary amputation 
have to be weighed carefully. Burgess and Matsen (1981) who are considered pioneers in 
amputation surgery stated that a higher level of amputation resulted in increased disability. 
According to Gottschalk (2002) patients with above knee amputation who have a high energy 
expenditure for walking and taking on a prosthesis is harder for them in comparison to a below 
knee amputee. 
The selection of the level of amputation depends on a number of factors. Based on studies of 
the impact of different methods of incision on the results of leg amputations, Datta et al. (2001) 
and Tisi et al. (2004) added that several aspects have to be taken into consideration, including 
healing rate, possibility of recovery, aspects related to prosthetics, the desires of the patient, 
hospital discharge, as well as the extent of affected tissue in the leg to be amputated. In addition, 
the functioning of the knee and hip, as well as the existence of any joint prostheses, has to be 
taken into account. As noted by Gibson et al. (2001), the decision regarding the amputation 
level has to be a balance between stump healing and optimizing limb function. 
Even though important advancements have been made in the field of vascular surgery, the 
prevalence of amputations carried out due to vascular insufficiency developed in patients with 
diabetes mellitus continues to grow and what is more, many re-amputations are still performed 
because the level of the first amputation was poorly selected. In their examination of 615 cases 
of leg amputations, Wutschert et al. (1997) observed a vast variation in the success rate of 
amputations, from 10% to 50% over the last two decades. Gu, (2004) analysed the scoring 
system created in accordance with the pre-surgery angiogram to determine the condition of the 
run-off vessel in 390 subjects and observed that the failure rate of trans-tibial amputations 
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exhibited a 10-50% variation, with a mean failure rate of 20%. 
In order to ensure as complete a recovery, Malone et al. (1981) recommended a number of 
goals that any amputation treatment should strive to attain: (i) employ peripheral vascular 
reconstruction to ensure minimum limb loss; (ii) quantitative evaluation of the most suitable 
level of amputation; (iii) carry out the most distal type of amputation to enhance the healing 
process; (iv) restore functionality with a prosthetic limb; (v) minimize hospitalization without 
adversely affecting recovery; (vi) cost-efficient treatment; and (vii) multidisciplinary care 
input. The researchers proposed taking into account two essential aspects when deciding where 
the amputation level should be. The first aspect was carrying out the most distal amputation, 
given the circumstances. The second aspect was ensuring that the blood circulation in the 
amputation site is adequate to support the healing process. This would be achieved by carrying 
out the amputation at the most appropriate level. However, Moore (1974) argued that neither 
of these two considerations is feasible for a standard application. Reliance on the first 
consideration determined several unsuccessful healing processes which called for additional 
surgery, endangering the life of the patient. The level of the last amputation could be chosen 
from the beginning, thus avoiding all the complications. The application of the second 
consideration generated an acceptable healing rate, but also a considerable disability which 
affected the restoration of limb function with the use of a prosthetic device. 
Clinical parameters are often used in conjunction with non-invasive techniques of circulation 
to evaluate the extent of arterial blockage. In healthy patients, the peripheral circulation is 
investigated with the use of the Doppler ultrasonography and the ankle-brachial pressure index. 
However, in patients with diabetes mellitus, the accuracy of ankle-brachial pressure index is 
reduced due to the calcification of the walls of the distal arteries, which limits the compressive 
properties of the vessels, creating an artificially high pressure in the ankle (Goss, 1991). Ballard 
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et al. (1995) proposed a different modality of evaluating the healing rate of diabetic foot ulcers 
with potential peripheral ischaemia; namely, to employ photoplethysmography to measure the 
systolic toe pressure or to determine the distal transcutaneous oxygen tension. These two 
methods can only be carried out in specialised diabetic foot centres or vascular laboratories and 
provide a general estimate of the healing rate, prior to the use of angiography.  
A considerable number of studies have been conducted to identify the most suitable technique 
of establishing an adequate amputation level, as well as to weigh the positive and negative 
aspects of more distal amputations (Pinzur, 1993). Nonetheless, the developments in the field 
of prosthetics may increase the functionality of more proximal amputations (Pasquina et al. 
2005). 
2.11 Trends in lower limb amputation 
Vamos et al. (2010) conducted a study on the non-traumatic leg amputations procedures used 
on patients with diabetes mellitus and patients out with diabetes mellitus in the period 1996-
2005, in the UK. The results revealed that a total of about 84,000 patients had undergone 
105,193 amputations, of which about 56,000 were minor and 48,569 were major, during 
101,115 hospitalizations. Four percent of the patients (4078) had undergone concomitant 
bilateral procedures. Similarly, López-de-Andrés et al. (2011) carried out a study on non-
traumatic leg amputations performed on patients with diabetes mellitus and patients without 
diabetes mellitus during the period 2001-2008, in Spain. It was noted that about 90,000 people 
had undergone amputations, of which about 46,000 were minor and about 43,000 were major, 
correlated with about 86,000 discharges. On average about 4% of the patients had undergone 
concomitant bilateral procedures. Another study done by Ikonen et al. (2010) looked at the 
trends of major amputation in Finland in patients with diabetes mellitus over a decade (1997-
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2007). They reported that 9,481 patients had undergone first major amputations during this 
period. Patients with diabetes mellitus accounted for 53.2% of cases (5,047); of these 973 had 
type 1 diabetes mellitus and 4,074 had type 2 diabetes mellitus. In their study, Van-Houtum et 
al. (2004) examined the prevalence rate of leg amputations among patients with diabetes 
mellitus during the period 1991-2000 in the Netherlands and noted that there was a decline in 
the prevalence rate, from 55.0 to 36.3 per 10,000 patients with diabetes mellitus (p<0.05) of 
both sexes (men – 71.8 to 46.1; women – 45.0 to 28.0). 
2.11.1 Trends in lower limb amputation- Patient characteristics 
In the study conducted by Vamos et al. (2010), 40% of the leg amputations carried out during 
the period 1996-2005 were performed on patients with diabetes mellitus, of which 13.5% had 
type 1 diabetes mellitus and 26.5% had type 2 diabetes mellitus. In addition, 66% of patients 
who had undergone amputation were older than 65 years. Male patients with diabetes mellitus 
had a higher prevalence rate of limb amputation than female patients with diabetes mellitus, 
the male-female proportion being two times as large as that of healthy individuals. A 
considerable decline in the average age at which patients of both sexes had undergone 
amputation, from 71.2 to 69.4, was also recorded.  The percentage of men with diabetes 
mellitus, as well as without diabetes mellitus, exhibited a growth from 60% to 67%. The 
prevalence of major limb amputations decreased among patients older than 45 years, but grew 
among patients younger than 44 years. The estimated average age of patients subjected to leg 
amputations was 69.5 years; the average age of patients with type 1 diabetes mellitus was 62.09 
years, that of patients with type 2 diabetes mellitus was 70.7 years, and the average age of 
patients without diabetes mellitus was 70.2 years (López-de-Andrés et al. 2011). According to 
Ikonen et al. (2010), men were more likely to undergo major amputation at a younger age than 
women, with average ages of 69.8 and 78.6 years, respectively. Similarly, patients with diabetes 
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mellitus were more likely to undergo amputation at a younger age than patients without 
diabetes mellitus, with average ages of 73.2 and 75.5 years, respectively. The results obtained 
by Van-Houtum et al. (2004) were also similar; they observed that the average age at which 
patients were first subjected to amputation was 71.5 years, which remained constant throughout 
the period of study. The average age of men subjected to amputation was 69 years, whereas the 
average age of women was 74.3 years. 
Based on the results of the study, Vamos et al. (2010) noted that there was a decline in the 
prevalence rate of major amputations, from 1.3 to 0.7 per 100,000 people in type 1 diabetes 
mellitus and from 7 to 4.9 per 100,000 people without diabetes mellitus. However, in the case 
of type 2 patients with diabetes mellitus, the prevalence rate of leg amputations experienced an 
increase, from 2 to 2.7 per 100,000 people. A similar decline in the prevalence rate of major 
amputations from 0.59 to 0.22 per 100,000 people in type 1 diabetes mellitus was reported by 
López-de-Andrés et al. (2011) as well. The prevalence rate of major limb amputations in 
patients with type 2 diabetes mellitus exhibited a more substantial increase, from 7.12 to 7.47. 
It was estimated that the prevalence rate for first major amputations was 7.4 times higher in 
patients with diabetes mellitus than the patients without diabetes mellitus (Ikonen et al. 2010). 
2.11.2 Trends in lower limb amputation- Hospital stay 
Patients who underwent major amputations as a result of type 1 and type 2 diabetes mellitus, 
as well as other diabetes mellitus-related complications, had a longer period of hospitalization 
than those who underwent amputation as a consequence of other conditions, the average for 
type 1 diabetes mellitus being 36 days, type 2 diabetes mellitus 37 days and non-diabetes 
mellitus 30 days respectively (Vamos et al. 2010). According to López-de-Andrés et al. (2011) 
length of hospital stay was similar among patients undergoing major lower limb amputation. 
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According to Van-Houtum et al. (2004), there has been a decline in the average length of 
hospital stay among both sexes during the period 1991 to 2000, from 45 days (44.4) to 36.2 
days (SD 38.4). 
2.11.3 Trends in lower limb amputation- Mortality rates 
In the UK, during the period 2000 to 2004, there was no substantial increase in the mortality 
rates for the first month and 12 months following the major limb amputation procedures, on 
the contrary, the rates experienced a decline in this period (Vamos et al. 2010). During the 
period 2001 to 2008, the mortality rate in patients with type 1 diabetes mellitus who had 
undergone major amputations experienced only a slight increase, from 8.3% to 8.7%; the 
mortality rate increase was more substantial among patients with type 2 diabetes mellitus, from 
9.7% to 10.1%. Among patients without diabetes mellitus who underwent amputation, the 
mortality rate decreased, from 15.1% to 14% (López-de-Andrés et al. 2011). During the first 
year following the first major amputation, the mortality rate was recorded as being high and 
varying between 27% and 57%, according to the age of the patients. The mortality rate during 
the five years following amputation was 60-90% (Ikonen et al. 2010). 
2.12 Stump healing  
2.12.1 Introduction 
The time and the ability of a patient to walk with a prosthetic limb who has undergone a lower 
limb amputation is determined largely by the process of wound healing (White et al. 1997). In 
addition to the type of treatment, the characteristics of the wound and the condition of the 
patient also influence the stump healing process. Pino et al. (2011) concluded, after reviewing 
19 studies about lower limb amputation in patients with diabetes mellitus, that complete 
preoperative workup is desirable before an amputation and emphasis should be put on 
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evaluation of probable rate of healing, the functioning condition of the limb prior to surgery, 
control or treatment of any additional diseases that the patient might suffer from, as well as 
selection of the level of amputation based on up-to-date techniques. 
2.13 Complications of stump healing 
Lower limb amputation surgery is a major surgery done in patients who have multiple co-
morbidities. A large number of patients with diabetes mellitus are admitted to hospital due to 
lower limb-related problems (Boulton et al. 2005). McIntosh et al. (2009) carried out a 
retrospective study from 2005 to 2007 in 231 patients who underwent major amputations of 
lower extremities. They observed that 7.3% of the patients experienced wound infection, 
phantom pain, poor body image, depression and myocardial infarction following major 
amputation procedures. 
2.13.1 General complications 
Diabetics are two times more likely to experience congestive cardiac failure after amputation 
than patients without diabetes mellitus and the risk for deep vein thrombosis (DVT) is 11% 
(Schofield et al. 2006). 
2.13.2 Local complications 
2.13.2.1 Infection of the stump 
Patients who have undergone amputation can develop severe problems as a result of infection, 
especially if they suffer from diabetes mellitus. The amputated stump frequently becomes 
infected requiring re-amputation (Godoy et al. 2010). The wound infection rates following 
major lower limb amputation have been indicated to vary between 13% and 40%. Methicillin-
resistant Staphylococcus aureus (MRSA) was the most common infection causing organism 
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(Godoy et al. 2009). The morbidity and mortality rates usually increase as a result of MRSA 
infection in vascular patients (Malde et al. 2006). 
As indicated by Ray (2000), patients with diabetes mellitus are five times more predisposed to 
wound infection than patients without diabetes mellitus. The presence of peripheral vascular 
disease increases the risk of infection even further. In a study by Aulivola et al. (2004), infection 
developed in 5.5% of cases of trans-tibial amputations and 6.7% of cases of trans-femoral 
amputations. A wound infection can produce excess discharge and disrupt the suture line 
(Stringfellow et al. 2000). Baxter (2003) indicated that an extensive infection can even generate 
wound rupture and tissue death, requiring additional surgical interventions. According to the 
Infection Surveillance Service in England (Infection Surveillance Service, England 2006), leg 
amputations are associated with the highest risk of infection, because many patients are 
subjected to this procedure as a consequence of severely infected ulcerations. Additionally, 
there are several factors which may increase the likelihood of infection, such as inadequate 
blood circulation, weak immune system and poorly controlled diabetes mellitus. 
2.13.2.2 Pain in the stump 
Pain is a significant problem in lower limb amputation wounds and can be very complex to 
deal with. Incision stump pain and phantom limb pain are the two kinds of pain that patients 
who have undergone amputation suffer from. Stump pain occurs only in the area closely 
surrounding the stump and amputation site (Ellis, 2002). If left untreated, stump pain can 
adversely influence the wound healing process and, consequently, reduces the quality of life of 
the patient. It has been demonstrated that opiates and non-steroidal anti-inflammatory agents 
can alleviate stump pain. 
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2.13.2.3 Tissue necrosis of the stump 
As a large number of amputations are performed due to ischaemia, inadequate circulation in 
the stump area can cause tissue necrosis in the aftermath of the amputation procedure. Dead 
tissue manifests as changes in skin colour, dry gangrene, or wet gangrene. Ray (2000) pointed 
out that changes in skin colour around the incision line can determine wound rupture following 
surgical intervention or tissue death in areas that are not viable a number of weeks after the 
procedure. 
Debridement is a good technique to accelerate wound healing (Harker, 2006). Dead tissue 
present in reduced amounts is left to be removed through the process of autolysis, once it is 
ascertained that it does not pose any danger. But in cases of significant necrosis, wound 
debridement is preferred. A decision must be made as to which method is best suited for the 
removal of dead tissue (Flanagan, 1997). A number of factors have to be taken into 
consideration at the time of making this decision, including convenience, wound type, location, 
and expenses (NICE Guidelines, 2015). The use of sterile maggots, known as larval therapy, is 
one method of debridement that is frequently employed in the United Kingdom. The 
preponderant use of this method is attributed to the fact that it is the only viable option in most 
cases, the presence of co-morbidities preventing surgical revision or the use of other methods 
of stump debridement (Jones et al. 1999).  
2.13.2.4 Stump oedema 
Stump oedema is a common problem faced after lower limb amputation especially in patients 
who are suitable for prosthesis fitting. According to Ray (2000), among the factors believed to 
cause extensive and protracted oedema are pre-existing venous deficiency, generalised fluid 
retention - normally as a result of congestive heart failure, and chronic hypervascularity. The 
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latter is frequently encountered in patients with diabetes mellitus without a severely disrupted 
circulation. 
2.13.2.5 Osteomyelitis   
Osteomyelitis remains a dreaded complication post amputation as it can result in life 
threatening sepsis (Kapoor et al. 2007). The bone in the amputation area can become exposed 
as a consequence of muscle withdrawal over the stump and exposure of the underlying bone 
through the skin (Ray, 2000). A ruptured wound can facilitate bone exposure, as well, 
increasing the risk of osteomyelitis. If the extent of exposed bone is considerable and the 
granulation tissue cannot cover it through secondary healing, surgical intervention is needed.  
2.13.2.6 Haematoma in the stump 
Bale et al. (1997) defined a haematoma as a localised accumulation of blood inside an organ, 
cavity or tissue. A haematoma provides a suitable environment for the development of infection 
and can generate dead space, undermining the suture line and expanding the level of tension in 
the wound (Baxter, 2003). Haematomas usually drain freely and do not necessitate surgery. 
Nevertheless, surgical debridement is employed to remove considerable quantities of 
coagulated blood (Ray, 2000). Morrison et al. (1997) highlighted the fact that there is an 
increased likelihood of haematoma formation under the suture line in the case of wounds 
without drainage, which can lead to the development of tension, oedema and infection. 
Furthermore, the blood circulation can also be affected by the increased tension under the 
suture line, causing wound rupture and tissue death (Partridge, 1998). In order to identify a 
haematoma, efficient evaluation methods should be employed, and the patient must be referred 
if warranted to surgery immediately upon discovery of haematoma. 
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2.13.2.7 Wound dehiscence   
Wound dehiscence usually happens suddenly along the suture line and is accompanied by a 
sharp rise in sero-sanguineous drainage (Heller et al. 2006). It comes to pass in cases where 
the wound is too weak to resist any exterior forces applied to it such as shear or direct trauma 
(Bale et al. 1997). Wound dehiscence also occurs as a result of premature removal of sutures 
or stump oedema which creates tension in the wound. Total dehiscence can potentially 
determine exposure of muscle and bone (Baxter, 2003). 
2.13.2.8 Non-healing requiring a higher level amputation 
Re-amputation refers to a revision of an amputation to a higher level secondary to non-healing 
of the stump. There are a number of factors which may substantiate the need for re-amputation, 
such as stump pain and/or phantom limb pain, delayed stump infection, the formation of 
symptomatic bone spurs, assessment of the skin flap designed to preserve stump length, and 
preparation of the stump for the prosthetic device. Dillingham et al. (2005) observed that re-
amputation is more likely to occur in patients with diabetes mellitus than in patients without 
diabetes mellitus. Reiber (2001) estimated that 9% to 20% of patients with diabetes mellitus 
with an initial leg amputation undergo re-amputation within the first year, and 28% to 51% of 
patients with diabetes mellitus necessitate re-amputation within five years of the original 
amputation. 
2.13.2.9 Death following inability to heal stump 
Criqui et al. (1992) revealed that the likelihood of patients with peripheral vascular disease 
who had undergone lower limb amputation to die because of cardiovascular complications 
within ten years of the amputation is six times higher than that of patients without peripheral 
vascular disease. Lee et al. (1993) reported that the most common cause of death after a lower 
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limb amputation was diabetes mellitus (37.3%), cardiovascular disease (29.1%), and renal 
disease (7.3%). According to Mayfield et al. (2001), the mortality rate among patients with 
renal disease, cardiovascular disease or proximal amputation level was high during the first 12 
months of the procedure. Toursarkissian et al. (2002) indicated that in the period immediately 
following the amputation, after one year and after five years of the procedure, the mortality 
rates were up to 23%, 41% and 80%, respectively.   
The five-year mortality rates associated with above-knee amputation and below-knee 
amputation were estimated at 90% and 70%, respectively (Hambleton et al. 2009). Tentolouris 
et al. (2004) found that a similar percentage (61%) of patients with diabetes mellitus with ages 
between 67 and 76 years who had undergone amputation, were likely to die within 5 years of 
the operation. Heikkinen et al. (2007) reported that, despite being younger, the mortality rate 
among patients with diabetes mellitus with amputations was much higher than the mortality 
rate of patients without diabetes mellitus post amputations. According to Schofield et al. 
(2006), the mortality rate among patients with diabetes mellitus with amputations was 55% 
higher than among patients without diabetes mellitus. One reason for the high mortality rate 
may be the emphasis put on rescuing the limb and amputation being resorted to only when 
revascularization is not feasible. 
2.14 Prediction of stump healing  
2.14.1 Introduction 
The crucial part of any lower limb amputation is the stump healing process, which represents 
the central goal of post-surgery management. Despite the importance attributed to this process, 
a standard set of guidelines regarding efficient healing methods is yet to be formulated. The 
prognosis of the stump healing rate is fraught with considerable difficulties since this process 
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is influenced by a number of factors in addition to blood circulation, including nutrition, 
surgical methods, post-surgery treatment, development of infection, and stump trauma. 
According to Chalmers and Tambyraja (2002), no prediction of stump healing is completely 
accurate. Nawijn et al. (2005) added that a general rule for the prediction of stump healing is 
yet to be formulated. 
2.14.2 Blood markers and factors 
Several factors can influence the healing of a stump after a lower limb amputation as discussed 
below.  
2.14.2.1 Diabetes and glycaemic control (HbA1c) as a marker for lower limb amputation 
As pointed out by Imran et al. (2006), poor diabetes mellitus control increases the likelihood 
of amputation among patients with diabetic foot disease, and underpins vascular and 
neuropathic complications. The association between amputation and elevated glycaemic levels 
is well documented (Brownlee, 2005). Among the causes of vascular insufficiency, diabetes 
mellitus remains the main contributor to the rates of lower limb amputation. HbA1c which 
estimates the average glucose reading in the last 3 months is a useful and effective indicator of 
diabetes mellitus control. Several studies have shown that improving glycaemic control could 
help healing of the diabetic foot ulcer. 
2.14.2.2 Age as a patient marker for lower limb amputation 
According to Gilliver et al. (2007), it is possible that the healing of acute wounds is adversely 
affected by internal aging processes. Ashcroft et al. (1998) have highlighted the impact on age-
related debilitated healing process exhibited by prolonged inflammation, up-regulated protease 
action, and decreased matrix generation. 
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Older patients are more likely to experience limited wound healing as a result of physiological 
changes associated with aging, such as reduced skin elasticity and loss of collagen (Van De 
Kerkhof et al. 1994). In addition, there is a higher risk of infection among older individuals as 
their immunity is reduced. The circulation and oxygenation of the wound can be negatively 
influenced by the presence of other chronic diseases. In their study on older patients suffering 
from diabetes mellitus, Liu et al. (2008) observed that the wound healing process was also 
slowed down by the decrease in the production of transcription factor Hypoxia-Inducible 
Factor 1α. 
2.14.2.3 Gender as a patient marker for lower limb amputation 
Wound healing in older patients is also subject to the influence of sex steroid hormones, which 
have been shown to determine an inflammatory reaction in vivo. This can be kept in control 
with the use of topical and systemic oestrogen therapy, which has also enhanced the rate of 
acute wound healing in both sexes, but more pronounced in older women (Ashcroft et al. 2002). 
Dehydroepiandrosterone has been indicated to have a similar effect, due to the fact that it can 
be converted to oestrogen (Mills et al. 2005). On the other hand, Ashcroft et al. (2002) 
demonstrated that the male produced testosterone hormone slows down endogenous wound 
healing in the elderly. They explained that this is by a direct upregulation of proinflammatory 
cytokine expression by macrophages in response to testosterone. This may be the reason why 
old men exhibit a lower rate of wound healing than old women, as the level of testosterone in 
men may remain quite high despite aging. However, other studies including the one undertaken 
by Demling and Dennis (2000) argued that anabolic agents like oxandrolone which is a 
testosterone analogue improved wound healing in patients with severe burns compared to a 
placebo group (13 ± 3 days to 9 ± 2 days) in a randomized double-blinded placebo-controlled 
study. Labrie et al. (2001) argued that reduced wound healing in older patients is caused by the 
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loss of the protective action of oestrogen and Dehydroepiandrosterone (DHEA), as their levels 
diminish with age. According to Ashcroft et al. (2003), who did extensive research on the role 
of sex hormones on wound healing, the effect of oestrogen on cutaneous wound healing is 
expressed as adjustment of the inflammatory reaction, cytokine activity and matrix generation, 
as well as enhancement of the process of re-epithelialization, angiogenesis and the control of 
proteolysis. Oestrogen attenuates localised inflammation by limiting invasion of inflammatory 
cells and hindering the production of pro-inflammatory cytokines. An increased production of 
elastase was found to stimulate extensive tissue destruction associated with chronic wounds; 
oestrogen restricts neutrophil migration and the production of neutrophil-derived elastase, thus 
reducing extensive tissue destruction (Herrick et al. 1997). Taylor et al. (2002) reported that 
older patients are affected in a proportion of 70% by leg ulcers. Decrease in the levels of 
oestrogen and Dehydroepiandrosterone that accompanies aging may partly account for this 
high incidence of chronic wounds in the elderly.  
2.14.2.4 Kidney function (blood urea, serum creatinine and serum electrolytes) as a 
marker for lower limb amputation 
Acute renal failure results when there is an insult to the kidneys thereby increasing the urea 
and serum creatinine and resulting in a decline in the glomerular filtration rate. It has an impact 
on wound healing in various ways. According to Druml (2005) renal failure is associated with 
fundamental alterations of metabolism and immunocompetence including the induction of a 
pro-oxidative and pro-inflammatory state which results in a poor healing process. Janssen et 
al. (2002) and Okada et al. (2003) conducted molecular analyses on patients with diabetes 
mellitus suffering from renal disease and discovered that inflammation is an integral part of 
diabetic nephropathy, alongside activation of protein kinase C, the production of advanced 
glycation end products and excessive manifestation of the Transforming Growth Factor (TGF)-
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β (Brownlee, 2001). During the period 1996-2005, Akha et al. (2010) examined 244 patients 
with kidney disease and diabetic foot ulcers, observing that the patients who had undergone leg 
amputation had a high serum creatinine. Patients with End Stage Renal Disease secondary to 
diabetes mellitus have a high incidence rate of peripheral neuropathy and peripheral vascular 
disease, both being significant risk factors for leg amputation and frequently accompanied by 
uraemia (Fernando, 1991). The results of the three year study conducted by Eggers et al. (1999) 
on End-Stage Renal Disease patients subjected to amputation revealed that End Stage Renal 
Disease had an adverse effect on the wound healing process and was associated with high rates 
of morbidity and mortality following the amputation procedure. 
2.14.2.5 Infection markers (white cell count, C-reactive protein) as a marker for lower 
limb amputation 
One of the common causes of delayed wound healing is infection of the wound. There are a 
number of factors involved in the development of wound infection, including the number and 
type of bacterial growth, the reaction of the host’s immune system, as well as the virulence and 
synergistic action of the different bacterial species. This infection could be at many levels. If 
the infection spread to the ligaments, tendons and bones, septic thrombosis and gangrene can 
develop independent of macroangiopathy. According to de Godoy et al. (2010), who reviewed 
231 patients retrospectively from 2005 to 2007, infection of stump wound had a high incidence 
rate of up to 40% and caused impaired healing, thus requiring a re-amputation. It has been 
argued that there is a delicate balance between the mechanisms of protection activated by 
phagocyte invasion and the conditions which stimulate exaggerated invasion, which, if 
disrupted, impedes wound healing. Dovi et al. (2003) noted that patients with peripheral 
vascular disease and diabetes mellitus often experience chronic wound recurrence as a result 
of excessive leukocyte invasion which determines extensive production of proteolytic 
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enzymes, oxygen-free radicals and pro-inflammatory cytokines. The wound healing process is 
also slowed down by disruption of leukocyte recruitment (Miller et al. 2006). According to 
Kim et al. (2008) protein-polymorphonuclear leukocyte (EGFP-PMN) and neutrophils’ entry 
into the healing site play a key role in wound closure, which can be compromised in patients 
with diabetes mellitus secondary to intracellular hyperglycaemia. According to Nather et al. 
(2008), the type of organism causing the infection is also important as some pathogens, such 
as Methicillin-resistant Staphylococcus aureus, represented a risk factor for amputation in 
patients older than 60 years. 
Apart from being a marker of inflammation, C-reactive protein plays an essential role in the 
innate immune system of the host and contributes to protection against autoimmunity. It is one 
of the most important proteins that is rapidly produced by hepatocytes during an acute-phase 
response upon stimulation by Interlukin- 6 (IL-6), Tissue Necrotic Factor- α (TNF-α), and 
Interlukin-1- β (IL-1-β) originating at the site of inflammation or pathology (Vermeire et al. 
2004) 
2.14.2.6 Coagulation profile (International Normalised Ratio/Prothrombin Time) as a 
marker for lower limb amputation 
Immediately after a wound is formed, platelet aggregation and haemostasis are activated to 
prevent local haemorrhage, and white blood cells, fibroblasts and blood vessels migrate to the 
wound area to begin the healing process (Laurens et al. 2006). The activity of the blood 
platelets is stimulated by endothelial injury and they form a platelet plug, known as primary 
haemostasis process, which halts bleeding. At the same time, the process of coagulation is 
activated, transforming soluble fibrinogen to a system of insoluble fibrin fibres and providing 
stability to the platelet plug by creating a more extensive system which incorporates platelets 
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through the adherence of fibrin to the activated platelets receptors (Fang et al. 2005). The latter 
produce a series of growth factors such as the platelet-derived growth factor. In turn, the growth 
factors prompt the fibroblasts to generate collagen, glycosaminoglycans and proteoglycans, 
thus advancing the process of healing (Brissett et al. 2003). The fibrin matrix has a role in 
arresting the haemorrhage, as well as in tissue regeneration, leukocyte cell attachment, and the 
movement of endothelial cells during the process of angiogenesis. After a series of cascading 
events, a fibrin clot is formed, and it is soon invaded by the phagocytes. Chemo-attractant 
factors, such as fibrinopeptides, divided from fibrinogen by thrombin, as well as collagen and 
enzymatically active thrombin, control the infiltration of granulocytes and monocytes into the 
wound area. Laurens et al (2006) concluded that fibrinogen and thrombin play an important 
role in wound healing. 
2.14.2.7 Smoking as a marker for lower limb amputation 
Many researchers (Harvey et al. 2002; Hoogendoorn et al. 2002) have argued that smoking 
slows down healing and increases the risk of infection and osteomyelitis. Ueng et al. (1999) 
observed that vascularisation in areas of bone healing is considerably diminished by nicotine, 
thus slowing down healing. According to Castillo et al. (2005) who carried out a retrospective 
multivariate analysis on the impact of smoking on wound healing in lower limb fractures 
concluded that non-smokers were more likely to heal a wound site in comparison to smokers 
(40.1% vs 42.9%). They also added that non-smokers were also less likely to develop infections 
(14.8% vs 24.8%) and osteomyelitis (4.9% vs 17.1%). According to Vanross et al. (2009) 
smoking and delayed mobilisation after lower limb amputation impeded stump healing. The 
detrimental effect of smoking on wound healing is due to the toxic components of cigarettes, 
especially nicotine, carbon monoxide, and hydrogen cyanide. Nicotine, as a vasoconstrictor, 
can contribute to the development of ischaemia and poor wound healing as it decreases 
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cutaneous circulation. It can also increase the likelihood of formation of thrombotic 
microvascular occlusion as it amplifies the adhesive properties of platelets. Silverstein (1992) 
noted that nicotine also decreases the production of erythrocytes, fibroblasts and macrophages. 
Carbon monoxide which is noted to be in higher quantities in smokers, has an adverse effect 
on oxygen transport and metabolic activity, and also prevents the action of enzymes, which is 
required for the oxidative metabolic activities and oxygen transport to the cells. 
2.14.2.8 Cholesterol markers (serum cholesterol, serum Low Density Lipids, serum High 
Density Lipids) as a marker for lower limb amputation 
Physiological and pathological processes, such as angiogenesis, reconstruction of arterial 
lesions and vascular graft healing, depend on endothelial cell migration. Oxidised Low-Density 
Lipoproteins (LDL) stimulate the intracellular development of reactive oxygen factors in 
endothelial cells, which in turn prevents their migration resulting in impaired wound healing 
(van Aalst et al. 2004). According to Rosenbaum et al. (2012), hypercholesterolaemia is 
associated with increased oxidative stress, which disrupts the activity of endothelial and smooth 
muscle cells, impairing the healing process following arterial injury. Cakmak et al. (2009), 
based on a histopathological analysis, argued that the administration of Simvastatin, which 
reduces the level of cholesterol, enhances the healing process by stimulating re-
epithelialization, limiting the development of granuloma and ischaemic necrosis, and reducing 
the spread of inflammation to the muscles. It was noted that abnormal lipid profile not just 
plays a negative role in atherosclerosis but also delays wound healing. 
There are other methods employed to estimate stump healing. As pointed out by Davis et al. 
(2004), most of the methods that have been proposed for estimating the healing rate of stump 
wounds entail the evaluation of the distal circulation. Toe pressures have been demonstrated to 
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correspond to the healing potential of a leg amputation (Ballard et al. 1995). Malone et al. 
(1987) have argued that the ankle brachial pressure index, intra-dermal xenon-133, or absolute 
popliteal artery Doppler systolic pressure values do not generate an accurate prognosis of stump 
wound healing. What is more, Doppler pressures and ratios were demonstrated to be incapable 
of distinguishing between unsuccessfully and successfully healed trans-tibial amputations 
(Wagner et al. 1988). This may be due to the development of arterial media calcification present 
in diabetic vessels, which has a detrimental effect on vessel compliance and the possibility of 
occluding the artery with the use of an external cuff, thus determining an excessively high 
arterial pressure. Pino et al. (2011) recommended increasing transcutaneous oxygen pressure 
while breathing 100% oxygen in a hyperbaric chamber to generate a prognosis of healing rate. 
Similarly, Vanross et al. (2009) recommended the increasing transcutaneous oxygen tension 
(TcPo2), which is a non-invasive method that can provide an effective indication of the 
likelihood of stump healing for the fitting of prosthetic limb in below-knee amputations. 
Another method of estimating stump healing is the tactile evaluation of skin temperature. 
Henderson et al. (1978) observed that the use of thermography could enhance the accuracy of 
determining amputation level in one third of the cases studied. Thermography was employed 
by Spence et al. (1981) as well, who obtained an 80% success rate, which was similar to that 
attained by clinical impression alone. Among all the non-invasive methods that were assessed 
by Wagner et al. (1988), it was proposed that at a temperature of 90°F (32.2°C), the skin 
exhibited the most efficient combination of sensitivity, specificity, accuracy and prognosis. 
These results could be further enhanced by comparing the temperature of the skin to that of the 
surrounding environment.  
As noted by Martinez-Hernandez (1988), an essential component of the wound healing process 
is vascularisation. The suitability of perfusion has been indicated as particularly essential for 
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the healing process (Harker, 2006). The circulation in the wound area is a significant indicator 
of healing. There is no method of evaluating peripheral circulation that has received unanimous 
approval and clinical judgement alone is not enough to generate a prognosis of the healing rate 
of an amputation (Sarin et al. 1991). Angiography was indicated by Solakovic et al. (2008) as 
being suitable for estimating the amputation level. This affirmation was opposed by Huber et 
al. (2003), who argued that angiography is basically a morphological method and despite 
providing abundant anatomical information, it cannot demonstrate functional circulation. 
However, the success of an amputation procedure depends largely on the proper selection of 
the amputation level, in accordance with evaluation of limb perfusion and limb functionality. 
Healing and fitting of prosthetic limb also depend on nutrition, age of the patient, the existence 
of co-morbidities, particularly renal failure, diabetes mellitus and anaemia, as well as on the 
surgical procedures employed (Taylor et al. 2005). Regarding below-knee amputation, there is 
no particular surgical method that has an influence on wound healing, development of 
infection, likelihood of re-amputation or functionality of prosthetic limb (Tisi et al. 2004). 
However, Chen et al. (2008) argued that the use of a suitable surgical procedure, as well as 
post-operative wound care, can enhance wound healing and overcome the effect of the 
unalterable factors such as amputation level, age, and the presence of co-morbidities, including 
End Stage Renal Disease, dementia, and coronary artery disease. The factors identified by 
Eneroth (1999) as having a negative impact on stump healing were smoking, reduced 
haemoglobin and/or haematocrit, inadequate nutrition, diabetes mellitus and no administration 
of prophylactic antibiotics. It has been estimated that a patient has to have at least 1500 
cells/mm lymphocyte count to ensure the successful completion of the stump healing process 
(Ballard et al. 1995). Naidu et al. (2005) suggested that the prognosis of stump healing in 
patients with below-knee amputation can be made based on the existence of microvascular 
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changes, such as thickening of the inner walls and thinning of the medial walls of the arteries. 
Biomarkers provide a dynamic and powerful approach to understanding the spectrum of any 
disease with applications in observational and analytic epidemiology, randomized clinical 
trials, screening and diagnosis and prognosis. A good biomarker is relevant to the study, cost 
effective, easily reproducible, has a high sensitivity and specificity, validity proven towards 
that disease and least prone to measurement errors and bias. The markers used in this study are 
factors that play a role in healing of a diabetic foot ulcer as noted in several studies and play a 
role in the pathophysiological pathways of peripheral vascular disease and diabetes which are 
the main causes for a lower limb amputation surgery.  These biomarkers are easy to use, readily 
available for a surgeon/physician on a day to day basis for decision making, are cost effective 
and do not require any equipment or any expertise to use or interpret. The blood markers used 
are readily available via the laboratory in any hospital setting almost on a daily basis for any 
inpatient who has regular blood check for his illness.  
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3. Methodologies 
3.1 Research design 
This study was a single centre exploratory study. The aim of the study was to evaluate risk 
factors and blood markers in predicting the results of stump healing following a major (above 
knee and below knee) lower limb amputation surgery. This study was divided into two parts, 
namely retrospective and prospective. In the first part, to develop a predictive model, data was 
obtained from patients who underwent a major (above knee and below knee) amputation at the 
Royal Infirmary of Edinburgh. The data collated included 300 lower extremity amputees, who 
underwent amputation (above or below knee) surgery between 2006 and 2009. One hundred 
patients who underwent major (above knee and below knee) amputation surgery between 2010 
and 2011 were included in the prospective part of the study.  This latter data was used to 
validate the model that had been developed from the retrospective data. This method of 
development and validation of prediction model was adopted to estimate the probability of 
developing a particular outcome in the future (which was stump healing in this study) (Collins 
et al. 2011). Predictive tools, such as this model, are not a substitute for clinical assessment but 
are intended to be supplementary and reinforce medical opinion. As reported by Ross et al. 
(2002), prediction models deliver enhanced reliability and accuracy compared to forecasts 
based on subjective evaluations. 
External validation of the predictive performance of a prediction model which is an evaluation 
of a predictive model, in datasets that were not used to develop the model, is critical prior to 
employing it in the clinical setting (Steyerberg et al. 2009). Externally validating the model 
reflects its effectiveness and ability to differentiate between the development and validation 
cohorts. The model’s performance evaluation involves assessing calibration and 
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discrimination. Therefore, the model must be empirically appraised using data separate to that 
which was used to create the model (Steyerberg et al. 2013). This empirical appraisal highlights 
any shortcomings in the statistical models used in developing this predictive model as well as 
gauging the potential for using this model in different clinical settings. 
3.2 Sample size of the retrospective and prospective study 
The purpose of this exploratory research study was to explore associations between lower limb 
stump healing defined as complete closure of the wound adequate to take a prosthesis for 
functional/cosmetic purposes (dependent variable) and biomedical variables (independent 
variables) in predicting stump healing.   
Logistic regression predictive models can be used to help determine the prognosis for stump 
healing (healed/not healed). For a statistical study to be successful and achieve its objectives, 
analysis of the sample size is critical.  For binary logistic regression, effective sample size can 
be estimated by the number of events or non-events (van Houwelingen and le Cessie, 1990). 
In other words, the number of healed/not-healed events can be used to guide the effective 
sample size suitable for logistic regression. 
Vergouwe et al. (2005) recommended that, ideally, at least 100 events and 100 non-events 
should be used to ensure that the external validation studies are accurate. Therefore, a model 
should be developed from a base of no fewer than 100 events and 100 non-events to ensure 
adequacy of power. This recommendation has been based on the observation that samples 
consisting of approximately 100 events were able to identify considerable discrepancies in 
model efficiency in almost 80% of cases. The proportion of events (stump healing rates) varied 
greatly in previous studies and the lowest healing rate was taken in order to have enough 
patients to power the study which was 30% (Dormandy et al. 1999). This would mean that a 
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sample size of 100 patients would provide 30 events and in order to obtain 100 events, a sample 
size of 330 would be needed to adequately power the model. According to Vergouwe et al. 
(2005) statistically significant variations in model performance can be highlighted from an 
approximation of 80% power provided by an initial sample of 100 events. As a generalisation, 
prognostic models tend to be overly optimistic and as such, do not always work well in practice.  
Both the condition of the patient and the model configuration dictate the development and the 
external validity of a model. Prognostic models do not always work well in practice, so it is 
widely recommended that they need to be validated in a new patient dataset (Altman and 
Royston, 2000). The development process of the model and the subsequent new patient set (for 
the prospective study) to which the model is applied contribute to the model’s external 
validation. In this instance, data was collected from 400 patients; 300 patients were recruited 
to develop the model (retrospective study) and 100 for the model validation (prospective study) 
(Stone, 1974). 
3.3 Ethical approval of the retrospective and prospective study 
This study was reviewed and given favorable ethical opinion by the South East Scotland NHS 
Research Ethics Committee, NHS Research and Development and the Queen Margaret 
University Research Ethics Committee (Appendix I). Approval of the Ethics Committee was 
obtained for both the Retrospective and Prospective part of the study. 
3.4 Consent process 
3.4.1 Consent process for the retrospective study 
Consent for the retrospective study was not required as the data collected was anonymised and 
the data collection link was broken. 
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3.4.2 Consent process for the prospective study 
The welfare and security of patients and their information were paramount. In accordance with 
ethical guidelines, participating patients were recruited as volunteers, fully aware that they 
were free to withdraw from the study at any time without reason and without penalizing their 
treatment. To enable patients to make an informed decision about being a participant in the 
study, detailed information was provided to each one (Appendix III) and enough time was given 
for the participants who were interested in the study to reading and understanding the Patient 
information sheet with a subsequent session booked if the participant had any questions about 
the study before giving consent. Patients gave written informed consent to become a participant 
and where this could not be obtained, the patient was excluded from the study (Appendix IV). 
3.5 Retrospective study (development of prognostic model) 
The potential participants were retrospectively purposively chosen by the researcher on the 
basis of the inclusion and exclusion criteria from those who underwent a below or an above 
knee amputation procedure at the Royal Infirmary of Edinburgh. 
3.5.1 Inclusion and exclusion criteria 
3.5.1.1 Inclusion criteria:  
● Patients whose age was 18 years and above. 
● Both genders (male and female) were eligible for the study. 
● Patients who had an amputation at a level of below or above knee for the first time. 
3.5.1.2 Exclusion criteria: 
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● Patients who had a revision of their stump either at the same level or at a higher level. 
● Patients who had a traumatic amputation due to an accident. 
● Patients who had did not have complete information available required for the study. 
Figure 8: Flow diagram showing steps of retrospective study from recruitments of 
subjects to data analysis. 
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A list detailing patients who had undergone above or below knee amputation surgery was 
initially obtained from the Department of Vascular surgery, Royal Infirmary of Edinburgh. To 
recruit patients a selective sampling technique was used. The hospital’s vascular database was 
probed for a retrospective case note review of patients who had received amputation surgery. 
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Case files were obtained from the medical records (Proton® software, and Apex® software) 
for those patients whose amputation surgery was conducted at the Royal Infirmary Edinburgh 
between 2006 and 2009. Analysis of potential participants was undertaken through 
interrogation of the data. Patients' pre-operative assessments, the clinical outcomes of their 
operation and follow up case notes were all utilised to compile a full report on each patient. 
A total of 384 lower limb amputation surgical procedures were performed during the period. 
From these 300 cases were selected who underwent either a below knee or an above knee 
amputation surgery for the first time. Patients were excluded due to incomplete information in 
relation to the stump healing outcomes (n=36) or those who had a revision of their stump either 
at the same level (n=31) (BKA followed by a revision at the same level) or at a higher level 
(n=17) (BKA followed by an AKA). 
To perform the retrospective study, a systematic process was employed; this entailed 
identifying, screening and recruiting participants followed by collecting their data for statistical 
analysis (Figure 8). 
3.6 Predictive measure - stump healing 
Stump healing was defined as the complete painless closure of the wound/stump fit enough to 
take a prosthesis for functional purposes (Tisi et al. 2008). It was determined at the end of 12 
weeks from the day of lower limb amputation surgery by the vascular consultant in the Royal 
Infirmary of Edinburgh (Vigier et al. 1999; Wong et al. 2000; Nawijn et al. 2005). 
3.7 Data collection 
A comprehensive review of the patient’s inpatient and outpatient records including the medical 
and surgical history was performed. The relevant demographic and clinical data collected from 
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all medical and surgical consultations was examined and entered into an Excel spreadsheet 
(Microsoft, USA).  The Principal investigator was aware about the identity of the patients in 
order to access the patients’ notes. All data was collected as per the Caldicott principles.  
3.8 Prospective study (validation of prognostic model) 
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Figure 9. Flow diagram showing steps of prospective study from identification   of 
subjects to data analysis. 
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The prospective study employed the same systematic process as used for the retrospective 
study, i.e. the identification, screening and recruitment of participants was followed by 
subjecting the collected data to statistical analysis using suitable statistical tests. (Figure 9). 
3.8.1 Inclusion and Exclusion criteria 
3.8.1.1 Inclusion criteria 
• Aged 18 years and older.  
• Both genders (male/female) were eligible for the study. 
• A planned procedure for first major (below or above knee) lower limb amputation.  
•  Patients who could manage a follow up period for at least three months. 
• Ability to give informed consent. 
3.8.1.2 Exclusion criteria 
• Patient who had a revision of their stump either at the same level or at a higher level. 
• Participant’s refusal. 
• Patients who had a traumatic amputation due to an accident. 
3.8.2 Recruitment of participants 
The secondary objective of the study was to validate the regression model by recently treated 
patients who had a lower limb amputation from 2010 to 2011. The potential participants were 
selected by the consultant vascular surgeon based on the inclusion and exclusion criteria from 
the vascular clinic and the vascular ward in the Department of Vascular Surgery at the Royal 
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Infirmary of Edinburgh.  
The Consultant then introduced the Principal investigator who was the PhD student who was 
conducting the study to the potential participants who were then invited by the Principal 
Investigator to take part in the research when they attended the vascular clinic or when they 
were admitted into the vascular ward. Patients who showed an interest were given an 
information pack which contained patient information sheet and the consent form. They were 
given at least 24 hours to read the information pack. Those interested in participating then 
contacted the principal investigator. The principal investigator then went through the patient 
information sheet and the consent form in detail with the participant. The patient information 
sheet included the contact details of the researcher and an independent advisor if the potential 
participants wished to know further details about the study (See Appendix III). Patients who 
had a revision of their stump or a higher level amputation within 12 weeks of the first surgery 
were excluded from the study. 
According to Stone, (1974) in regression analysis the sample size for model validation should 
be ideally one third of the sample size for model development. The purpose of the recruitment 
process for the prospective study was to recruit 100 patients. A total of 145 patients were 
approached to take part in this study by the principle investigator for prospective clinical 
research who had undergone below or above lower limb amputation surgery at the Royal 
Infirmary of Edinburgh between the years 2010 and 2011 in order to recruit 100 patients. Of 
these, 17 did not want to participate and 18 were excluded as they did not meet the inclusion 
criteria; 10 participants subsequently dropped out at follow-up. Personal commitments were 
given as the prime reason for not wanting to take part. Exclusion criteria included the inability 
to give informed consent (n=4) (non-native English speakers) and second major amputation of 
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the same leg (n=14) (revision at the same level of the initial amputation or at a higher level). A 
total of 100 patients were recruited into the prospective study. 
3.8.3 Data collection 
After taking informed consent, patient assessments were conducted at least 24 hours prior to 
their surgery.  For this pragmatic study, and to ensure the validity of the data, the researcher 
was present throughout the process and all procedures were undertaken by NHS-accredited 
staff. The researcher additionally ensured that standard NHS operating procedures were utilised 
and that the collection and use of patient data was fully compliant with the relevant NHS 
regulations. The following paragraphs describe the process.  
Before, during and after each assessment, every participant was given the opportunity to ask 
questions and raise their issues. The following baseline demographic information was 
collected: age, gender, amputation history, risk factors including, diabetes mellitus, 
hypertension and smoker status. Blood samples of approximately 10 ml were collected by 
venipuncture of the cubital vein; the venipuncture procedure was conducted by NHS staff as a 
regular procedure for pre-operative tests. The timing of the preoperative blood samples was the 
same for the retrospective and prospective study (0900). The samples were analysed for 
coagulation profile, C-reactive protein, full blood count, HbA1C, kidney function and lipid 
profile. For the benefit of the coagulation profile, the blood was collected into a blue bottle 
(Figure 10), as these contain buffered sodium citrate, which reversibly bind to calcium ions in 
the blood; this disrupts the clotting cascade. Transfusion blood products are also treated with 
sodium citrate preserving the blood in an uncoagulated state. 
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Figure 10. Blue bottle used for haematological tests 
 
Yellow bottles, as depicted in Figure 11, were used to collect blood for serum analysis of 
creatinine, electrolytes (sodium and potassium), lipids (TC, HDL and TG) and urea. This bottle 
is known in the laboratory as the serum separating tube. Yellow bottles contain silica particles 
that activate clotting and an inert polymer serum separating gel to facilitate easy centrifugal 
separation of serum. 
Patients were seen at 12 weeks to assess for stump healing by the vascular surgeon according 
to the standard protocol which involved assessment of the stump including the suture line, 
stump oedema and skin around the stump. This was done at the vascular outpatient clinic in the 
Royal Infirmary of Edinburgh.  
 
  
Figure 11. Yellow bottle use for kidney function test and lipid profile 
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3.9 Statistical analysis 
For the prognostic model development, a total of 300 participants were recruited with the 
resultant demographic data yielding descriptive statistics including both mean and standard 
deviation.  Univariate logistical regression was employed to determine the relationship between 
independent and dependent variables, noting in particular that reliance on univariate statistical 
significance may produce indiscrimination through the pre-selection of predictors. As such, in 
place of depending solely on statistical pre-selection, expert opinion and previous research 
offers a superior alternative for the first selection of predictors. 
From a set of 300 patient’s data, the following set of clinically important predictors of stump 
healing were identified: 
Kidney Function Test 
 Blood Urea  
 Creatinine  
Coagulation Test 
 Prothrombin Time (PT)  
 International Normalization Ratio (INR)  
Lipid Profile 
 Total Cholesterol (TC)   
 Triglyceride (TG)  
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 Low Density Lipoprotein (LDL)  
 High Density Lipoprotein (HDL)  
Electrolytes   
 Serum Sodium  
 Serum Potassium 
Inflammatory markers  
 White Cell Count (WCC)  
 C-reactive protein (CRP) 
Glycaemic control 
 Glycosylated Haemoglobin (HbA1c) 
In addition to these biomedical markers demographic data were analysed.  
 Age 
 Gender 
 Type of Amputation 
 Diabetic status 
 Hypertension  
 Smoking status (ever versus never)  
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Statistical analyses were conducted using SPSS (IBM, SPSS Statistics 20.0) and data are 
expressed as the mean and 95% Confidence Interval (CI). At first, the model only considered 
individual predictor and the outcome measure to explore the relationship between these two 
variables. This was followed by univariate analysis of categorical variables using a Chi square 
test to establish which of the risk factors differed significantly between stumps that healed and 
the ones which did not. Univariable logistic regression was used to explore the relationship 
between the independent variables and stump healing (dependent variable). A logistic 
regression model neither assumes the linearity in the association between the risk factors and 
the response variable, nor does it require normally distributed variables. For a variable to be 
entered into the model, a p value of 0.25 or less was required. Only those predictors with a p-
value of 0.25 or less were determined to be relevant and included in the next stage. 
Regression model was used for the prediction of stump healing. There are different types of 
regression modelling.  
 Linear Regression (if outcome variable is continuous) 
 Multinomial Logistic Regression (if outcome variable is more than two) 
 Logistic Regression (if outcome variable is binary or dichotomous) 
 Cox regression model (can be used for a “time to event” model) 
The relationship between a dichotomous (categorical) dependent variable and dichotomous 
(metric/categorical) independent variable was analysed by employing logistic regression, since 
this method, in terms of the independent variables, makes no prior supposition of normality, 
linearity or homogeneity of variance. As discriminant analysis would require qualification of 
these assumptions which the data could not satisfy, logistic regression was the superior method 
of choice.  
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The equation for simple linear regression is: 
     𝑌 = 𝑎 + 𝑏𝑥 + 𝑒𝑖 
Where y-outcome, a- intercept, b- slope related to x (explanatory variable), e- error term or 
random noise. 
𝑌 = 𝑙𝑜𝑔𝑖𝑡 (𝑝) = 𝑎 + 𝑏𝑥 + 𝑒𝑖 
log (
𝑝
1 − 𝑝
) = 𝑎 + 𝑏𝑥 + 𝑒𝑖 
The regression equation estimated by logistic regression is given by: 
log (
𝑝
1 − 𝑝
) =  𝛽0 + 𝛽1𝑋1 + 𝛽2𝑋2+. . . . . . +𝛽𝑛𝑋𝑛 
Where p is the probability of event and effect of independent variable (x) increase or decrease 
risk of this event. β0 is the intercept and β1 till βn are the regression coefficients. 
  
3.9.1 Performance of prognostic model 
A method to assess the fit of a logistic regression model is by comparing the expected and 
observed numbers of positives for different subgroups of the data. In a robust model, the 
observed and expected numbers are sufficiently close. The Hosmer-Lemeshow test was used 
to assess the accuracy of the predictive model by comparing the predicted probabilities against 
the observed probabilities. 
To establish the discriminatory power of the model a Receiver Operating Characteristic Curve 
(ROC) was generated. This was used to determine the model’s effectiveness in differentiating 
between a healed and non-healed stump. The range of Receiver Operating Characteristic Curve 
ranges from 0 to 1. A value of 0.5 means that the model has no discrimination power. The 
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discrimination power increases as the value increases from 0.5 to 1. The larger the Area Under 
the Curve, the better the diagnostic test. If the area is 1.0, the test is “ideal” because it achieves 
100% sensitivity and 100% specificity. If the Area Under the Curve is 0.5, then you have a test 
that has effectively 50% sensitivity and 50% specificity, which is no better than flipping a coin 
(Brubaker, 2008). The area under the Receiver Operating Curve for a prognostic model is 
typically between 0.6 and 0.85 (Royston et al. 2009). Sensitivity and specificity analysis were 
reported. Sensitivity is the proportion of the true positive outcomes (for example, truly diseased 
subjects) that are predicted to be positive. Specificity is the proportion of the true negative 
outcomes (for example, truly disease-free subjects) that are predicted to be negative. 
3.9.2 Validation of the developed model 
 As Vergouwe et al. (2005) indicated, predictive logistic regression models are important tools 
to provide estimates of patient outcome probabilities. Hence model validation is the most 
important step of developing a prediction rule. For this purpose, 100 participants were 
recruited.  
In general, there are two forms of validation. The first type of validation also called internal 
validation is performed in the context of an individual study, for example, by splitting the study 
data set into one data set to build the model (development set) and one data set to test 
performance (test set, also called the validation set). The appealing feature of internal validation 
is its convenience, as it does not require collection of data beyond the original study. The 
second form of validation which is the external validation utilises a different data set provided 
by a different study circumvents these issues. Validation on heterogeneous external data sets 
allows for evaluation of the generalizability of the risk prediction tool to wider populations 
than originally reported. In this study, the latter approach was taken for validation. 
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A total of 100 participants were recruited for the model validation phase. A model precisely 
predicting probabilities for patients in the retrospective data would not guarantee accurate 
predictions for new patients from related populations, for example patients treated not long ago 
or patients from a different centre, therefore, the performance of prognostic models needed to 
be verified in the newly treated patient group (external validation) (Harrell et al. 1996). 
External validation was performed on those data obtained from an independent set of 
consecutive patients who had undergone vascular access surgery using the final development 
model. Predicted probabilities for individual patients in the validation set were calculated. 
Model discrimination was assessed by Receiver Operating Characteristic Curve analysis. 
Evaluation of calibration is important if model predictions are used for making clinical 
decisions. A calibration plot formed by the Hosmer-Lemeshow test, which illustrates how the 
observed and expected proportions compare, assessed the calibration of the final model for 
stump healing.  
3.9.3 Data protection 
Throughout the duration of the study, the information collected from patients was securely 
stored in a safe place in the vascular department of the Royal Infirmary of Edinburgh and 
accessibility was restricted to research team members only. Each patient was issued with a 
unique identification number, which corresponded to his or her personal details, information 
and consent forms. This same number was used in all stages of the study to ensure 
confidentiality and to protect identifying personal details. Access to the link anonymised data 
collected by the principal investigator throughout the study was only available to the key 
investigators and associated collaborators. The procedure detailed above maintained the duty 
of confidence to the participants throughout the study. Collected data was stored on a password-
protected laptop and back-up discs. Data storage and subsequent destruction was in accordance 
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with the Data Protection Act 1998. Patients’ confidentiality was paramount during the 
collection of the events and the subsequent submission of manuscripts for publication. The data 
files included only basic demographic data such as participant number, age, sex etc. Written 
documentation and data were stored in a paper format in the participants’ medical notes as per 
normal clinical practice. As per the health care records policy, these records will be destroyed 
after 5 years following discharge. 
3.9.4 Indemnity 
All participants were informed about the procedure followed during the study. They were also 
informed about any possible harm they might suffer and how it would be addressed. If patients 
had any concern about any aspect of this study, they were given the contact details of the 
principal researcher. They were also provided with the principal investigator’s contact details 
if they had any questions. Alternatively, they could also contact the independent advisor who 
was aware about the project but was not directly involved in this research (contact details given) 
or the NHS complaints team, if they wished to complain formally. Further information could 
be viewed in Appendix VIII. 
3.10 Validity and reliability  
3.10.1 Measurement of blood pressure 
Measuring blood pressure (BP) in the arm (brachial artery) provides an accurate representation 
of the corresponding pressure in the aorta. The BP was measured using sphygmomanometer 
with a stethoscope with a standard procedure. The measurement of the blood pressure was 
carried out after the participants had relaxed for ten minutes in a room with an average room 
temperature of 20-25-degree Celsius temperature, the cuff of the sphygmomanometer being 
positioned on the left arm of the participants, 2-3 cm above the cephalic vein. For an accurate 
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measurement, the participants were requested to position their arm on a flat surface in such a 
way that the cuff was aligned to the heart; additionally, the size of the cuff was checked to 
ensure that it was adequate for each participant, as shown below: 
 Small Cuff (16-24cm) 
 Medium Cuff (24 - 36cm) 
 Large Cuff (26 - 45cm) 
 Extra Large Cuff (42 - 60cm) 
In accordance with Beevers et al. (2001) and Perloff et al. (1993), the procedure was explained 
to the participants in order to provide reassurance in the event that their blood pressure was 
initially high. 
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4.1 Retrospective study analysis  
4.1.1 Descriptive statistics of the retrospective group 
A total of three hundred patient’s data who underwent a major lower extremity amputation 
operation between the years 2006 and 2009 at the Royal Infirmary of Edinburgh were identified 
after a search of the vascular unit electronic patient record (Proton® and Apex® software) at 
the Royal Infirmary of Edinburgh. Two hundred and fourteen (71.3%) of the 300 identified 
patients were male with 86 being females (28.7%).  
Ages of the participants ranged from 34 to 97 years, with a mean age of 71.16 ± 14.5 years. 
Percentage of patients found to have diabetes mellitus was 46.0% (n=138) hypertension 94.3% 
(n=283) and 81.7% (n=245) were smokers. Percentage of patients who underwent an above 
knee amputation was 53.7% (n=161) with 46.3% (n=139) undergoing a below knee 
amputation. Seventy one percent (n=214) were noted to be males. Percentage of patients found 
to have an abnormal serum potassium and abnormal serum sodium were 16% (n=48) and 
10.7% (n=32) respectively. Twenty two percent (n=68) and 48.7% (n=125) of patients were 
found to have abnormal serum creatinine and serum urea respectively. Among the subjects 
71.3% (n=62) were noted to have poor diabetes control. Fifty nine percent (n=179) had 
abnormal white cell count.  Healing of the stump as defined was achieved in sixty three percent 
(n=189) of patients. General distribution of independent variables is shown in Table 3. 
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Table 3: Characteristics of independent predictive variables for lower limb stump 
healing in the retrospective group 
 
Clinical characteristics  (n=300) % Total 
Gender 
Male 
Female 
Amputation 
AKA 
BKA 
Age 
 
214 
86 
 
161 
139 
 
71.3 
28.7 
 
53.7 
46.3 
≤50 yrs. 13 4.3 
>50 yrs. 287 95.7 
diabetes mellitus   
No 162 54 
Yes 
Hypertension(mm/Hg) 
No 
Yes 
138 
 
17 
283 
46 
 
5.7 
94.3 
Smoker   
No 55 18.3 
Yes 245 81.7 
K+ (3.6-5 mmol/L)   
Abnormal 48 16 
Normal 252 84 
Na+ (135-145 mmol/L)   
Abnormal 32 10.7 
Normal 268 89.3 
Creatinine (60-120 
µmol/L) 
  
Abnormal 68 22.7 
Normal 232 77.3 
Urea (2.5-6.6 mmol/L)   
Abnormal 125 48.7 
Normal 175 58.3 
CRP   
≤ 5 15 5.1 
> 5 282 94.9 
WCC (4-11x10/l)   
Abnormal 179 59.5 
Normal 121 40.5 
PT (seconds)   
≤13.5 173 57.7 
>13.5 127 42.3 
INR   
≤1.2 206 68.7 
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>1.2 94 31.3 
TC (mmol/L)   
≤ 5 249 84.4 
>5 46 15.6 
TG (mmol/L)   
≤ 2.1 239 82.4 
>2.1 51 17.6 
HDL(mmol/L)    
≤ 1.1 178 61.6 
>1.1 
HbA1c (%) 
≤6.5 
6.5-7.5 
>7.5 
112 
 
5 
20 
62 
38.4 
 
5.7 
23.0 
71.3 
 
Table 3: Independent patient factors and blood markers distribution in the subgroups. Data 
values are expressed as number and percentage (%). n- number of participant, PVD-Peripheral 
Vascular Disease, diabetes mellitus-diabetes mellitus, HTN-Hypertension, CRP- C reactive 
protein, WCC- white cell count, K-Potassium, Na-Sodium, PT-Prothrombin time, INR- 
International normalization ratio, TC- Total Cholesterol, TG- Triglyceride, HDL- High density 
lipoprotein. The normal ranges for the blood markers were adopted from the RIE laboratory 
protocols as mentioned in the appendix.  
 
4.1.2 Association between gender and stump healing in the retrospective group 
Two hundred and fourteen (71.3%) of the total patients (300) were men, and eighty six (28.7%) 
women. The figure 12 shows the association between stump healing and gender in patients who 
underwent lower limb amputation. Out of two hundred and fourteen male patients, one hundred 
and forty one had a healed lower limb stump (65.9%) and seventy three patients’ stumps failed 
to heal (34.1%). Male gender was noted to be associated with stump healing (p=0.001⃰). Among 
the female patients, forty eight patients had healed their stumps out of a total of eight six 
(55.8%) and failure to heal was noted in 44.4% (n=38). No significant (p=0.281) difference 
was observed between the healed and non-healed stump among the female gender. The table 
below shows the gender wise distribution of the number of patients who healed their stumps. 
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Stump healing was not found to be associated (p=0.102) with male and female gender (Table 
4). 
Table 4: Gender and stump healing in the retrospective group 
 
 Healed Not Healed Total Chi-Square P value 
Female 48 32 86   
Male 141 73 214 2.671 0.102 
Total 189 111 300   
Table 4: The distribution and association between stump healing (healed or not healed) and 
gender (male or female).  p=0.102 indicating that stump healing was independent of the gender.  
 
 
 
Figure 12: Stump healing in males and females in the retrospective group 
 
 
Figure 12 showing association between success and failure of stump healing among male and 
female gender who underwent lower limb amputation. Numbers written on top of the bar 
indicate the percentage. p value for males and female gender were p=0.001⃰ and p=0.281 
respectively. 
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4.1.3 Association between type of amputation and stump healing in the retrospective 
group 
Two types of lower limb amputation were considered, that is, above knee and below knee. The 
figure 13 shows the association between stump healing and the type of amputation in patients 
who underwent lower limb amputation. Out of three hundred patients, one hundred and sixty 
one (53.7%) had an above knee amputation among which healing was seen in 68.3% (n=110). 
A significant (p=0.001⃰) difference was observed between healed and non-healed stump among 
the above knee amputation group. The total numbers of below knee amputations were one 
hundred and thirty nine (46.3%) out of which seventy nine healed (56.8%) (Figure 13). No 
significant (p=0.107) difference was observed between stump healing and below knee 
amputation. The table shows distribution of the number of patients who healed their stumps 
based on the type of amputation. Stump healing was found to be associated (p=0.040⃰) with 
type of amputation (Table 5).  
 
Table 5: Type of amputation and stump healing in the retrospective group 
 
Type of 
Amputation 
Healed Not Healed Total Chi-Square P value 
AKA 110 51 161   
BKA 79 60 139 4.224 0.040 ⃰ 
Total 189 111 300   
Table 5 shows the distribution and association between stump healing (healed or not healed) 
and type of amputation (above knee or below knee). p=0.040 ⃰ indicating that stump healing 
was dependent on the type of amputation.  
 
Figure 13: Stump healing and the types of amputation in the retrospective group 
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Figure 13 showing association between success and failure of stump healing among subjects 
who underwent lower limb amputation (above knee and below knee). Numbers written on top 
of the bar indicate the percentage. p value for above and below knee amputation were p=0.001⃰ 
and p=0.107 respectively. 
 
4.1.4 Association between age and stump healing in the retrospective group 
The figure 14 shows the association between stump healing and age in patients who underwent 
lower limb amputation. Of the 300 patients included in the study, two hundred and eighty seven 
were above the age of 50 years (95.7%) and thirteen below the age of 50 years (4.3%). The 
youngest patient was aged 34 years and the oldest, 97 years the average age being 71.16. Out 
of 287 patients above the age of 50 years, 179 healed their stump (62.4%) and 108 patient’s 
stumps failed to heal (37.6%) (Figure 14). A significant difference was observed between 
stump healing and patients above the age of 50 years (p=0.001⃰) but not the group below the 
age of 50 years (p=0.052). The table shows an age wise distribution of the number of patients 
who healed their stumps. The healing of the stump was independent of the age (p=0.288) (Table 
6).  
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Table 6: Age and stump healing in the retrospective group 
 
Age Healed Not Healed Total Chi-Square P value 
≤ 50 10 3 13   
> 50 179 108 287 1.130 0.288 
Total 189 111 300   
Table 6 shows the distribution and association between stump healing (healed or not healed) 
and type of amputation (above knee or below knee). p=0.288 indicating that stump healing was 
independent of age.  
 
 
 Figure 14: Stump healing and age in the retrospective group 
 
 
Figure 14 showing association between success and failure of stump healing among subjects 
who underwent lower limb amputation (above knee and below knee). Numbers written on top 
of the bar indicate the percentage. p value for patients with above and below the age of 50 years 
were p=0.001⃰ and p=0.052 respectively. 
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4.1.5 Association between diabetes mellitus and stump healing in the retrospective group 
The figure 15 shows the association between stump healing and diabetes mellitus in patients 
who underwent lower limb amputation. Out of the 300 included patients, there were one 
hundred and thirty eight in the diabetes mellitus cohort and one hundred and sixty two in the 
non-diabetes mellitus cohort. Among the diabetic population, 85 (61.6%) healed and 53 
(38.4%) failed to heal their stump. In the non-diabetics, 104 healed their stump (64.2%) in 
comparison to 58 (35.8%) who failed to heal their stump (Figure 15). A significant difference 
was observed between stump healing and both diabetic (p=0.006 ⃰) and non-diabetic patients 
(p=0.001 ⃰). The table below shows the distribution of the number of patients who healed their 
stumps in the diabetic and the non-diabetic group. However, stump healing was independent 
of diabetes mellitus (p=0.642) (Table 7).  
 
Table 7: Diabetes mellitus and stump healing in the retrospective group 
 
Diabetes 
mellitus 
Healed Not Healed Total Chi-Square P value 
No 104 58 162   
Yes 85 53 138 0.217 0.642 
Total 189 111 300   
Table 7 shows the distribution and association between stump healing (healed or not healed) 
and type of amputation (above knee or below knee). p=0.642 indicating that stump healing was 
independent of diabetes.  
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Figure 15: Stump healing in patients with diabetes mellitus in the retrospective group 
 
 
 
 
Figure 15 showing association between success and failure of stump healing among subjects 
who underwent lower limb amputation (above knee and below knee). Numbers written on top 
of the bar indicate the percentage. The p value for patients with diabetes and without diabetes 
were (p = 0.006 ⃰) and (p = 0.001 ⃰) respectively. 
 
4.1.6 Association between hypertension and stump healing in the retrospective group 
A total of two hundred and eighty three patients were hypertensive and seventeen were non 
hypertensive among 300 patients who underwent major lower limp amputation surgery. The 
figure below shows the association between stump healing and hypertension in patients who 
underwent lower limb amputation. In the hypertensive group the stump healing rate was 61.8% 
(n=175) while the failure rate was 38.2% (n=108). On the other hand, 82.4 % (n=14) of the 
non-hypertensive healed their stump in comparison to 17.6% (n=3) whose stump did not heal 
(Figure 16). A significant difference was observed between stump healing and patients with 
(p=0.001⃰) and without hypertension (p=0.008 ⃰). The table shows a distribution of the number 
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of patients who healed their stumps in the hypertensive and the non-hypertensive group. 
Overall stump healing was independent of the classification of blood pressure (p=0.089) (Table 
8) 
 
Table 8: Hypertension and stump healing in the retrospective group 
 
 
HTN Healed Not Healed Total Chi-Square P value 
No 14 3 17   
Yes 175 108 283 2.896 0.089 
Total 189 111 300   
Table 8 shows the distribution and association between stump healing (healed or not healed) 
and type of amputation (above knee or below knee). p=0.089 indicating that stump healing was 
independent of hypertension. 
 
 
Figure 16: Stump healing and hypertension in the retrospective group  
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Figure 16 showing association between success and failure of stump healing among subjects 
who underwent lower limb amputation (above knee and below knee). Numbers written on top 
of the bar indicate the percentage. p value for patients with and without hypertension was 
(p=0.001⃰) and (p=0.008 ⃰) respectively. 
 
4.1.7 Association between smoking and stump healing in the retrospective group 
The impact of smoking was analyzed for all patients (300) enrolled in the study. The figure 
below shows the association between stump healing and smoking in patients who underwent 
lower limb amputation. Among 300 patients 245 were smokers and 54 were non-smokers. 
About Sixty percent (60.8%) (n=149) achieved stump healing and 39.2% (n=96) failed to heal 
their stump. The success rate of stump healing was 74.1% (n=40) and 25.9% (n=14) failed to 
heal their stump among nonsmokers (Figure 17). A significant difference was observed 
between stump healing and both smokers (p=0.001⃰) and non-smokers (p=0.001⃰). The table 
below shows the distribution of the number of patients who healed their stumps among the 
smoking and non-smoking groups. Stump healing, however, was independent of the smoking 
(p=0.080) (Table 9).  
Table 9: Smoking and stump healing in the retrospective group 
 
Smoking Healed Not Healed Total Chi-Square P value 
No 40 15 55   
Yes 149 96 245 5.045 0.080 
Total 189 111 300   
Table 9 shows the distribution and association between stump healing (healed or not healed) 
and type of amputation (above knee or below knee). p=0.080 indicating that stump healing was 
independent of smoking.  
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Figure 17: Stump healing and smoking in the retrospective group 
 
 
Figure 17 showing association between success and failure of stump healing among subjects 
who underwent lower limb amputation (above knee and below knee). Numbers written on top 
of the bar indicate the percentage. p value for both smokers and non-smokers was (p=0.001⃰) 
and (p=0.001⃰) respectively. 
 
4.1.8 Association between HbA1c and stump healing in the retrospective group 
The impact of the diabetic control was analyzed for the diabetic patients (n=138) enrolled in 
the study. The figure 18 shows the association between stump healing and HbA1c in patients 
who underwent lower limb amputation. HbA1c in the last six months was available for eighty 
seven (63%) patients among the 138 diabetic patients. HbA1c was divided into three categories 
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namely HbA1c of 6.5% and below, HbA1c between 6.5-7.5% and HbA1c above 7.5%. These 
groups were based on the patient’s diabetic control (optimal, satisfactory and poor) (NICE 
guidelines, 2015). Eighty percent of the patients (n=4) achieved stump healing among the group 
with optimal control. The success rate of stump healing was 60% (n=12) and 62.9% (n=39) 
healed their stump among the satisfactory and poor control group. No significant difference 
was observed between stump healing and all the three groups; (p=0.324) for the optimal group, 
(p=0.061) for the satisfactory group and (p=0.052) for the poor control group. The table below 
shows the distribution of the number of patients who healed their stumps based on their HbA1c. 
Stump healing was independent of diabetic control (p=706) (Table 10).  
Table 10: HbA1c and stump healing in the retrospective group 
 
HbA1c Healed Not Healed Total Chi-Square P value 
≤6.5 4 1 5   
6.5-7.5 12 8 20 0.697 0.706 
≥7.5 
Total 
39 
55 
23 
32 
62 
87 
  
 
Table 10 shows the distribution and association between stump healing (healed or not healed) 
and type of amputation (above knee or below knee). p=0.706 indicating that stump healing was 
independent of diabetic control. 
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Figure 18: Stump healing in different HbA1c groups in the retrospective group 
 
 
Figure 18 showing association between success and failure of stump healing among subjects 
who underwent lower limb amputation (above knee and below knee). Numbers written on top 
of the bar indicate the percentage. p value for the different groups were p=0.324 for the optimal 
group, p=0.061 for the satisfactory group and p=0.052 for the poor control group 
 
4.1.9 Association between serum sodium and stump healing in the retrospective group 
The impact of serum sodium on stump healing was analyzed for all patients (300) enrolled in 
the study. The figure below shows the association between stump healing and serum sodium 
in patients who underwent lower limb amputation. Among 300 patients, 268 had an abnormal 
serum sodium and 32 patients had a normal sodium. About sixty three percent (63.4%) (n=170) 
achieved stump healing and 36.6% (n=98) failed to heal their stump (Figure 19). Stump 
healing, however, was independent of the classification of serum sodium (p=0.653) (Table 11).  
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Table 11: Serum sodium and stump healing in the retrospective group 
 
Sodium Healed Not Healed Total Chi-Square P value 
Normal 19 13 32   
Abnormal 170 98 268 0.202 0.653 
Total 189 111 300   
Table 11 shows the distribution and association between stump healing (healed or not healed) 
and serum sodium. p=0.653 indicating that stump healing was independent of classification of 
serum sodium.  
 
Figure 19: Serum sodium and stump healing in the retrospective group 
 
Figure 19 showing association between success and failure of stump healing among subjects 
who underwent lower limb amputation (above knee and below knee). Numbers written on top 
of the bar indicate the percentage.  
 
4.1.10 Association between serum potassium and stump healing in the retrospective group 
A total of two hundred and fifty two patients had a normal serum potassium among 300 patients 
who underwent major lower limp amputation surgery. The Figure 20 below shows the 
association between stump healing and serum potassium in patients who underwent lower limb 
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amputation. In the patients with a normal serum potassium the stump healing rate was 62.7% 
(n=158) while the failure rate was 37.3% (n=94) (Figure 20). The table shows a distribution of 
the number of patients who healed their stumps in both the groups. Overall stump healing was 
independent of the classification of serum potassium (p=0.804) (Table 12) 
 
 
Table 12: Serum potassium and stump healing in the retrospective group 
 
Potassium Healed Not Healed Total Chi-Square P value 
Normal 158 94 252   
Abnormal 31 17 48 0.061 0.804 
Total 189 111 300   
Table 12 shows the distribution and association between stump healing (healed or not healed) 
and serum potassium. p=0.804 indicating that stump healing was independent of classification 
of serum potassium.  
 
Figure 20: Serum potassium and stump healing in the retrospective group 
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Figure 20 showing association between success and failure of stump healing among subjects 
who underwent lower limb amputation (above knee and below knee). Numbers written on top 
of the bar indicate the percentage.  
 
4.1.11 Association between serum creatinine and stump healing in the retrospective group 
The impact of serum creatinine on stump healing was analyzed for all patients (300) enrolled 
in the study. The Figure 21 below shows the association between stump healing and serum 
creatinine in patients who underwent lower limb amputation. Among 300 patients, 232 had an 
abnormal serum creatinine and 68 patients had a normal creatinine. About sixty five percent 
(65.5%) (n=170) achieved stump healing and 34.5% (n=80) failed to heal their stump (Figure 
21). Stump healing, however, was independent of the classification of serum creatinine 
(p=0.095) (Table 13).  
 
Table 13: Serum creatinine and stump healing in the retrospective group 
 
Creatinine Healed Not Healed Total Chi-Square P value 
Normal 152 80 232   
Abnormal 37 31 68 2.782 0.095 
Total 189 111 300   
Table 13 shows the distribution and association between stump healing (healed or not healed) 
and serum creatinine. p=0.095 indicating that stump healing was independent of serum 
creatinine.  
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Figure 21: Serum creatinine and stump healing in the retrospective group 
 
Figure 21 showing association between success and failure of stump healing among subjects 
who underwent lower limb amputation (above knee and below knee). Numbers written on top 
of the bar indicate the percentage.  
 
4.1.12 Association between urea and stump healing in the retrospective group 
A total of one hundred and seventy five patients had a normal urea among 300 patients who 
underwent major lower limp amputation surgery. The Figure 22 below shows the association 
between stump healing and urea in patients who underwent lower limb amputation. In the 
patients with a normal urea the stump healing rate was 62.3% (n=109) while the failure rate 
was 37.7% (n=66) (Figure 22). The table shows a distribution of the number of patients who 
healed their stumps in both the groups (normal and abnormal urea). Overall stump healing was 
independent of the classification of urea (p=0.762) (Table 14) 
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Table 14: Urea and stump healing in the retrospective group 
 
Urea Healed Not Healed Total Chi-Square P value 
Normal 109 66 175   
Abnormal 80 45 125 0.092 0.762 
Total 189 111 300   
Table 14 shows the distribution and association between urea, p=0.762 indicating that stump 
healing was independent of classification of urea.  
 
Figure 22: Urea and stump healing in the retrospective group 
 
Figure 22 showing association between success and failure of stump healing among subjects 
who underwent lower limb amputation (above knee and below knee). Numbers written on top 
of the bar indicate the percentage.  
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patients who healed their stumps in both the groups (normal and abnormal CRP).  The healing 
of the stump was independent of classification of CRP (p=0.829) (Table 15).  
 
Table 15: C-reactive protein and stump healing in the retrospective group 
 
CRP Healed Not Healed Total Chi-Square P value 
Normal 9 6 15   
Abnormal 177 105 282       0.047 0.829 
Total 189 111 300   
 
Figure 23: C-reactive protein and stump healing in the retrospective group 
 
 
Figure 23 showing association between success and failure of stump healing among subjects 
who underwent lower limb amputation (above knee and below knee). Numbers written on top 
of the bar indicate the percentage.  
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4.1.14 Association between white cell count and stump healing in the retrospective group 
The figure 24 shows the association between stump healing and white cell count in patients 
who underwent lower limb amputation. The table shows a distribution of the number of patients 
who healed their stumps in both the groups (with and without normal white cell count). Overall 
stump healing was independent of the classification of white cell count (p=0.900) (Table 16) 
 
Table 16: White cell count and stump healing in the retrospective group 
 
WCC Healed Not Healed Total Chi-Square P value 
Normal 77 44 121   
Abnormal 112 66 179 0.016 0.900 
Total 189 111 300   
Table 16 shows the distribution and association between stump healing (healed or not healed) 
and white cell count, p=0.900 indicating that stump healing was independent of classification 
of white cell count.  
 
Figure 24: White cell count and stump healing in the retrospective group 
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Figure 24 showing association between success and failure of stump healing among subjects 
who underwent lower limb amputation (above knee and below knee). Numbers written on top 
of the bar indicate the percentage 
 
4.1.15 Association between prothrombin time and stump healing in the retrospective 
group 
The figure 25 shows the association between stump healing and prothrombin time in patients 
who underwent lower limb amputation. Out of the 300 included patients, there were one 
hundred and seventy three patients with normal PT and one hundred and twenty seven with 
abnormal PT. The table below shows the distribution of the number of patients who healed 
their stumps in both the groups. However, stump healing was independent of the classification 
of PT (p=0.811) (Table 17).  
 
 
 
 
Table 17: Prothrombin time and stump healing in the retrospective group 
 
PT Healed Not Healed Total Chi-Square P value 
Normal 108 65 173   
Abnormal 81 46 127 0.057 0.811 
Total 189 111 300   
Table 17 shows the distribution and association between stump healing (healed or not healed) 
and PT. p=0.811 indicating that stump healing was independent of the classification of PT.  
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Figure 25: Prothrombin time and stump healing in the retrospective group 
 
Figure 25 showing association between success and failure of stump healing among subjects 
who underwent lower limb amputation (above knee and below knee). Numbers written on top 
of the bar indicate the percentage 
 
4.1.16 Association between INR and stump healing in the retrospective group 
The impact of INR was analyzed for all patients (300) enrolled in the study. The figure 26 
below shows the association between stump healing and INR in patients who underwent lower 
limb amputation. The table below shows the distribution of the number of patients who healed 
their stumps among both the groups (normal and abnormal INR). Stump healing, however, was 
independent of the classification of INR (p=0.406) (Table 18).  
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Table 18: INR and stump healing in the retrospective group 
 
INR Healed Not Healed Total Chi-Square P value 
Normal 133 73 206   
Abnormal 56 38 94 0.689 0.406 
Total 189 111 300   
Table 18 shows the distribution and association between stump healing (healed or not healed) 
and PT, p=0.406 indicating that stump healing was independent of the classification of PT.  
 
Figure 26: INR and stump healing in the retrospective group 
 
Figure 26 showing association between success and failure of stump healing among subjects 
who underwent lower limb amputation (above knee and below knee). Numbers written on top 
of the bar indicate the percentage 
 
 
4.1.17 Association between serum total cholesterol and stump healing in the retrospective 
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patients who underwent major lower limp amputation surgery. The figure 27 below shows the 
64.60%
59.60%
35.40%
40.40%
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
70.00%
Normal Abnormal
INR
Healed Not healed
 Chapter 4 
140 
 
association between stump healing and serum total cholesterol in patients who underwent lower 
limb amputation. The table and the figure 27 shows a distribution of the number of patients 
who healed their stumps in both he groups. Overall stump healing was independent of 
classification of total cholesterol (p=0.293) (Table 19) (Figure 27). 
 
 
 
 
Table 19: Serum total cholesterol and stump healing in the retrospective group 
 
TC Healed Not Healed Total Chi-Square P value 
Normal 161 88 249   
Abnormal 26 20 46 1.108 0.293 
Total 189 111 300   
Table 19 shows the distribution and association between stump healing (healed or not healed) 
and serum total cholesterol. p=0.293 indicating that stump healing was independent of the 
classification of serum total cholesterol.  
 
Figure 27: Serum total cholesterol and stump healing in the retrospective group 
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Figure 27 showing association between success and failure of stump healing among subjects 
who underwent lower limb amputation (above knee and below knee). Numbers written on top 
of the bar indicate the percentage 
 
 
4.1.18 Association between serum triglycerides and stump healing in the retrospective 
group 
The figure 28 shows the association between stump healing and serum triglycerides in patients 
who underwent lower limb amputation. The table below shows the distribution of the number 
of patients who healed their stumps in both the groups (with normal and abnormal serum 
triglycerides). However, stump healing was independent classification of serum triglycerides 
(p=0.638) (Table 20).  
 
Table 20: Serum triglycerides and stump healing in the retrospective group 
 
TG Healed Not Healed Total Chi-Square P value 
Normal 151 88 239   
Abnormal 34 17 51 0.221 0.638 
Total 189 111 300   
Table 20 shows the distribution and association between stump healing (healed or not healed) 
and serum triglycerides. p=0.642 indicating that stump healing was independent of 
classification of serum triglycerides.  
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Figure 28: Serum triglycerides and stump healing in the retrospective group 
 
Figure 28 showing association between success and failure of stump healing among subjects 
who underwent lower limb amputation (above knee and below knee). Numbers written on top 
of the bar indicate the percentage 
 
4.1.19 Association between serum high density lipids and stump healing in the 
retrospective group 
The figure 29 shows the association between stump healing and serum HDL in patients who 
underwent lower limb amputation. The table below shows the distribution of the number of 
patients who healed their stumps in both the groups (with normal and abnormal serum HDL). 
However, stump healing was independent classification of serum HDL (p=0.054) (Table 21).  
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Table 21: Serum high density lipids and stump healing in the retrospective group 
 
HDL Healed Not Healed Total Chi-Square P value 
Normal 121 57 178   
Abnormal 63 48 112 3.721 0.054 
Total 189 111 300   
Table 21 shows the distribution and association between stump healing (healed or not healed) 
and serum HDL. p=0.804 indicating that stump healing was independent of classification of 
serum HDL. 
 
Figure 29: Serum high density lipids and stump healing in the retrospective group 
 
Figure 29 showing association between success and failure of stump healing among subjects 
who underwent lower limb amputation (above knee and below knee). Numbers written on top 
of the bar indicate the percentage 
 
4.2 Descriptive statistics by type of amputation in the retrospective group 
4.2.1 Association between gender and stump healing by amputation type 
The figure 30 shows the association between stump healing and gender in patients who 
underwent lower limb amputation. Out of 300, one hundred and thirty nine had a below knee 
68.00%
56.80%
32.00%
43.20%
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
70.00%
80.00%
Normal Abnormal
High density lipids
Healed Not healed
 Chapter 4 
144 
 
amputation of which one hundred and five (75.5%) were males and thirty four (24.5%) were 
females (Table 22). Out of the one hundred and five male patients, sixty patients had a healed 
lower limb stump (57.1%) and forty five patients stumps failed to heal (42.9%). Of the healed 
group (n= 79), 75.9% (n=60) were males and 24.1% (n=19) were females. Among the female 
group, 55.9 % (n=19) stumps had healed and failure to heal was noted in 44.1% (n=15). No 
significant difference was observed between stump healing and the male (p=0.187) or female 
gender (p=0.206). Stump healing was not found to be associated (p=0.897) with gender among 
the below knee amputation group.  
Among the above knee amputation group (n=161), one hundred and nine (67.7%) were males 
and fifty two (32.3%) were females (Table 22). Of the healed group (n= 103), 75.7% (n=78) 
were males and 24.3% (n=25) were females. Among the male patients, eighty one (74.3%) had 
a healed lower limb stump while twenty eight (25.7%) patients stumps failed to heal their 
stump. Among the female group, 55.8% (n=29) stumps had healed and failure to heal was noted 
in 44.2% (n=23). A significant difference was observed between stump healing and the male 
(p=0.001⃰) but not with the female gender (p=0.405). The table below shows the gender wise 
distribution of the number of patients who healed their stumps. Stump healing was found to be 
associated (p=0.018⃰) with gender among the above knee amputation group. 
 
 
Table 22: Gender and stump healing by amputation type 
 
 
 Healed 
AKA     BKA 
Not Healed 
AKA   BKA 
Total 
AKA   BKA 
Chi-Square 
AKA   BKA 
P value 
AKA   BKA 
Female 29 19 23 15       
Male 81 60 28 45       
Total 110 79 51 60 161 139 5.593 0.017    0.018 ⃰ 0.897 
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Table 22 shows the distribution and association between stump healing (healed or not healed) 
and gender (male or female) among AKA and BKA.   
 
 
 
Figure 30: Stump healing in males and females by amputation type 
 
 
Figure 30 showing association between success and failure of stump healing among subjects 
who underwent lower limb amputation (above knee and below knee). Numbers written on top 
of the bar indicate the percentage. p=0.018 ⃰ for the AKA group indicating that stump healing 
was dependent of the gender while the p=0.897 BKA group indicating there was no relation 
between gender and stump healing. 
 
4.2.2 Association between age and stump healing by amputation type 
The figure 31 shows the association between stump healing and age in patients who underwent 
lower limb amputation. Of the 136 patients who had a below knee amputation in the 
retrospective study, 92.8% (n=129) were above the age of 50 years and 7.2% (n=10) below the 
age of 50 years. The youngest patient was aged 34 years and the oldest, 86 years the average 
74.30%
55.80% 57.10% 55.90%
25.70%
44.20% 42.90% 44.10%
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
70.00%
80.00%
Male Female Male Female
AKA BKA
P
er
ce
n
ta
ge
 H
ea
le
d
Gender
Healed Not healed
 Chapter 4 
146 
 
age being 73.27. Out of 129 patients above the age of 50 years, 72 healed their stump (55.8%) 
and 57 patient’s stumps failed to heal (44.2%) (Figure 31). Among the group who were below 
50 years, 30% (n=10) failed to heal their stump. No significant difference was observed 
between stump healing and both patients below the age of 50 years (p=0.206) and above the 
age of 50 years (p=0.187). The healing of the stump in the below knee amputation group was 
independent of the age (p=0.383) (Table 23).  
Of the161 patients included in the study who had an AKA, 158 (98.1%) were above the age of 
50 years and 3 (1.9%) below the age of 50 years. The youngest patient was aged 34 years and 
the oldest 97 years, the average age being 73.36. Out of 158 patients above the age of 50 years 
67.7% (n=108) healed their stump and 32.3% (n=53) patient’s stumps failed to heal (Figure 
17). A significant difference was observed between stump healing and both patients above the 
age of 50 years (p=0.001⃰). No p value was noted for the group below the age of 50 years. The 
table shows an age wise distribution of the number of patients who healed their stumps. The 
healing of the stump was independent of the age (p=0.234) in the above knee amputation group 
(Table 23).  
 
 
 
Table 23: Age and stump healing by amputation type 
 
 
Age Healed 
AKA     BKA 
Not Healed 
AKA   BKA 
Total 
AKA   BKA 
Chi-Square 
AKA   BKA 
P value 
AKA   BKA 
≤ 50 1 7 2 3       
> 50 107 72 51 57       
Total 108   79 53 60 161 139 1.417 0.761 0.234 0.383 
Table 23 shows the distribution and association between stump healing (healed or not healed) 
and type of amputation (above knee or below knee).  
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Figure 31: Stump healing and age by amputation type 
 
 
Figure 31 showing association between success and failure of stump healing among subjects 
who underwent lower limb amputation (above knee and below knee). Numbers written on top 
of the bar indicate the percentage. p=0.234 and p=0.383 for AKA and BKA group indicating 
that stump healing was independent of age. 
 
4.2.3 Association between diabetes mellitus and stump healing by amputation type 
The figure 32 shows the association between stump healing and diabetes mellitus in patients 
who underwent lower limb amputation. Out of the 139 patients who underwent below knee 
amputation, there were 78 in the diabetes mellitus cohort and 61 in the non-diabetes mellitus 
cohort. Among the diabetic population 57.7% (n=45) healed and 42.3% (n=33) failed to heal 
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their stump. In the non-diabetics, 55.7% (n=34) healed their stump in comparison to 44.3% 
(n=27) who failed to heal their stump (Figure 32). No significant difference was observed 
between stump healing and both diabetic (p=0.174) and non-diabetic patients (p=0.370). Stump 
healing was independent of diabetes mellitus in the below knee amputation group (p=0.817) 
(Table 24).  
Out of AKA group (n=161), there were 60 in the diabetes mellitus cohort and 101 in the non-
diabetes mellitus cohort. Among the diabetic population, 66.7% (n=40) healed and 33.3% 
(n=20) failed to heal their stump. In the non-diabetics, (n=104) healed their stump 69.3% 
(n=70) in comparison to 30.7% (n=31) who failed to heal their stump (Figure 32). A significant 
difference was observed between stump healing and both diabetic (p=0.010⃰) and non-diabetic 
patients (p =0.001⃰). The table below shows distribution of the number of patients who healed 
their stumps among the diabetic and non-diabetic groups. Stump healing was independent of 
Diabetes (p=0.642) in the above knee amputation group (Table 24).  
 
 
 
 
Table 24: Diabetes mellitus and stump healing by amputation type 
 
 
Diabetes 
mellitus 
Healed 
AKA     BKA 
Not Healed 
AKA   BKA 
Total 
AKA   BKA 
Chi-Square 
AKA   BKA 
P value 
AKA   BKA 
No 70 34 31 27 86      
Yes 40 45 20 33 214      
Total 110 79 51 60 161 139 0.121 0.53 0.728  0.817 
Table 24 shows the distribution and association between stump healing (healed or not healed) 
and diabetes mellitus.  
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Figure 32: Stump healing in patients with diabetic mellitus by amputation type 
 
 
 
Figure 32 showing association between success and failure of stump healing among subjects 
who underwent lower limb amputation (above knee and below knee). Numbers written on top 
of the bar indicate the percentage. p=0.728 and p=0.817 for AKA and BKA group indicating 
that stump healing was independent of diabetes. 
 
4.2.4 Association between hypertension and stump healing by amputation type 
The figure 33 shows the association between stump healing and hypertension in patients who 
underwent lower limb amputation. A total of 136 patients were hypertensive and 3 were non 
hypertensive among 139 patients who underwent major lower limp amputation surgery. In the 
hypertensive group the stump healing rate was 56.6% (n=77) while the failure rate was 43.4% 
(n=59). On the other hand, 66.7 % (n=2) of the non-hypertensive healed their stump in 
comparison to 33.3% (n=1) whose stump did not heal.  No significant (p=0.68) difference was 
observed between stump healing and patients with (p=0.123) and without hypertension 
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(p=0.564). Stump healing in the below knee amputation group was independent of the blood 
pressure (p=0.728) (Table 25) 
Among 161 patients who underwent an above knee amputation surgery, 147 were hypertensive 
and 14 were non hypertensive. In the hypertensive group, the stump healing rate was 66.7% 
(n=98) while the failure rate was 33.3% (n=49). On the other hand, 85.7 % (n=12) of the non-
hypertensive healed their stump in comparison to 14.3% (n=2) who failed to heal. (Figure 33). 
A significant difference was observed between stump healing and patients with (p=0.001⃰) and 
without hypertension (p=0.008⃰). The table below shows a distribution of the number of patients 
who healed their stumps in the hypertensive and the non-hypertensive group. Stump healing 
was independent of the blood pressure in the above amputation group (p=0.143) (Table 25). 
 
 
Table 25: Hypertension and stump healing by amputation type 
 
 
HTN Healed 
AKA     BKA 
Not Healed 
AKA   BKA 
Total 
AKA   BKA 
Chi-Square 
AKA   BKA 
P value 
AKA   BKA 
No 12 2 2 1       
Yes 98 77 49 59       
Total 110 79 51 60 161 139 2.143 0.121 0.143 0.728 
Table 25 shows the distribution and association between stump healing (healed or not healed) 
and hypertension 
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Figure 33: Stump healing and hypertension by amputation type 
 
 
 
Figure 33 showing association between success and failure of stump healing among subjects 
who underwent lower limb amputation (above knee and below knee). Numbers written on top 
of the bar indicate the percentage. p=0.143 and p=0.728 for AKA and BKA group indicating 
that stump healing was independent of hypertension. 
 
4.2.5 Association between smoking and stump healing by amputation type 
The figure 34 shows the association between stump healing and smoking in patients who 
underwent lower limb amputation. Among 139 patients who underwent below knee 
amputation, 114 were smokers and 25 were non-smokers. Among the smoking group, 54.4% 
(n=62) achieved stump healing and 45.6% (n=52) failed to heal their stump. The success rate 
of stump healing was 68% (n=17) and 32% (n=8) failed to heal their stump among nonsmokers 
(Figure 34). No significant (p=0.68) difference was observed between stump healing and both 
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smokers (p=0.349) and non-smokers (p=0.072). Stump healing was independent of the 
smoking (p=0.213) among the below knee amputation group (Table 26).  
Among 161 patients who underwent above knee amputation, 132 were smokers and 29 were 
non-smokers. Among the smoking group, 66.4% (n=88) achieved stump healing and 33.6% 
(n=44) failed to heal their stump. The success rate of stump healing was 79.3% (n=23) and 
20.7% (n=6) failed to heal their stump among nonsmokers (Figure 34). A significant difference 
was observed between stump healing and both smokers (p=0.020⃰) and non-smokers (p=0.001⃰). 
The table below shows the distribution of the number of patients who healed their stumps 
among the smoking and non-smoking groups. Stump healing was independent of the smoking 
in the above knee amputation group (p=0.080) (Table 26).  
 
Table 26: Smoking and stump healing by amputation type 
 
 
Smoking Healed 
AKA     BKA 
Not Healed 
AKA   BKA 
Total 
AKA   BKA 
Chi-Square 
AKA   BKA 
P value 
AKA   BKA 
No 23 17 6 8       
Yes 88 62 44 52       
Total 111 79 50 60 161 139 1.839 1.549 0.175 0.213 
Table 26 shows the distribution and association between stump healing (healed or not healed) 
and smoking.  
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Figure 34: Stump healing and smoking by amputation type 
 
 
Figure 34 showing association between success and failure of stump healing among subjects 
who underwent lower limb amputation (above knee and below knee). Numbers written on top 
of the bar indicate the percentage. p=0.175 and p=0.213 for AKA and BKA group indicating 
that stump healing was independent of smoking. 
 
4.3 Univariate analysis of independent variables 
Retrospective analysis of the derivation set of 300 lower limb stumps that were performed 
between 2005 and 2009 revealed a failure to heal rate of 37% (n = 111). Access characteristics 
and univariate analysis of clinical variables for the prediction of stump healing are shown in 
Table 27. Univariate analysis found seven variables to be associated with lower limb stump 
healing: type of amputation (OR 1.638; 95% CI 1.022-2.627), gender (OR 1.529; 95% CI 
66.40%
79.30%
54.40%
68.00%
33.60%
20.70%
45.60%
32.00%
0.00%
10.00%
20.00%
30.00%
40.00%
50.00%
60.00%
70.00%
80.00%
90.00%
Smokers Non smokers Smokers Non smokers
AKA BKA
P
er
ce
n
ta
ge
 H
ea
le
d
Smoking
Healed Not healed
 Chapter 4 
154 
 
0.971-2.549) , hypertension (OR 0.347; 95% CI 0.098-1.236) , smoking (OR 0.347; 95% CI 
0.098-1.236), serum sodium (OR 1.711 95% CI 1.039-2.818), serum creatinine (OR 1.592; 
95% CI 0.920-2.755) and High Density Lipids (OR 1.617; 95% CI 0.991-2.640). Further 
variables, namely age (OR 2.01; 95% CI 0.542-7.470), diabetes mellitus (OR 0.894; 95% CI 
0.559-1.431), white cell count (OR 1.031; 95% CI 0.639-1.665) and Prothrombin Time (OR 
0.994; 95% CI 0.587-1.517) were added to the model secondary to their strong clinical 
association with the stump healing. 
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Table 27: Univariate analysis of independent variables to lower limb stump healing 
 
 
Clinical 
characteristics 
% Stump  
Healed 
Total % Crude OR 
(95% CI) 
P Value 
Age     
≤ 50 yrs.                                                  76.9 4.3 2.011(0.542-7.470) 0.297 
> 50 yrs. 62.4 95.7   
Gender     
Male 65.9 71.3 1.529 (0.971-2.549) 0.103* 
Female 55.8 28.7   
Type of Amputation     
AKA 68.3 53.7 1.638(1.022-2.627 0.04* 
BKA 56.8 46.3   
Diabetes mellitus     
No 64.2 54 0.894(0.559-1.431) 0.642 
Yes 61.6 46   
Smoker     
No 74.1 18.3 0.543 (0.281-1.052) 0.191* 
Yes 60.8 81.7   
HTN     
No 82.4 5.7 0.347 (0.098-1.236) 0.103* 
Yes 61.8 94.3   
K+     
Abnormal 64.6 16 0.922 (0.48-1.756) 0.804 
Normal 62.7 84   
Na+     
Abnormal 54.3 10.7 1.711 (1.039-2.818) 0.035* 
Normal 67 89.3   
WCC     
Abnormal 62.9 59.5 1.031 (0.639-1.665) 0.901 
Normal 63.6 40.5   
CRP     
≤ 5 60 5.1 0.890 (0.308-2.571) 0.829 
>5 62.8 94.9   
Creatinine     
≤120  
>120 
65.5 
54.4 
77.3 
22.7 
1.592(0.920-2.755) 
 
0.097* 
 
Urea 
≤ 6.6 
 
62.3 
 
58.3 
 
0.929 (0.577-1.496) 
 
0.762 
> 6.6 64 41.7   
PT     
≤ 13.5 62.4 57.7 0.944 (0.587-1.517) 0.811 
> 13.5 63.8 42.3   
INR     
≤ 1.2 64.6 68.7 1.236 (0.789-2.041) 0.407 
> 1.2 59.6 31.3   
TC     
≤ 5 64.7 84.4 1.407 (0.743-2.664) 0.294 
>5 56.5 15.6   
TG     
≤ 2.1 63.2 82.4 0.858 (0.453-1.625) 0.638 
> 2.1 66.7 17.6   
HDL     
≤ 1.1 68 61.6 1.617 (0.991-2.640) 0.054* 
> 1.1 56.8 38.4   
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Table 27: Independent patient factors and blood markers that underwent in univariate analysis 
and their association with lower limb stump healing. Data values are expressed as value (%), 
Odds Ratio (OR), Confidence interval (CI) and level of significance (p). *Is used for significant 
variables having p value <0.25,*Is used for significant variables, diabetes mellitus-diabetes 
mellitus, HTN-Hypertension, CRP-C Reactive Protein, WCC- White Cell Count, K-Potassium, 
Na-Sodium, PT-Prothrombin time, INR- International normalization ratio, TC- Total 
Cholesterol, TG- Triglyceride, HDL- High density lipoprotein. 
 
  
4.4 Correlation 
Logistic regression models often experience serious multi collinearity problems resulting from 
strong correlations between independent variables. A significant correlation between variables 
affects the selection of predictors. A correlation table of all the potential predictors was 
therefore generated with a value greater than 0.70 suggesting a strong correlation. A correlation 
coefficient was computed to assess the association between the independent variables. Overall, 
no significant correlation was found between independent variables as summarized in Table 
28.
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Table 28: Correlation matrix between independent variables 
 
Constant Amp Gender HTN Smoking    Na   HDL    Age DM    PT WCC 
Step 1 Constant 1.000 -.447 -.090 -.005 -.030 -.230 -.310 -.049 -.285 -.068 -.022 
Amp  -.447 1.000 .104 .067 .029 .014 .021 .146 -.137 _.095 -.075 
Gender -.090 .104 1.000 .020 -.114 -.055 -.027 -.019 .048 .073 .020 
HTN  .005 .067 .020 1.000 -.096 -.062 -.035 .018 -.119 .006 -.044 
Smoking -.030 .029 -.114 -.096 1.000 .085 -.002 -.015 -.114 .036 .049 
Na -.230 .014 -.055 -.062 .085 1.000 .090 .072 .110 -.066 -.036 
HDL -.310 .021 -.027 -.035 -.002 .090 1.000 .001 -.056 -.078 .029 
Age -.049 .146 -.019 .018 -.015 -.072 .001 1.000 -.075 -.023 -.036 
DM   -.285 -.137 .048 -.119 -.114 .110 -.056 -.075 1.000 -.113 .019 
PT    -.068 _.095 .073 .006 .036 -.066 -.078 -.023 -.113 1.000 -.012 
WCC 
 
-.022 -.075 .020 -.044 .049 -.036 .029 -.036 .019 -.012 1.000 
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Table 28: *Is used for significant variables, diabetes mellitus-diabetes mellitus, HTN-
Hypertension, CRP-C Reactive Protein, WCC- White Cell Count, K-Potassium, Na-
Sodium, PT-Prothrombin time, INR- International normalization ratio, TC- Total 
Cholesterol, TG- Triglyceride, HDL- High density lipoprotein. 
 
4.5 Multivariable associations 
In this study, backward stepwise model selection procedure was used for multivariate 
associations. In backward regression analysis, the model contains all the predictors and 
SPSS software systematically removes the largest non-significant p-value term until a 
subset that consists of entirely statistically significant terms are left. All the selected 
variables are entered at the same time into the model. With each step the variable with the 
highest p-values is removed (that is, the variable contributing the least). Then the model 
is re-run with the remaining variables. This step is repeated until there are no variables left 
with a p-value greater than 0.05. Selection is based on the statistical significance of 
covariables in the data set under study. For the predictive model for lower limb stump 
healing, variables whose p-value was ≤0.25 were assigned to enter multiple logistic 
regression. So, type of amputation, gender, hypertension, smoking, serum sodium, serum 
creatinine and HDL cholesterol along with the variables with strong clinical association 
namely age, diabetes mellitus, white cell count and Prothrombin Time were added to run 
backward regression to develop the adjusted odd ratio and scoring (Table 28). Three 
variables were identified which influenced lower limb stump healing in the multivariable 
model. The lower limb stump healing was relatively 75% more likely in patients with 
normal serum sodium compared to that of patients with abnormal serum sodium (OR 
1.756; 95% CI 1.048-2.942; p 0.031). Patients with normal serum creatinine were 66% 
more likely to have their stump healed (OR 1.664; 95% CI 0.94 to 2.946; p 0.046). A 
normal serum High Density Lipid cholesterol resulted in a 75% more likely chance of 
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healing compared to those with abnormal serum High Density Lipid cholesterol (OR 
1.753; 95% CI 1.061 to 2.895; p <0.026). 
A predictor score developed using the regression coefficients of these variables is shown 
in Table 29. To generate score for each predictor variables, score is assigned by dividing 
Beta Coefficient to significant error. The overall probability for each patient was analysed 
by adding the scores of each factor. The following prognostic model was derived by using 
the above prediction model. 
 
Table 29: Multivariable predictors of lower limb stump healing in the retrospective 
data 
 
 
Clinical characteristics 
 
Adjusted OR 95% CI P Value 
Serum Sodium (Normal) 
 
1.756 0.310-0.866 0.031 
Serum Creatinine (Normal) 
 
1.664 1.49-5.854 0.046 
Serum HDL (Normal) 
 
1.753 2.221-11.315 0.026 
 
Table 29: showing the predictors which played significant role in lower limb stump 
healing in the multivariate analysis. 
 
The overall risk score for each patient was estimated by summing the scores of each 
significant independent variable. Using the prediction model, the following prognostic 
equation was developed: 
𝑹𝒊𝒔𝒌 𝑺𝒄𝒐𝒓𝒆(− 𝐥𝐨𝐠 𝒐𝒅𝒅𝒔) =  𝜷𝟎 + 𝜷𝟏𝑿𝟏 + 𝜷𝟐𝑿𝟐+. . . . . . +𝜷𝒏𝑿𝒏  
Where 
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 Β0 is the intercept, β1 till βn are the regression coefficients and X1 to Xn are independent 
variables. 
 
Risk Score- log odds of failure of stump healing [log/ (1/1- P)] = -1.82 + (0.563 × Se 
Na) + (0.509 × Se Creatinine) + (0.561 × HDL) 
Where 
Se Na=serum sodium levels, Se Creatinine=serum creatinine levels and 
HDL=serum High Density Lipid cholesterol 
 
Where all variables are coded 0 for no or 1 for yes. The value −0.182 is called the intercept 
and the other numbers are the estimated regression coefficients for the predictors, which 
indicate their mutually adjusted relative contribution to the outcome risk. 
4.5.1 Hosmer-Lemeshow Goodness of Fit Test 
It’s important to examine the appropriateness of fitted models. This was carried out by 
using the Hosmer and Lemeshow goodness of fit test. The null hypothesis for this test is 
that the model fits the data, and the alternative is that the model does not fit. The Hosmer-
Lemeshow statistic which tests the null hypothesis and plots difference between observed 
and predicted data was not significant (p>0.87). 
Receiver Operating Characteristic Area 
The Receiver Operating Characteristic curve area was studied as the indicator of a model 
performance which suggests how well a parameter can distinguish between two predictive 
outcomes. The Receiver Operating Characteristic curve, which is defined as a plot of test 
sensitivity as the y coordinate versus its 1-specificity or false positive rate as the x 
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coordinate, is an effective method of evaluating the performance of prognostic model. 
Sensitivity and specificity, which are defined as the number of true positive decisions/the 
number of actual positive cases and the number of true negative decisions/the number of 
actually negative cases, respectively, constitute the basic measures of performance of 
diagnostic tests (Park et al. 2004) (Table 30). 
 
Table 30: The decision matrix 
Test Results Positive Negative Total 
Positive TP FP TP/(TP+FP) 
Negative FN TN TN/(FN+TN) 
Total TP/(TP+FN) TN/(FP+TN)  
  
Table 30: Where TP: true positive = test positive in actually positive cases, 
FP: false positive = test positive in actually negative cases, FN: false negative 
= test negative in actually positive cases, TN: true negative = test negative in 
actually negative cases. Sensitivity and Specificity of a Test are Defined as 
TP/ (TP+FN) and TN/ (FP+TN) respectively. Positive predictive value and 
Positive predictive value are defined as TP/ (TP+FP) and TN/ (FN+TN) 
respectively. 
  
Receiver Operating Characteristic curve figures are two-dimensional figures in which true 
positive rate is plotted on the Y axis and false positive rate is plotted on the X axis. In this 
study Receiver Operating Characteristic curve was constructed by calculating the 
sensitivity and specificity for consecutive cut-off points according to the predicted 
probabilities from the logistic regression models. The green line in the figure is the slope 
of the tangent line at a cut point which gives the likelihood ratio (LR) for that value of the 
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test. The blue line is the curve showing the result of the study. The closer the curve follows 
the left-hand border and then the top border of the ROC space, the more accurate the test. 
The closer the curve comes to the 45-degree diagonal of the ROC space, the less accurate 
the test. The area under the Receiver Operating Characteristic curve for prediction of 
stump healing was 0.612 (95% bias-corrected CI: 0.546 - 0.679), which indicates good 
model discrimination (Figure 35, Table 31). For binary outcomes, C-index is equal to the 
area under the ROC curve; C-index varies between 0.5 and 1.0 for sensible models; the 
greater the value, the better the performance of prognostic model (Miller et al. 1993; 
Harrell et al. 1996). Table 31 shows the cut-off score for prediction of stump healing was 
0.621 (sensitivity 15.2%, specificity 91.3%, PPV 50% and NPV 65%). 
 
Figure 35: Receiver Operating Curve analysis for prognostic model performance
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Figure 35 showing Receiver operating characteristics of stump healing. Area under the 
curve was 0.612 (95% CI: 0.546-0.679), indicating good discriminatory ability of Stump 
healing.  
 
 
Table 31: Specificity and sensitivity of the model 
Area under the 
Curve 
Sensitivity Specificity Positive 
Predictive 
Value 
Negative 
Predictive 
Value 
           0.612 15.2% 91.3% 50..5% 65.8% 
 Table 31 showing the area under the ROC is 0.612, which is indicating 61% ability to 
discriminate between patients with stump healing. 
 
4.6 Validation of prognostic model 
Clinical and demographic characteristics of patients in the development and validation 
sets are shown in Table 32. Patients in the development and validation set were age of 
71.16 ± 14.5 and 68±15.5 respectively (p=0.55). The significant difference between the 
development and validation set was evaluated against p<0.05. Baseline exploration of 
patients’ characteristic discovered the four variables to be significantly different in both 
development and validation cohort. Patients in the development set compared with the 
patients in the validation set were more frequently male. Mean of serum creatinine, serum 
High Density Lipid cholesterol and C reactive protein was statistically different in 
development and validation set. Overall both cohorts’ participant characteristic were 
similar. 
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Table 32: Summary of the baseline characteristic of independent variables in the 
prospective group 
 
Characteristic  Development Set Validation Set p-Value 
Age (≤50/>50) 4.3/95.7 3/97 0.55 
Gender (Male/Female) 71.3/28.7 61/39 0.054 
Amputation(AKA/BKA) 53.7/46.3 53/47 0.90 
diabetes mellitus (Yes/No) 46/54 44/56 0.72 
HTN (Yes/No) 94.3/5.7 98/2 0.13 
Smoker (Yes/No) 81.7/18.3 85/15 0.39 
Urea, mean ±SD (mmol/L) 7.5±5.5 6.6±4.1 0.11 
Creatinine, mean ±SD (µmol/L) 100.6±70.4 82.5±43.1 0.003* 
K+, mean ±SD (mmol/L) 4.2±0.59 4.1±0.46 0.09 
Na+, mean ±SD (mmol/L) 136.3±4.1 135±3.9 0.47 
CRP, mean ±SD (mmol/L) 111.3±94.6 90.9±74.6  0.03* 
WCC, mean ±SD (mmol/L) 12.8±5.3 11.7±4.2 0.66 
PT, mean ±SD (second) 14.3±6.4 14.1±5.0 0.81 
INR, mean ±SD (ratio) 1.2±0.5 1.2±0.4 0.23 
TC, mean ±SD (mmol/L) 3.9±1.1 3.9±1.1 0.88 
TG, mean ±SD (mmol/L) 1.6±0.8 1.5±0.7 0.21 
HDL, mean ±SD (mmol/L) 1.1±0.4 1.3±0.8 0.01* 
LDL, mean ±SD (mm) 1.9±0.7 1.7±0.8 0.81 
Table 32: *Is used for significant difference between two cohorts’ p value <0.05, ±SD, 
Standard Deviation, diabetes mellitus-diabetes mellitus, HTN-Hypertension, PVD-
Peripheral Vascular Disease, K-Potassium, Na-Sodium, CRP-C-Reactive Protein, PT-
Prothrombin Time, INR- International Normalization Ratio, TC- Total Cholesterol, TG- 
Triglyceride, HDL- High Density Lipoprotein. 
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4.7 Prospective study analysis 
4.7.1 Descriptive statistics for the prospective group 
4.7.2 Association between gender and stump healing in the prospective group 
The figure 36 shows the association between stump healing and gender in patients who 
underwent lower limb amputation. Sixty one (61%) of the total patients (n=100) were 
men, and thirty nine (39%) women (Figure 36). Of the two sixty one males, thirty seven 
(60.7%) had a healed lower limb stump and twenty seven (39.3 %) failed to heal their 
stumps. No significant (p=0.159) difference was observed between stump healing and the 
male gender. Among the female patients, 48.7 % (n=19) stumps had healed and failure to 
heal was noted in 51.3% (n=20). No significant (p=0.873) difference was observed 
between healed and non-healed stump among the female gender. The table below shows 
a gender wise distribution of the number of patients who healed their stumps. Stump 
healing was not found to be associated (p=0.241) with male and female gender (Table 33).  
 
Table 33: Gender and stump healing in the prospective group 
 
 
 Healed Not Healed Total Chi-Square P value 
Female 19 20 39   
Male 37 24 61 1.376 0.241 
Total 56 44 100   
Table 33 shows the distribution and association between stump healing (healed or not 
healed) and gender (male or female). p=0. 241 indicating that stump healing was 
independent of the gender.  
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Figure 36: Stump healing and gender in the prospective group 
 
 
Figure 36 showing association between success and failure of stump healing among 
subjects who underwent lower limb amputation (above knee and below knee). Numbers 
written on top of the bar indicate the percentage. p value for males and female gender were 
p=0.159 and p=0.873 respectively. 
 
 
4.7.3 Association between type of amputation and stump healing in the prospective 
group 
Two types of lower limb amputation were considered - above knee and below knee. The 
figure 37 shows the association between stump healing and the type of amputation in 
patients who underwent lower limb amputation. Out of the one hundred patients, fifty 
three (53%) had an above knee amputation among which healing was seen in 60.4% 
(n=32). No significant (p=0.216) difference was observed between healed and non-healed 
stump among the above knee amputation group. The total numbers of below amputations 
were forty seven (47%) out of which twenty four healed (51.1%) (Figure 37). No 
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significant (p=0.884) difference was observed between stump healing and below knee 
amputation. The table below shows distribution of the number of patients who healed their 
stumps based on the type of amputation. Stump healing was not found to be associated 
(p=0.349) with type of amputation (Table 34).  
 
Table 34: Type of amputation and stump healing in the prospective group 
 
Type of 
Amputation 
Healed Not Healed Total Chi-Square P value 
AKA 32 21 53   
BKA 24 23 47 0.877 0.349 
Total 56 44 100   
Table 34 shows the distribution and association between stump healing (healed or not 
healed) and type of amputation (above knee or below knee). p= 0.349 indicating that 
stump healing was dependent on the type of amputation.  
 
 
Figure 37: Stump healing and types of amputation in the prospective group 
 
 
 
 
Figure 37 showing association between success and failure of stump healing among 
subjects who underwent lower limb amputation (above knee and below knee). Numbers 
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written on top of the bar indicate the percentage. p value for above and below knee 
amputation were p=0.216 and p=0.884 respectively. 
 
4.7.4 Association between age and stump healing in the prospective group 
The figure 38 shows the association between stump healing and gender in patients who 
underwent lower limb amputation. Of the 100 patients included in the study, 97 were 
above the age of 50 years (97%) and 3 below the age of 50 years (3%). The youngest 
patient was aged 43 years and the oldest, 98 years with the average age being 72.28 years. 
Out of 97 patients above the age of 50 years 53 healed their stump (54.6%) and 44 patient’s 
stumps failed to heal (45.4%) (Figure 38). No significant difference was observed between 
stump healing and above the age of 50 years (p=0.477). A p value could not be calculated 
for the group of patients below the age of 50 years. The table below shows an age wise 
distribution of the number of patients who healed their stumps. The healing of the stump 
was independent of the age (p=0.119) (Table 35).  
 
Table 35: Age and stump healing in the prospective group 
 
Age Healed Not Healed Total Chi-Square P value 
≤ 50 3 0 3   
> 50 53 44 97 1.130 0.119 
Total 56 44 100   
Table 35 shows the distribution and association between stump healing (healed or not 
healed) and type of amputation (above knee or below knee). p=0.119 indicating that stump 
healing was independent of age.  
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Figure 38: Age and stump healing in the prospective group 
 
Figure 38 showing association between success and failure of stump healing among 
subjects who underwent lower limb amputation (above knee and below knee). Numbers 
written on top of the bar indicate the percentage. p value for patients with above the age 
of 50 years was p=0.477. 
 
4.7.5 Association between diabetes mellitus and stump healing in the prospective 
group 
The figure 39 shows the association between stump healing and diabetes mellitus in 
patients who underwent lower limb amputation. Out of the 100 included patients, there 
were 44 in the diabetes mellitus cohort and 56 in the non-diabetes mellitus cohort. Among 
the diabetic population 61.4 % (n=27) healed their stump and 38.6% (n=17) failed to heal 
their stump. In the non-diabetics 29 healed their stump (51.8%) in comparison to 27 
(48.2%) who failed to heal their stump (Figure 39). No significant difference was observed 
between stump healing and both diabetic (p=0.132) and non-diabetic patients (p=1.00). 
The table below shows the distribution of the number of patients who healed their stumps 
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in the diabetic and the non-diabetic group. Stump healing was independent of Diabetes 
(p=0.338) (Table 36).  
 
Table 36: Diabetes mellitus and stump healing in the prospective group 
 
 
Diabetes 
mellitus 
Healed Not Healed Total Chi-Square P value 
No 29 27 56   
Yes 27 17 44 0.917 0.338 
Total 56 44 100   
 
 
 
Figure 39: Stump healing in patients with diabetes mellitus in the prospective 
group 
 
 
 
 
Figure 39 showing association between success and failure of stump healing among 
subjects who underwent lower limb amputation (above knee and below knee). Numbers 
written on top of the bar indicate the percentage. The p value for patients with Diabetes 
and without Diabetes were (p=0.132) and (p=1.00) respectively. 
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4.7.6 Association between hypertension and stump healing in the prospective group 
The figure 40 shows the association between stump healing and hypertension in patients 
who underwent lower limb amputation. A total of 98 patients were hypertensive and 2 
were non hypertensive among 100 patients who underwent major lower limb amputation 
surgery. In the hypertensive group, the stump healing rate was 56.1% (n=55) while the 
failure rate was 43.9% (n=43). On the other hand, the healing rate was 50% for both 
hypertensive and the non-hypertensive group. No significant difference was observed 
between stump healing and patients with (p=1.00) and without hypertension (p=0.312). 
The table below shows a distribution of the number of patients who healed their stumps 
in the hypertensive and the non-hypertensive group. Stump healing was independent of 
the blood pressure (p=0.863) (Table 37) 
 
Table 37: Hypertension and stump healing in the prospective group 
 
 
HTN Healed Not Healed Total Chi-Square P value 
No 1 1 2   
Yes 55 43 98 0.030 0.863 
Total 56 44 100   
Table 37 shows the distribution and association between stump healing (healed or not 
healed) and type of amputation (above knee or below knee). p=0.863 indicating that stump 
healing was independent of hypertension. 
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Figure 40: Stump healing and hypertension in the prospective group 
 
 
 
 
Figure 40 showing association between success and failure of stump healing among 
subjects who underwent lower limb amputation (above knee and below knee). Numbers 
written on top of the bar indicate the percentage. p value for patients with and without 
hypertension was (p=1.00) and (p=0.312) respectively. 
 
 
 
4.7.7 Association between smoking and stump healing in the prospective group 
The figure 41 shows the association between stump healing and smoking in patients who 
underwent lower limb amputation. Among the 100 patients, 85 were smokers and 15 were 
non-smokers. Among the smoking cohort, 52.9% (n=45) achieved stump healing and 
47.1% (n=40) failed to heal their stump. The success rate of stump healing was 73.3% 
(n=11) and 26.7% (n=4) failed to heal their stump among nonsmokers (Figure 41). No 
significant difference was observed between stump healing and both smokers (p=0.588) 
and non-smokers (p=0.197). The table below shows the distribution of the number of 
patients who healed their stumps among the smoking and non-smoking groups. Stump 
healing was independent of the smoking (p=0.142) (Table 38).  
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Table 38: Smoking and stump healing in the prospective group 
 
 
Smoking Healed Not Healed Total Chi-Square P value 
No 11 4 15   
Yes 45 40 85 2.152 0.142 
Total 56 44 100   
 
 
Figure 41: Stump healing and smoking in the prospective group 
 
Figure 41 showing association between success and failure of stump healing among 
subjects who underwent lower limb amputation (above knee and below knee). Numbers 
written on top of the bar indicate the percentage. p value for both smokers and non-
smokers was (p=0.588)  and (p=0.197) respectively. 
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diabetic patients (n=44) enrolled in the study. HbA1c was divided into three categories 
namely HbA1c of 6.5% and below, HbA1c between 6.5-7.5% and HbA1c above 7.5%. 
These groups were based on the patient’s diabetic control (optimal/satisfactory and poor) 
(NICE guidelines. 2015). One hundred percent (n=2) achieved stump healing among the 
patients with optimal control. The success rate of stump healing was 77.8% (n=12) and 
45.8% (n=39) among the satisfactory and poor control group respectively. No significant 
difference was observed between stump healing and all the three groups; (p=0.301) for 
the optimal group, (p=0.091) for the satisfactory group and (p=0.722) for the poor control 
group. The table below shows the distribution of the number of patients who healed their 
stumps based on their HbA1c. Stump healing was independent of diabetic control. 
(p=0.057). (Table 39).  
 
Table 39: HbA1c and stump healing in the prospective group 
 
 
Smoking Healed Not Healed Total Chi-Square P value 
≤6.5 2 0 2   
6.5-7.5 14 4 18 5.746 0.057 
≥7.5 
Total 
11 
27 
13 
17 
24 
44 
  
 
Table 39 shows the distribution and association between stump healing (healed or not 
healed) and type of amputation (above knee or below knee). p=0.057 indicating that stump 
healing was independent of diabetic control. 
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Figure 42: Stump healing in different HbA1c groups in the prospective group 
 
Figure 42 showing association between success and failure of stump healing among 
subjects who underwent lower limb amputation (above knee and below knee). Numbers 
written on top of the bar indicate the percentage. p value for the different groups were; 
p=0.301 for the optimal group, p=0.091 for the satisfactory group and p=0.722 for the 
poor control group. 
 
4.8 External Validation  
Optimism is a well-known problem of predictive models. Their performance in new 
patients is often worse than expected based on performance estimated from the 
development data set (Van Houwelingen and Le Cessie. 1990; Harrell et al. 1996). Hence 
the need for external validation. External validation was performed on data obtained from 
an independent data set of patients who underwent major lower limb amputation surgery 
at the Royal Infirmary of Edinburgh between year 2010 and 2011. The discriminative 
ability of the final model for the stump healing was calculated by measuring the area under 
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performance (Bleeker et al. 2003). The Receiver Operating Characteristic curve was 
constructed by calculating the sensitivity and specificity for consecutive cut-off points 
according to the predicted probabilities from the logistic regression models.  
To assess the fit of a logistic regression model is to see what proportion of true positives 
it classifies as being positive (the sensitivity) and what proportion of true negatives it 
classifies as being negative (the specificity). Discrimination indicates how well the model 
discriminates between people with and without the outcome. An Area Under the Curve of 
0.5 indicates that the model is not discriminating very well (no different to tossing a coin); 
an Area Under the Curve of 1.0 indicates perfect discrimination. Receiver Operating 
Characteristic curve for external validation was developed, based on the predicted 
probabilities for every patient and calculating the sensitivity and specificity for 
consecutive cut-off points according to the predicted probabilities from the logistic 
regression models.  
  
 𝑃𝑟𝑒𝑑𝑖𝑐𝑡𝑒𝑑 𝑃𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦 =  
𝑒(𝛽0+𝛽1𝑋1+𝛽2𝑋2+⋯+𝛽𝑛𝑋𝑛)
1+𝑒(𝛽0+𝛽1𝑋1+𝛽2𝑋2+⋯+𝛽𝑛𝑋𝑛)
 
 𝑃𝑟𝑒𝑑𝑖𝑐𝑡𝑒𝑑 𝑃𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦 =  
1
1+𝑒−(𝛽0+𝛽1𝑋1+𝛽2𝑋2+⋯+𝛽𝑛𝑋𝑛)
 
Where 
 Β0 is the intercept, β1 till βn are the regression coefficients and X1 to Xn are independent 
variables. 
 
𝑃𝑟𝑒𝑑𝑖𝑐𝑡𝑒𝑑 𝑃𝑟𝑜𝑏𝑎𝑏𝑖𝑙𝑖𝑡𝑦 =
1
1 + 𝑒−(−1.82+(0.563𝑋𝑆𝑒 𝑁𝑎)+(0.509𝑋 𝑆𝑒 𝐶𝑟𝑒𝑎𝑡𝑖𝑛𝑖𝑛𝑒)+(0.561 × 𝐻𝐷𝐿)
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Se Na=serum sodium levels, Se Creatinine=serum creatinine levels and HDL=serum 
High Density Lipid cholesterol. 
By using the above formula, predicted probability of each patient was calculated. The area 
under the Receiver Operating Characteristic curve for the prediction of stump healing was 
calculated using predicted probabilities and patients’ outcomes (healed or not healed) of 
each patient.  
Figure 43: Receiver Operating Curve analysis for validation of the prognostic 
model 
 
Figure 43 showing receiver operating characteristics of stump healing. Area under the 
curve was 0.584 (95% CI: 0.365-0.612), indicating good discriminatory ability of stump 
healing. 
 Chapter 4 
178 
 
The area under the Receiver Operating Characteristic curve for the prediction of stump  
healing in lower limb amputation in the validation set was 0.584 (95% bias-corrected CI: 
0.365-0.612), consistent with good model discrimination (Figure 43). 
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The results of this study identified 3 blood markers namely serum sodium, serum 
creatinine and serum High Density Lipid cholesterol to be useful predictors of lower limb 
stump healing out of 7 markers which were noted to have association with stump healing 
in multivariate analysis. Each of these markers were independently associated with stump 
healing following a major lower limb amputation. Healing of the stump as defined was 
achieved in sixty three percent (n=189) patients. The healing rates were noted to be 68.3% 
(n=109) in the above knee amputation group and 56.8% (n=80) in the below knee 
amputation group. 
All the biomarkers markers used were interpreted as dichotomous variables rather than as 
a continuous variable due to the methodology of the study.  According to Harrell et al. 
(1996) for continuous predictors (independent variables), logistic regression assumes that 
predictors are linearly related to the log odds of the outcome. However, if this assumption 
is violated, logistic regression underestimates the strength of the association and rejects 
the association too easily, that is being not significant where it should be significant. Hence 
it is preferable to categorize the continues variables into dichotomous data. The authors of 
this study however, realize that in conversion of the continuous variables into categorical 
data, useful information could be lost.  
5.1 Gender and stump healing 
In the present study, gender emerged as a significant marker for the prediction of stump 
healing in univariate analysis but not in multivariate analysis. In other words, gender had 
a strong association with stump healing on its own but when the relative contribution of 
each of the predictors to the total variance was seen, it showed no association. This could 
be the effect of unbalanced sample size with the males being in higher proportions 
 Chapter 5 
181 
 
compared to the females (n=214 versus n=86). Wang et al. (1994) who carried out a 
prospective study evaluating parameters capable of predicting wound healing in patients 
with peripheral vascular disease in forty-four amputations also noted that gender was not 
associated with predicting wound healing. In addition, Eneroth (1993) in a study on 177 
patients with amputated limbs looked into factors which could potentially reduce the 
average age for amputation surgery and which could indicate success rate of lower limb 
amputations in patients with vascular disease also reported a similar finding. The lack of 
association in the above studies could be due to a small sample size and a larger 
prospective study could have different outcomes. 
There are other studies that showed that gender was a significant marker for lower limb 
stump healing. According to López-de-Andrés et al. (2011), who looked at 90,064 non-
traumatic amputations between 2001 and 2008, (46,536 minor and 43,528 major) 
performed in Spanish population reported that men were more likely to experience 
complications of lower limb amputations, including poor stump healing than women 
(male-to-female ratio being >2:1 (Type 1 diabetes mellitus: 2.23, Type 2 diabetes mellitus: 
2.18). Vamos et al. (2010) studied the incidence of lower extremity amputations in 
individuals with and without diabetes mellitus in England between 2004 and 2008.  They 
observed that the incidence of lower limb amputations was significantly higher among 
men than among women with diabetes mellitus (p<0.001). A study by Faglia et al. (2001) 
who reviewed a total of 115 subjects suffering from diabetes mellitus from 1990 to 1993 
with a new major amputation and their survival rates noted an association with stump 
healing and female sex (p=0.027) in the multivariate analysis. A study undertaken in the 
Netherlands by van-Houtem et al. (2004) indicated a gender trend in amputees. Reviewing 
data for 1991–2000, the researchers reviewed a total of 2,409 amputations. In 1991, there 
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were 818 male amputees and 869 female amputees; in 2000, the number of male amputees 
had risen to 971 but for women it had fallen to 702. The differences are statistically 
significant (p<0.001). One possible explanation for the increase in male amputations is 
diabetes mellitus had increased proportionately more in men between 1991 and 2000 
(114,000 to 211,000 cases, representing an increase of 84.9%) than in women (193,000 to 
251,000 cases; 29.9% increase).  
The growing prevalence of lower extremity amputation among men, as observed in this 
study and other studies quoted above however, cannot be attributed solely to the increasing 
incidence of diabetes mellitus in men. Delayed manifestation of atherosclerotic disease in 
women assumed secondary to the exposure to endogenous oestrogens during the fertile 
period of life could also be contributory. The research findings of Margolis et al. (2002) 
suggested that, in comparison to postmenopausal women who did not take hormone 
replacement therapy, those that did had a lesser risk of developing venous and pressure 
ulcers. Furthermore, in patients who took hormone replacement therapy, the age-based 
relative risk prediction for formation of venous and pressure ulcers was 0.65 (95% CI, 
0.61 to 0.69) and 0.68 (95% CI, 0.62 to 0.76), respectively. Several other studies including 
Pirila et al. (2002) noted beneficial effects of oestrogen on wound healing. Mechanisms 
underlying the effects of oestrogen on the complex process of wound healing have not 
been fully established but the anti-inflammatory properties including suppressive effect of 
oestrogen on Poly Morphonuclear Leukocytes (PMN) chemotaxis play a role (May et al. 
2006). 
5.2 Type of amputation and stump healing 
In this study, sixty three percent (n=189) of lower limb stumps healed.  The trans-femoral 
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amputation (above knee amputation) healing rate was better than the trans-tibial 
amputation (below knee amputation) (68.3% vs. 56.8%). This study’s findings that 
primary healing rates are better in above knee stumps in comparison to below knee stumps 
are consistent with other studies including that of Dormandy et al. (1999) who added that 
a wide variation was exhibited by the rates of healing of amputations conducted below or 
above knee. Above-knee amputations have been shown to heal in 90% of cases, whilst the 
healing rate of below-knee amputations varies greatly, from 30% to 92%, an average being 
60% in below knee amputations. VanRoss et al. (2009) who conducted clinical trials in 
250 new lower-limb amputees reported that the healing rates in below knee stumps were 
74%. These results appear to be logical form an anatomical perspective wherein the higher 
the amputation the better the blood supply.  
However, there are other studies where stump healing was noted to be better in below knee 
amputation. According to Jensen and Mandrup-Poulsen (1983) the success rate of below 
knee amputations with regards to stump healing and prosthetic fitting was 83% in contrast 
to 69% healing rates and prosthesis fitting in above knee amputation. Similar findings 
were reported in other studies (Christensse, 1976). Burgess et al. (1971) who reviewed 
177 consecutive patients who underwent lower limb amputations noted that out of 145 
below knee amputations, only 12 failed to heal compared to 8 of the 40 that had above 
knee amputation.  Chilversa et al. (1971) reviewed 53 lower limb amputations and 
postulated that a below knee amputation was the most feasible option in the case of 
patients suffering from ischaemia of the lower extremities, because it had a healing rate 
of 70%. Though the healing rates for above knee stumps were better than the below knee 
in this study, the level of amputation was found to be a significant marker for stump 
healing only in the univariate analysis. 
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The generalisation that above knee amputation generally have better healing rates and 
lower reoperation rates compared to below knee amputation stems from the fact that the 
vascular supply decreases distally in patients with peripheral arterial disease. However, 
when tissue ischaemia or infection proximal to the below knee amputation level is evident, 
above knee amputation is also the level of choice for lower limb amputation (Rosen et al. 
2014). However, several other studies reported that above-knee amputation was not only 
correlated with a higher mortality rate, potentially as a result of advanced and severe 
disease, but was also more prevalent among elderly patients. One such study was that 
undertaken by Pell et al. (1999), which investigated 2759 patients from Scotland who had 
major amputation during the period 1989-1993 due to peripheral arterial disease supported 
this. The main causes of death associated with above- and below-knee amputation were 
identified by Rush (1981) as being myocardial infarction and sepsis, respectively. 
Meanwhile, Dormandy (1991) suggested that the risk factors most likely associated in 
death within three months after major amputation were ischaemic heart disease and 
diabetes mellitus. On the other hand, the fact that cardiovascular disease, cerebrovascular 
disease and diabetes mellitus become more prevalent with age provides an alternative 
explanation for the higher mortality rate among older patients that has been reported by 
numerous studies. 
In this study, the healing rates were better in the above knee amputation group. As this 
study did not look into arterial imaging of the lower limb, it was presumed that the patients 
with above knee amputation had good blood supply along the femoral arteries. There could 
also be variation secondary to the previous vascular procedures which the patients would 
have undergone previous to the amputation surgery. Most of the above-mentioned studies 
also did not exclude patients with previous vascular procedures as this would dwindle 
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sample size. There are however other factors that prompts the surgeon to perform a above 
knee amputation despite having good distal circulation. These include poor possibility of 
harnessing skin flaps around the site of the amputation. The reason behind the decision 
for the level of the surgery was not taken into account in this study. Future studies could 
look into the indications for the level of surgery and correlate the stump healing with the 
indication. 
One of the key parameters for the level of amputation being the blood supply has not been 
looked at in this study. As a result, the outcomes of this study only aid the surgeon to 
decide the level of amputation but does not provide conclusive evidence for an ideal level 
of amputation.  
5.3 Age and stump healing  
The age of the patients who underwent lower limb amputation surgery varied between 34 
and 97 years, the mean age being 70.16 ± 14.5 years. In this study, age was not found to 
be a predictive marker for stump healing both in univariate and multivariate analysis. 
Similar findings were reported by Eneroth et al. (1993) who prospectively analysed stump 
healing in 177 cases and noted that age had no relation with healing rates.  Low et al. 
(1996) who reviewed 60 below knee amputations in patients with diabetes mellitus also 
reported that age did not play a role in stump healing (p=0.40). However, this was an 
observational study with a small sample size.  
However, other studies including a study by Taylor et al. (2005) looking into preclinical 
factors predicting functional outcomes in 553 patients who had lower limb amputation 
and they concluded that older patients aged more than 70 years who experience non-
ambulatory status were 10 times less likely to heal their stump or wear prosthesis. Chen 
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et al. (2008) did a five year review (2002-2006) on factors effecting stump healing and 
functional outcomes post lower limb amputation. One hundred seventy-nine patients were 
included whose ages ranged from 28 to 85 years (average 64.3 ± 12.9 years) and the mean 
follow-up time was 28.3 ± 13.0 months. They added that unchangeable factors including 
age significantly affected stump healing (p<0.001).  
In a retrospective study of all non-traumatic amputations in patients with (n=100) and 
without (n=151) diabetes mellitus performed between 1990-1995, Tentolouris et al. 
(2004), noted that patients without diabetes mellitus who had lower limb amputation were 
older than patients who suffered from diabetes mellitus who underwent the same 
procedure. They added that the older patients also went on to have higher revision rates 
secondary to poor stump healing (p=0.001). In other words, amputations in individuals 
with diabetes mellitus are performed at a younger age, a finding observed in other studies 
including a retrospective study by Mayfield et al. (2001) who looked at the common 
demographic and comorbid conditions that affect survival following non-traumatic 
amputation. They added that survival following a lower-limb amputation is impaired by 
advancing age secondary to poor wound healing and other co-morbidities including 
cardiovascular and renal disease. Faglia et al. (2001) reviewed a total of 115 subjects with 
diabetes mellitus from 1990 to 1993 for new ulceration and new major amputation and 
their survival rates and noted their association with ankle-brachial index ≤0.5 (p=0.005), 
age (p=0.003), and female sex (p=0.027) in the multivariate analysis. Pell et al. (1999) 
studied 2759 patients undergoing major amputation between 1989 and 1993 for peripheral 
arterial disease. The study reported that sixty percent of amputations (n=924) performed 
in patients under 65 years of age were below knee amputations, compared to 53% (n=621) 
in those over the age of 80 years undergoing above knee amputations. Thus, proximal 
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amputation was found to be more common in older patients. They concluded that age was 
an independent predictor of death at 30 days (p<0.0001), 6 months (p<0.001), 12 months 
(p<0.0001) and 2 years (p<0.0001) post-operation secondary to poor stump healing and 
other co-morbidities. Patients in the above knee amputation group were older than those 
in the below knee amputation group (mean age of 77 years compared to 69 years, 
p=0.039). Though this was large sample study, it had a retrospective study design. 
Duration of diabetes mellitus and advancing age independently predicted diabetes mellitus 
morbidity and mortality rates. According to Elbert et al. (2014) for a given age group, the 
rates of each complication including lower limb amputation increased dramatically with 
longer duration of the disease (1.28 per 1000 person-years vs 4.26 per 1000 person-years). 
According to Fowler (2008) with advancing age and worsening diabetic neuropathy and 
atherosclerosis, the incidence of macrovascular complications including lower limb 
amputation increased accordingly.  
The finding that advancing age impaired stump healing could be explained by the fact that 
ageing generally impairs wound healing. The manner in which body systems, 
environmental stresses and disease interact with the ongoing process of aging increases 
the likelihood of older patients experiencing difficulties with wound healing. Several 
studies have provided evidence that diminishing levels of glycosaminoglycan and 
collagen, changes in the physical attributes of collagen and elastic fibres, and disruption 
in the organisation of the microcirculation all contribute to delayed healing in older 
individuals (Minimas. 2007). 
However according to Hasanadka et al. (2011), who carried out a study in 4250 (2309 
below knee amputations and 1941 above knee amputations) patients over a 3 year period 
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younger patients (age group 50-59) were almost two times (Odds Ratio-1.9) more prone 
to having a wound occurrence after below knee amputation compared with their older age 
group comparators. Explanations for increasing wound occurrences according to them in 
this younger age group included having more aggressive atherosclerotic disease, 
subsequent early failure of revascularizations, and the combination of genetic 
predisposition, hypercoagulability, and virulent risk factors. They added that inappropriate 
delay in amputation from an overly aggressive desire to save the foot in a younger patient, 
difficulties in care compliance in a more physically active age group, biased belief that 
this group of patients may not need the same skilled longer-term care and rehabilitation to 
heal a below knee amputation compared with older counterparts could also be the reasons 
for their findings.  
This study had a cut of age of 50 years and patients were categorised accordingly into age 
below and above 50 years. This is in keeping with several other studies conducted in 
diabetic foot ulcer patients. It would be interesting to note if the same trend of healing 
would have been found if the age cut of was to be changed to say 65 years. It would also 
mean that the group numbers would also be relatively evenly matched thereby making the 
results better interpretable. This is one of the limitation of this study. Also, as mentioned, 
age here was used as dichotomous variable rather than a continuous variable due to the 
methodology used in this study. The authors agree that in doing so useful information 
could have been lost. 
5.4 Diabetes mellitus and stump healing 
Diabetes mellitus remains a risk factor for lower limb amputation. In this study, 138 
subjects had diabetes mellitus and 162 did not have the disease. The success of stump 
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healing in these groups was 61.6 % (n=85) and 64.2 % (n=104) respectively.  
Many studies have concluded that diabetes mellitus is an independent risk factor for foot 
ulcers and lower limb amputation. However, few studies have been done with regards to 
diabetes mellitus as a risk factor for stump healing. According to Low et al. (1996) who 
reviewed 60 below knee amputations in patients with diabetes mellitus, many risk factors 
for foot ulcer healing were common to those of stump healing in lower limb amputation. 
In other words, though there was an anatomical difference in the sites, the physiological 
factors that played a role in healing of a foot ulcer and a stump were the same. Reiber et 
al. (1992) who reviewed eighty patients with lower limb amputation associated with 
diabetes mellitus over a 30 month period in a case control study reported that diabetes 
mellitus was a predictor of stump healing (p=0.01), a finding shared by other studies 
including Moss et al. (1992) who investigated risk factors for lower extremity amputations 
in a cohort study (95% CI, 1.0-3.2), though both these studies were limited by their study 
design. Criado et al. (1992) who reviewed 79 patients with diabetes mellitus who 
underwent emergency lower limb amputation procedure for severe infection of the foot 
noted that diabetes mellitus was a risk factor for poor wound healing. However, this study 
had a small sample size (n=79). Similar findings were also reported by Apelqvist et al. 
(1992) who carried out a prospective study on 314 sequentially presenting patients with 
diabetic foot ulcers.  
In a study by Tentolouris et al. (2004), of the 257 amputations performed during 1990–
1995, 39.7% (n=102) were in patients with diabetes mellitus. They reported that more 
patients without diabetes mellitus had major amputations in comparison with patients who 
suffered from diabetes mellitus (62.3% vs 48.7%). However, often patients with diabetes 
mellitus had two or more amputations during the study period in comparison with non-
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diabetic patients (54.9 vs. 36.4%, respectively) due to failure of the stump healing. They 
also reported that the duration of diabetes mellitus was an independent predictor of 
mortality in the diabetic group (p=0.05). However, this was a retrospective and 
observational study, potentially suffers from the limitations of such observations. Cause-
specific mortality was also not examined in this study. 
In a study by Heikkinen et al. (2007), the mortality rate following major lower limb 
amputation was higher among vascular patients with diabetes mellitus than among non-
diabetics of both sexes, especially among male patients, despite the fact that those without 
diabetes mellitus were older than those with diabetes mellitus (mean age 76.7 and 73.2 
years, respectively, p<0.01). In other studies, coronary heart disease and stroke were the 
major reasons for the elevated mortality rate associated with diabetes mellitus (Mulnier et 
al. 2006). High HbA1c which shows poor diabetes mellitus control was strongly 
associated with atherosclerosis and was also strongly related to Low Density Lipid 
cholesterol and other cardiovascular risk factors. Several studies have also shown that 
improvements in glycaemic control can slow progression of atherosclerotic disease in 
individuals with both Type 1 (Larsen et al. 2004) and Type 2 diabetes mellitus 
(Wagenknecht et al. 2003). 
Although the above studies suggested a link between diabetes mellitus and stump healing, 
other studies found no relation between them. Eneroth et al. (1993), prospectively 
analysed stump healing in 177 cases who underwent lower limb amputation and observed 
that diabetes mellitus had no relation with healing rate. Of their sample size, 40% (n=70) 
of patients had diabetes mellitus. The relative risk reduction they noted for diabetes 
mellitus was 0.5 (95% CI of 0.1-0.8) which was lower than all the other factors which they 
looked into (sex, level of amputation, smoking, preoperative blood pressure, serum 
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creatinine, erythrocyte sedimentation rate and blood glucose). However, they did not 
exclude patients who had a re-amputation at the same or higher level which could 
potentially have skewed the results. They, however added that despite having no 
association with stump healing, diabetes mellitus lowered the mean amputation age by 3.2 
years (p=0.041). Wang et al. (1994) performed a prospective study on 44 amputations 
performed on 38 patients evaluating parameters predicting wound healing in patients with 
peripheral vascular disease. They reported no association between duration of diabetes 
mellitus and stump healing (p=0.021). However, these findings were collated based on a 
sample size of only 20 patients with diabetes mellitus. Low et al. (1996) reviewed 56 
patients with diabetes mellitus who underwent below knee amputations. They noted that 
duration (≤ 10 year versus ≥10 years) of diabetes mellitus (p= 0.27) and type of diabetes 
mellitus (Insulin dependent versus independent) (p=0.44) was found to have no predictive 
value on below knee amputation healing rates. This study however was retrospective in 
nature and the sample size was small.  
In this study, diabetes mellitus was not found to be a significant predictor of stump healing 
both in univariate and multivariable analysis. It could be argued that the foot and the lower 
limb stump are two different anatomical sites and that healing in these two sites could well 
be affected by a different set of factors. The blood supply for example is better in major 
blood vessels proximally and would decrease peripherally specially in diabetic patients 
who are known to have diffused atherosclerosis. Physical factors like offloading which 
are more relevant in the case of diabetic foot ulcer healing would also play a role in 
healing. This study did not take into account the duration and the type of diabetes in 
patients which could well play a role in healing. This is one of the limitation of this study. 
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5.5 Hypertension and stump healing 
In this study, essential hypertension was noted in 283 patients. In their analysis of a sample 
size of 110 patients suffering from peripheral vascular disease who underwent a lower 
limb amputation in the period 1987-1990, Lee et al. (1992) concluded that hypertension 
was more likely to have determined amputation than diabetes mellitus, as it was found to 
be more frequent than the latter (32 cases of hypertension, as opposed to 10 cases of 
diabetes mellitus). The considerable prevalence of hypertension led the researchers to 
suggest that future treatments of peripheral vascular disease should put more emphasis on 
effective control of hypertension, as a method of preventing amputation. Frugoli et al. 
(2000) who looked into the cardiovascular risk factors in 170 amputees noted that 
hypertension was higher in individuals with amputated limbs, with 42.7% (n=71) in 
contrast to 23% (n=39) in those without amputations. According to Tseng et al. (1994) 
who reviewed Chinese patients with diabetes mellitus after lower extremity amputations 
from 1982 to 1991, a history of uncontrolled hypertension was found to be an indicator 
for predicting a fatal outcome in relation to poor stump healing and mortality after a lower 
limb amputation with rate ratios of over two-fold. However, in this study hypertension 
was found to be an independent risk factors for stump healing in univariate analysis but 
not in multivariate analysis.  
Hypertension, however is a well-known risk factor for the development of atheromatous 
peripheral arterial disease. In patients presenting with peripheral arterial disease, 
hypertension is a major associated cardiovascular risk factor, present in up to 55% patients 
with peripheral arterial disease who are at risk of blood pressure-attributable progression 
of the peripheral vascular problems including high risk of death and disabling ischaemic 
events. According to Frugoli et al. (2000) three risk factors were elevated above the United 
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States population norms among the amputee population, namely; cholesterol, 
hypertension, and diabetes mellitus. About 47% of amputees suffered from hypertension 
which contributed to their higher cardiovascular mortality. According to Meijer et al. 
(2000) who looked into the atherosclerotic risk factors which were determinants for 
peripheral arterial disease in 6450 subjects noted that systolic blood pressure after 
multivariate analysis was a major risk factor and conferred an odds ratio for PAD of 
1.3(95% CI 1.2–1.5) per 10 mmHg systolic pressure. Many studies report that blood 
pressure management in peripheral arterial disease tends to be poor irrespective of the 
presence of diabetes mellitus as a comorbidity (Ostchega et al. 2004). In the PARTNERS 
study by Hirsch et al. (2001), hypertension was less often treated in new (84%) (n=312) 
and prior peripheral arterial disease (88%) (n=264) patients compared to treatment of 
hypertension in subjects with cardiovascular disease (95%; p<0.001). This may result in 
an increased incidence of lower limb amputation in patients with peripheral arterial 
disease and diabetes mellitus. 
The groups with hypertension and without hypertension were not evenly matched in this 
study. Hence the result will need to be interpreted with caution. The control of 
hypertension including anti-hypertensive medications was also not looked into, though 
most of the patients had good control (BP of less than 150/90).  
5.6 Smoking and stump healing 
Hughson et al. (1978) argued that smoking was a major risk factor for intermittent 
claudication. The association between smoking and healing of lower extremity amputation 
was investigated by Lind et al. (1991) based on a review of 165 primary above- and below-
knee amputations among a number of 137 patient. Results showed that, by comparison to 
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the patients who did not smoke, those who did were 2.5 times more likely to undergo a 
further amputation. 
Stewart (1987) confirmed that the incidence of amputation not only higher among patients 
who smoke, but was also required at a younger age. In a seminal paper looking at the 
effect of smoking in patients with diabetes mellitus with lower limb amputation, Liedberg 
and Persson (1983) looked at 188 lower limb amputees in Lund, Sweden and concluded 
that smoking of cigarettes positively correlated with a higher incidence of intermittent 
claudication (p<0.001) and that heavy smokers (defined as 10 cigarettes or more a day or 
10 g tobacco a day) were at three times the risk of developing intermittent claudication 
compared with non-smokers. 
Smokers with peripheral arterial disease exhibited a lower physical performance during 
treadmill assessment, including maximum oxygen uptake and quicker onset of 
claudication pain as a result of walking (Shimada et al. 2011). Meanwhile, Lu et al. (2013) 
reported that, by contrast to non-diabetics, patients with diabetes mellitus were 
considerably more likely to develop peripheral arterial disease, cigarette smoking 
enhancing this likelihood by an additional 50%. Identification of the determinants of the 
success rate of lower extremity amputation in individuals with vascular disease was the 
focus of the study conducted by Eneroth et al. (1993). To this end, the authors recruited 
177 number of patients who had undergone amputation; half of these never smoked, while 
26% and 24% were active and past smokers, respectively. Men accounted for 87% of the 
smokers. The average age at amputation was 59 and 74 years, respectively, in the case of 
individuals who smoked more than 15 cigarettes per day and those who smoked less. 
However, despite the fact that the difference between the two groups was non-significant 
(p=0.08), the failure rate at 6 months following amputation was lower among patients who 
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had never smoked (18%) than among those who smoked (31%). In addition, the likelihood 
of failure was 2.1 lower in patients who had never smoked by comparison to smokers 
(95%CI 0.3-13), and individuals were more likely to undergo amputation at a younger age 
by 8.6 and 3.2 years, respectively if they smoked (p=0.0001) or had diabetes mellitus 
(p=0.041). 
Wound healing is delayed by smoking (Sørensen, 2012), current smokers being more 
likely to experience incomplete healing of amputation stump (VanRoss et al. 2009; 
Hasanadka et al. 2011). Observations like these regarding the implications of smoking 
serve to highlight the importance of ongoing smoking cessation campaigns, even after 
healing of the primary amputation despite the fact that documentation of the correlation 
between smoking and contralateral amputation risk is yet to be established (Lind et al. 
1991). In a prospective study that investigated stump healing in 177 cases, Eneroth (1999) 
found that high levels of nicotine in blood reduced the blood flow speed, enhancing the 
likelihood of microthrombus formation. Furthermore, according to the findings of other 
studies, in contrast to individuals who did not smoke, those who did had higher levels of 
carboxyhaemoglobin. Carboxyhaemoglobin has been proposed as a determinant of wound 
infection and healing probability due to promotion of relative hypoxia which led to wound 
hypoxia (Sorensen et al. 2003). The cigarette components of nicotine, carbon monoxide 
and tar have an adverse effect on the functions of several endothelial cells including 
Connective Tissue Growth Factor (CTGF), eventually compromising their anticoagulation 
and prevention of clot formation capabilities, as well as diminishing their fibrinolytic 
activity. Additionally, the endothelium-dependent mechanism of vasodilation is also 
affected by smoking through interference with processing and release of nitric oxide. The 
compression, multiplication and movement of vascular smooth muscle cells can be 
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enhanced in conditions with reduced levels of nitric oxide (Newby, 1999).  
In this study, smoking was identified as an important indicator of stump healing only in 
the univariate analysis. According to Lo et al. (1995) one of the possible explanations for 
variables to show a tendency wherein they are significant in univariate analysis but not in 
multivariate regression analysis or vice versa could be if the sample size is unbalanced. In 
this study, the number of patients who smoked (n=245) were compared to the non-
smoking cohort (n=55) resulting in an unbalanced sample size. The smoking status was 
obtained from the data software in the retrospective study. This meant that important 
information like number of pack years, the duration of smoking and the type of smoking 
was not available. This could have potentially biased the results.  
5.7 Kidney function markers (including electrolytes) and stump healing  
In this study, serum urea was not shown to be a predictive marker in lower limb stump 
healing both in univariate as well as multivariate analysis. However, serum creatinine was 
found to be a predictor for lower limb stump healing both in the univariate as well as the 
multivariate analysis. The healing rate of patients with a normal concentration of serum 
creatinine increased by 66% (OR 1.664; 95% CI 0.94 to 2.946). Taylor et al. (2005) 
reviewed the correlation between preoperative clinical parameters and post-surgery results 
with regards to limb functionality in the case of patients who had been subjected to leg 
amputation, and concluded that patients suffering from end-stage renal disease performed 
poorly with transtibial amputation secondary to poor stump healing and recommended 
palliative transfemoral amputation instead. Renal failure is considered to be an important 
factor leading to amputation following stump healing complications. Blume et al. (2007) 
stated that end-stage renal disease and the failure of amputation stumps to heal exhibited 
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a strong correlation (p=0.0209). However, this study was restricted by its study design 
(retrospective study) and sample size (n=80). Similar findings were also reported in other 
studies at lower levels of lower limb amputations (Hodge et al. 1989). According to Steven 
(2000) uraemia caused significant impairment of the healing process. The adverse effects 
of uraemia were as a result of the changes in enzyme systems, biochemical pathways, and 
cellular metabolism. Different haemostatic disruptions are considered to be the cause of 
bleeding diathesis and pro-thrombotic condition in uraemia. However, Eneroth et al. 
(1993) in a study on 177 patients with amputated limbs looked into factors which could 
potentially reduce the average age for amputation surgery reported that kidney function 
played no role in lower limb stump healing. This could potentially be because of the mild 
degree of renal impairment in the subjects involved in this study (mean creatinine levels 
120). 
Serum sodium was found to be an important predictor for stump healing. Patients with a 
normal concentration of serum sodium had a lower limb stump healing rate of 75% 
(n=225) in comparison with those with an abnormal concentration of serum sodium (OR 
1.756; 95% CI 1.048-2.942; p=0.031). Yaghoubian et al. (2007) also made comparable 
observations in individuals with necrotising soft tissue infection who had had an 
amputation procedure. diabetes mellitus along with abnormal electrolytes interferes with 
the normal functioning of the metabolism, promoting pro-thrombotic state, endothelial 
function impairment, growth factor deregulation, and excessive deposit of extracellular 
matrix. The deranged serum sodium in patients who underwent major lower limb 
amputation in this study is probably as a consequence of the disruption to the metabolism 
secondary to the injury post a major surgery. It could also be a reflection of the systemic 
illness of the patient given the multiple comorbidities they suffer from. According to 
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Nissen et al. (1992) the preoperative physical condition and the presence of comorbidity 
influences not just the stump healing but also the functional outcomes following a lower 
limb amputation surgery including the prosthesis wearing rates.  This was also observed 
in another study done by Chen et al. (2008) who did a five year review (2002-2006) on 
factors effecting stump healing and functional outcomes post lower limb amputation on 
one hundred seventy-nine patients whose ages ranged from 28 to 85 years (average 64.3 
± 12.9 years). They added that in their series, the renal function factor (creatinine >1.4 
mg/dl or worse, p=0.045) affected the pre-prosthetic training waiting time (p=0.001) and 
also influenced the daily prosthesis usage time (p=0.01). This study however was limited 
by its study design (retrospective analysis). Other studies including a study done by 
Sheahan et al. (2005) who looked at 670 patients who underwent 920 minor amputations 
on 747 limbs noted that end-stage renal disease (serum creatinine levels >2.0 mg/dL) was 
an independent risk predictor (p<0.0001, OR 1.72, 95% CI 1.12-2.83) for limb loss and a 
further amputation at a higher level due to poor stump healing. Though this study had a 
large sample size, it was retrospective in nature.  
5.8 White cell count and stump healing 
In this study, white cell count was not noted to be of prognostic value in stump healing in 
lower limb amputation both in univariate as well as multivariate analysis. It could be 
argued that advanced atherosclerosis and poorly controlled diabetes mellitus are immune-
compromised states and the patients might not mount a response to infection and this could 
result in a minimal rise in the inflammatory markers which could explain the finding in 
this study. According to Calhoun et al. (2009), in chronic inflammation the blood 
leukocyte count is usually normal and most of the diabetic foot ulcers with both soft tissue 
and bony infections are chronic. Chronic infection is the result of the co-existence of 
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infected, nonviable tissues and an ineffective host response. 
Low et al. (1996) who reviewed 54 patients with diabetes mellitus with 60 below knee 
amputations in 1992 also reported that white cell count was not associated with stump 
healing (p=0.17). According to Tentolouris et al. (2004), however there is an independent 
association between a higher white cell count and survival in the amputees without 
diabetes mellitus. They found no association between higher white cell count and 
mortality in patients with diabetes mellitus. 
One of the explanations for studies not finding an association between inflammatory 
markers and stump healing could be because the degree of variation of infection itself in 
the studies. According to Ince et al. (2008) who compared populations and outcomes of 
diabetic foot ulcers managed in the United Kingdom and other countries including 
Germany from a series of 449 patients concluded that degree of infection varies 
considerably across different studies. There are also discrepancies in management of an 
infected diabetic foot ulcer. The degree of infection (presence of soft tissue versus bony 
infection) plays an important role not just in the treatment options but also on the outcome 
of the infection. Local microbiological susceptibility and epidemiology dictate the types 
of antibiotics that can be used. However, despite the importance of pathogenic agents and 
epidemiology in the selection of antibiotics, antibiotic administration cannot wait until 
culture and sensitivity results are generated. Hence, local epidemiological and 
susceptibility data are essential for preliminary empirical treatment.  According to Lipsky 
et al. (1999) the type of organism grown in the culture also plays a role in the severity of 
the infection. With so many factors playing a role in the management of infection control, 
variable outcomes are expected which will have an impact on the inflammatory markers 
and stump healing. 
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However, other studies have shown an association between raised inflammatory markers 
and poor stump healing. Of the 80 patients examined by Blume et al. (2007), 10% (n=8) 
had an abnormal number of leukocytes and slowed down the rate of limb healing, while a 
proportion of 68% (n=13 of 19) displayed no stump healing. These findings led to the 
proposition that leucocytosis and lack of amputation stump healing were correlated 
(p=0.0052). However, this was a retrospective study and the sample size was small. The 
correlation between nutrition and lower limb amputation proximal to the Symes level 
among 41 patients was the focus of the prospective study conducted by Kay et al. (1987). 
They found that, compared with patients with a higher number of lymphocytes, patients 
with a normal lymphocytic count who underwent lower extremity amputation were less 
likely to experience complications related to healing (p=0.05). Meanwhile, in a different 
study on 103 patients with diabetic foot ulcers, it was determined that leucocytosis 
(number of white cells > 11,000 cells/μL) was the only relevant marker of slow rate of 
healing and the only parameter that could be used in both univariate and multivariate 
analyses (multivariate odds ratio 9.7, 95% CI 1.0 to 92, p=0.048) (Fleischer et al. 2011). 
The systematic reviews of diabetic foot infection that were undertaken by Lipsky et al. 
(2006) and Zgonis et al. (2005) produced similar results. In another study, the 
determinants of the clinical outcome of below-knee amputation among diabetic foot 
patients during the period January 2006 – January 2010 constituted the focus of Wong et 
al. (2013). They noted that markers of infection such as high C reactive protein, 
erythrocyte sediment rate, neutrophils were significantly associated (p=0.01) with poor 
clinical outcome (good clinical outcome being defined as one not requiring proximal re-
amputation or whose stump healed well within 6 months).  Mortality rate was 21.2% 
within 6 months of operation, with sepsis being the most significant cause of death in their 
study. 
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5.9 Clotting factors (Prothrombin Time, International Normalised Ratio) and stump 
healing 
The clotting markers namely Prothrombin Time and the International Normalised Ratio in 
this study were not found to have a significant impact on lower limb stump healing both 
in univariate as well as multivariate analysis. However, Hasanadka et al. (2011) who 
carried out a study in 4250 (2309 below knee amputations and 1941 above knee 
amputations) patients over a 3 year period concluded that for lower limb amputations, 
increasing elevation in International Normalised Ratio predicted a higher wound incidence 
in the stump (OR = 1.5, p=0.024) and suggested normalization of the International 
Normalised Ratio prior to the surgery decreases wound incidence in the stump. However, 
this study was based on the National Surgical Quality Improvement Program (NSQIP) 
database which according to LaMuraglia et al. (2009) may not reflect the cross-section of 
patients or accepted treatment in present practice.  Monroe et al. (2012) proposed that the 
general wound healing response likely depended on a strong initial coagulation response 
followed by effective deposition of fibrin. Furthermore, given that the initial inflammatory 
response was inadequate when haemostasis was dysfunctional, they suggested that normal 
wound healing required ongoing haemostasis. Meanwhile, Roy-Chaudhury et al. (2006) 
highlighted that, aside from promoting proliferation of vascular intima, platelet activation 
from endothelial damage after an inflammatory reaction also contributed significantly to 
promotion of platelet aggregating agents like platelet-derived growth factor and 
thromboxane A2. A haematoma in the stump following a lower limb amputation is a known 
complication which acts as a focus for infection and can create dead space, weakening the 
suture line and thus increasing tension in the wound resulting in impaired healing (Baxter, 
2003).  
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It is standard practice to attempt surgery ideally when the International Normalised Ratio 
is normalised to prevent excessive bleeding peri and post procedure. To prevent 
haemorrhaging complications, warfarin-based anticoagulation must be withheld 4-6 days 
prior to invasive procedure. Even so, high International Normalised Ratio values are still 
exhibited by some patients on the day of the procedure, which may be postponed, 
depending on the policy of different centres. Elimination of vitamin K antagonists and the 
liver’s ability for synthesis of coagulation factors II, VII, IX and X determine prothrombin 
time normalisation, expressed as International Normalised Ratio, a marker restoration of 
haemostasis (Schwarz et al. 2006). In this study, 57.7% (n=173) were noted to have a 
normal Prothrombin Time out of which 62.4% (n=81) healed their stump and 31.3% 
(n=94) were noted to have an abnormal International Normalised Ratio out of which 
59.6% (n=56) healed their stump. 
 
This study did not take into account the medications that the patients were on including 
any anticoagulants. Most of the patients had cardiac/stroke related problems and were on 
anticoagulants including Warfarin. However, before any major surgery as is the usual 
protocol, all anticoagulants are withheld for at least a period of 3 days or more.   
 
5.10 Lipid profile (total cholesterol, serum triglycerides, serum High Density Lipid 
cholesterol) and stump healing 
Many studies have reported hypercholesterolaemia as a risk factor for lower limb 
amputation surgery. In our patient population, well established pro-atherogenic factors; 
hypercholesterolaemia, triglycerides, and High Density Lipoproteins influenced stump 
healing. Of the 300 patients, 64.7% (n=194) having cholesterol level equal or below 5 
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mmol/L healed their stump. Low High Density Lipoproteins cholesterol (below 1.1 
mmol/L) was noted in 111 patients of whom 56.8% (n=170) healed. The healing rate was 
68% (n=204) in patients who had a normal serum High Density Lipoproteins cholesterol 
(above 1.1 mmol/L). In this study, serum High Density Lipoproteins cholesterol was found 
to be a predictive marker for lower limb stump healing both in the univariate as well as 
the multivariate analysis. Patients with a normal serum High Density Lipoproteins had a 
75% likelihood of stump healing, in contrast to the patients with an aberrant serum High 
Density Lipoproteins cholesterol (OR 1.753; 95% CI 1.061 to 2.895; p<0.026).   
This study however did not take into account the anti-lipid medications which the patients 
were on both in the retrospective as well as the prospective parts. The cardiovascular risk 
factors optimisation was not looked into in this study. This is one of the limitations of the 
study.  
Few studies have looked at lipid profile as a marker for stump healing. However, the role 
of anti-lipid therapies and their effect on lowering the lipid profile leading to a decreased 
risk in cardiovascular mortality and morbidity is well document. The STENO-2 trial 
(Gæde et al. 2008) which had two arms namely intensive multifactorial intervention 
against conventional treatment showed that there was a 50% reduction in microvascular 
and macrovascular events in the intensive arm which included a target of total cholesterol 
below 175 mg/dl, and triglycerides below 150 mg/dl. In another multivariable analysis, 
Suckow et al. (2012) who studied 436 patients with lower limb amputations between 2003 
and 2008 found that the patients most likely to remain ambulatory after a lower extremity 
amputation were those with preoperative statin use. Similar findings were also reported 
by Lazzarini et al. (2012) who studied one hundred and eighty-six lower limb amputations 
in 2006-07 and Lee et al. (1993) who carried out a retrospective study on Oklahoma 
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Indians with non-insulin dependent diabetes mellitus (n=1012) who underwent lower limb 
amputation between 1972-1980. Chaturvedi et al. (2001) who reviewed risk factors, ethnic 
differences and mortality associated with lower-extremity gangrene and amputation in 
diabetes mellitus in 3443 subjects noted serum triglycerides to be an independent risk 
factor for lower limb amputation. 
In contrast to the findings by the above studies, the Heart Protection Study (2003) which 
randomly assigned 5963 people with diabetes mellitus to either simvastatin or placebo, 
showed no difference in amputation rates between the groups for leg amputation (67 
[2·2%] vs 67 [2·2%]), or leg ulcer (40 [1·3%] vs 46 [1·5%]), despite substantial reductions 
in total cholesterol and Low Density Lipoprotein cholesterol concentrations and modest 
changes in triglyceride and High Density Lipoprotein cholesterol concentrations in the 
intervention group compared with controls. Rajamani et al. (2009) who carried out the 
Fenofibrate Intervention and Event Lowering in diabetes mellitus (FIELD) study, a pre-
specified analysis of a randomised controlled trial with 9795 patients concluded that lipid 
profile or statin therapy did not alter the risk of a major amputation or effect stump healing 
(HR 0·93, 0·53–1·62; p=0·79).  Nevertheless, in comparison to the placebo group, the 
fenofibrate group was less likely to require primary non-traumatic amputation, among the 
115 diabetic patients with atleast one non-traumatic amputation (HR 0·64, 95% CI 0·44–
0·94; p=0·02); implying that fenofibrate was associated with a lower risk of minor 
amputation than the placebo (HR 0·54, 0·34–0·85; p=0·007). The authors argued that 
better regulation of lipid profile might not be the only effect of fenofibrate therapy with 
regard to amputation risk. They based this argument on the observation that multivariable 
analyses did not indicate any correlation between lipid variables and amputation risk, 
meaning that lipids did not underpin the influence of fenofibrate in diminishing the risk 
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of amputation in the Fenofibrate Intervention and Event Lowering in diabetes mellitus 
study. Correlation of fenofibrate with better endothelium vascular activity (Rosenson et 
al. 2009) and with diminished endothelial dysfunction and pro-inflammation markers (e.g. 
tumour necrosis factor α, interleukin, and interleukin 1β in plasma) (Ryan et al. 2007) 
have been suggested as potential mechanisms shedding light on the positive effects of 
fenofibrate on microvasculature. Koh et al. (2005) reported that flow-mediated dilator 
response to hyperaemia, adiponectin levels and insulin sensitivity were all favourably 
influenced by fenofibrate in patients with hypertriglyceridemia or metabolic syndrome. 
However, the lack of a standardised routine assessment at baseline to establish vascular 
status constituted a significant drawback of the Fenofibrate Intervention and Event 
Lowering in diabetes mellitus study. This raises the possibility of erroneous classification 
of some amputations due to non-detection of macro-vessel disease as a result of 
undisclosed angiograms or vascular studies. 
5.11 Validation of the prognostic model of stump healing in lower limb amputation 
The accuracy of the regression model prognosis depends on model assumptions. The more 
these assumptions are satisfied, the more accurate the prognosis will be. Nonetheless, 
experimental data does not allow the complete fulfilment of the assumptions; as such, 
assessment is geared towards the accuracy of prognosis of a model regarding the 
information related to new patients. Authentication plays a significant role in providing 
patients with a reliable appraisal of performance, comparable to the ones obtained in the 
development sample. Measuring the efficiency of a predictive model for new patients is 
hence, essential. The process of external validation entails the estimation of prognoses 
generated by an earlier developed model and their validation using new information, 
unrelated to the development sample. 
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The purpose of a predictive model is to assess potential risks and to manage treatment 
accordingly, in this case, to ensure successful stump healing. This practice can help to 
structure the process, ensure efficient management of resource distribution, and limit 
expenses. The ultimate objective is to expand the number of successfully performed lower 
limb amputation surgeries. 
The long-term objective of this research effort was to identify factors predicting lower 
limb stump healing. The purpose of this study was to develop and validate a prognostic 
model in the prediction of a successful stump healing. We hypothesized that blood and 
patient factors could be used to stratify risk of a lower limb stump’s failure to heal. In 
brief, using the development dataset of 300 subjects, we identified three variables 
associated with lower limb stump healing: serum sodium, serum creatinine and serum 
High Density Lipoprotein cholesterol, and these variables were validated by using 
validation dataset of 100 subjects.  
Our prognostic model performed well in the external validation of stump healing that 
involved patients who had not experienced previous lower limb amputation surgery. The 
performance of the developed model in this study was assessed by discrimination and 
calibration of the model. The area under the Receiver Operator Curve for a prognostic 
model is classically between 0.6 and 0.85 (Royston et al. 2009). In our study, Receiver 
Operator Curves was primarily designed for prognostic models, rather for diagnostic 
models. Receiver Operator Curve was 0.61 in the development model and 0.59 in the 
validation stage, meaning that the model had reasonable capacity to correctly distinguish 
between stumps that healed and stumps that didn’t. In other words, in a randomly selected 
patient the outcome would be 59% more likely to have an increased prognosticated 
probability than a randomly selected patient without the outcome. Ideally, the closer the 
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ROC is to 1.0, the better the ability to discriminate between the outcome. The researchers 
understand that the ability to discriminate between stump healing is not ideal. For clinical 
practice, providing insight beyond the c statistic has been a motivation for some recent 
measures, especially in the context of extension of a prediction model with additional 
predictive information from a biomarker or other sources (Cook, 2007; Pencina et al. 
2008) 
Accuracy of the model was assessed by examining calibration (Grzegorczyk-Martin et al. 
2012). To assess the validity of the predictive model developed using the development 
dataset, we applied the model to an independent or a validation dataset composed of 100 
subjects. There was reasonably good agreement between the predicted and observed 
percentage in predicting stump healing. We further note that a substantial size will be 
required for a validation sample to quantify validity in a reliable way, that is, with enough 
power to substantial decrease in discriminative ability (Steyerberg et al. 2004). In 
statistical language, the larger the sample size the more robust the results. The ideal sample 
size is a matter of discussion for any study. Several studies including that of Palazón-Bru 
et al. (2017) have proposed an algorithm to calculate the sample size best suited to 
externally validate a scoring system. However, the algorithm is complex and does not suit 
all research designs. 
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This chapter provides a brief summary of the study, relates the findings with their 
implications, discusses the limitations of this study and suggests possible directions for 
future studies. 
6.1 Conclusion of the study 
Successful stump healing is a pre-requisite for ambulation following a lower limb 
amputation surgery. This thesis has provided a detailed evaluation of the risks conferred 
by some of the key elements on lower limb stump healing. In order to identify which lower 
limb stumps would heal following a major lower limb amputation surgery, a pre-surgery 
prediction rule was formulated and verified. This was done in two phases; the development 
stage and the verification stage. The initial model was developed using data from 300 
patients who underwent major lower limb amputation surgery from 2006 to 2009 in the 
Royal Infirmary of Edinburgh. Three markers namely serum sodium, serum creatinine and 
serum High Density Lipids cholesterol were recognized as being important predictors of 
lower limb stump healing. In the second phase these finding were confirmed using data 
from 100 patients from 2010 to 2011 who underwent major lower limb amputation surgery 
in the Royal Infirmary of Edinburgh. Due to time restrictions, assessments were carried 
out pre-operatively and post-operatively without a further follow up assessment, which 
could provide information on the longer-term consequences. However, additional 
assessment of the clinical benefits of such a risk classification system in relation to stump 
healing, based on a larger sample, is necessary. It is of considerable importance that many 
of the issues described in this thesis continue to be explored, solutions developed, and 
outcomes improved in this especially large population of vulnerable patients. The safe and 
effective provision of successful healing of the stump following a lower limb amputation 
surgery therefore remains an area in which considerable improvements may be made in 
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the future. 
6.2 Clinical implications of research 
The results of this study may suggest a number of clinical implications.  
In cases where vascular reconstruction is not feasible or is hindered by the configuration 
of the blood vessels, an efficiently conducted amputation may be a viable solution. In 
general, the main purpose of an amputation is to restore limb function with the use of 
prostheses. To this end, as well as to prevent further surgical interventions, it is of the 
utmost importance to accurately assess the amputation level. However, there are currently 
no reliable standards that can be referred to prior to leg amputation surgery, even though 
nowadays, the procedure is carried out on a regular basis. The surgeon has to rely on his 
clinical judgment and other investigatory parameters including a pre-operative angiogram 
which has a major role in determining the level of amputation. A meta-analysis performed 
by Koelemay et al. (2001) demonstrated that Magnetic Resonance Angiography (MRA) 
was highly accurate in diagnosing >50% stenosis or occlusion of arteries in the lower 
extremity (Level IIa) and played an important part in decision making regarding the site 
of amputation. However, according to Gu (2004) who looked into the role of an angiogram 
in 250 amputees, it is not an entirely reliable tool and should be used only as one of the 
factors rather than the only factor to determine the level of amputation. This study makes 
this complex decision making easier and adds to the lists of the markers which can play a 
role in stump healing. 
This study has implication in the post amputation rehabilitation process. The amputation 
level dictates how successful the restoration of limb function will be. The greater the loss, 
the more is the prosthetic substitution required. Continuing improvements in prosthetic 
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design cannot substitute for the advantages of a low level of amputation. Retention of the 
knee is especially important. A functional knee often will allow an elderly person to walk, 
whereas he or she could not do so with an above-the-knee prosthesis. It is, therefore, of 
the utmost importance that the surgeon be able to assess accurately the viability of the 
limb so that amputation can be performed at the lowest reasonable level. Within its 
parameters this study concludes that if a patient has a normal serum sodium, serum 
creatinine and serum High Density Lipids, his/her stump is more likely to heal compared 
to a patients with abnormal serum sodium, serum creatinine and serum High Density 
Lipids and the chances of needing further revision or an anatomically higher amputation 
would decrease, resulting in preservation of the knee in a below knee amputation surgery 
and thereby aiding their rehabilitation. This has an impact not just on the patients but also 
on the staff involved in the post amputation rehabilitation process including prosthetics, 
and other allied healthcare professionals. 
The level of amputation in lower limb has an impact not just on the patient but also the 
health system. The three markers which the study has shown to be of significance namely 
serum sodium, serum creatinine and serum High Density Lipids are blood markers that 
are routinely done on patients in a clinical setting. The total cost of conducting the above 
mentioned test is nominal thereby making these markers a cost effective tool to determine 
stump healing. 
Taylor et al. (2005) noted that, in the near future, the challenge which both vascular 
surgeons and patients will be confronted with would be related to the financial and 
practical aspects of the staged method of limb preservation, which can require numerous 
surgical interventions and subsequent open bypass, re-do bypass, costly wound treatment, 
toe amputations, a whole foot amputation, below-knee and then above-knee. Given the 
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complexity of the staged method of limb preservation, a primary amputation may be a 
more beneficial solution for the patient. The number of revascularizations could be limited 
if the stump healing rate prediction was more accurate. The results of this study therefore, 
are a step forward towards finding an answer about stump healing and the need for 
revascularization procedures. 
6.3 Limitations of the study 
There are a number of limitations of this study. Patients were followed up for only 12 
weeks in the prospective study due to time restrictions. The formulation of the prediction 
rule relied on 400 lower limb amputation, constructed in the same medical centre in 
Scotland. It is possible that the recorded incidence of diabetes mellitus, peripheral vascular 
disease, and smoking is not illustrative of all the patients with advanced atherosclerosis in 
Scotland. Hence, this model being a single centre study, did not encompass all the 
differences in patient demographics and heterogeneity. The prevalence of diabetes 
mellitus/peripheral vascular disease/smoking in the derivation set may also not be 
representative of the Scotland amputee population. In the derivation set, surgeons with 
considerable experience carried out the amputations. However, even with extensive case-
mix adjustments seen in previous studies, certain factors which cannot be quantified, 
including surgical techniques and concepts of care, may be important (Pisoni et al. 2002).  
One of the major determinants of the level of amputation is the vascular supply. This is 
effectively measured by radiological imaging. This study did not take into account any 
form of radiological imaging techniques in determining ideal level of amputation and the 
subsequent stump healing.  
According to Kern et al. (2006), lower limb amputations are associated with a number of 
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risk factors, including chronic kidney disease and peripheral neuropathy. Most of the 
subjects included in this study had multiple co-morbidities, the severity of which was hard 
to quantify. The extent of some of the co-morbidities including the duration, control and 
extent of complications of diabetes mellitus and the extent of renal impairment were not 
taken into consideration. The impact of medication on stump healing including 
anticoagulation therapy (aspirin versus. warfarin) was not looked into. Surgical factor such 
as intraoperative heparin which may play an important role on the surgical outcome were 
not considered in this study (Feldman et al. 2003). The functional effect of multiple failed 
revascularizations which most of the patients underwent before an amputation was also 
not taken into account. Other risk factors for amputation such as depression (Tseng et al. 
2007) were not considered in this study. It is impossible to depict every potential case and 
result from lower limb amputation surgery with the use of computer simulation models as 
they can only generate simplified representations. 
6.4 Future research 
This study can have several follow-up studies. One of them could be the role of endothelial 
dysfunction markers in chronic limb ischaemia with relation to the haematological 
markers. Some of the endothelial dysfunction markers including Endothelin-1, von 
Willibrand factor, Vascular Endothelial Growth Factor (VEGF) and homocysteine, have 
been shown to be useful predictors to determine healing rates and death events in patients 
who underwent lower limb amputation (McLaren et al. 2002; Newton et al. 2005; 
Groeneweg et al. 2008; Newton et al. 2008). Haematological markers like preoperative 
haemoglobin which might be a useful predictor for lower limb stump healing could be 
looked at.  Lee et al. (2009) suggested that, prior to vascular surgery, it may prove useful 
and practical from an economic viewpoint to test and decolonize patients for infection, 
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particularly over a variety of strains of methicillin-resistant Staphylococcus aureus 
(MRSA). Though this study looked into wound cultures and infection secondary to its 
retrospective nature, the data obtained was limited and can be looked into by future 
prospective studies. Dowsett et al. (2004) noted that use of prophylactic antibiotics boosts 
the defense mechanism of patients having limb amputation surgery. Prophylactic 
antibiotics and its role in stump healing can be looked into on a larger scale. The 
rehabilitation post amputation plays a vital role in determining the ability of an amputee 
to walk (Brunelli et al. 2006). A follow up of this study could be on the factors that 
influence the rehabilitation outcomes in lower limb amputation. The impact of early 
mobility on stump healing could also be explored.  
Role of glycated haemoglobin which is an indicator for diabetic control has been 
investigated (Adler et al. 2010). However, the role of insulin vs oral hypoglycaemic agents 
(OHA) and glycated haemoglobin and its impact on stump healing is a subject for future 
research. Radiological investigations (radio-nucleotide scans, Magnetic Resonance 
Imaging) and its effect on stump healing can also be a topic for future research (Croll et 
al. 1996).
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PARTICIPANT CONTACT DETAILS 
 
Study No.  
First Name  
Surname  
D.O.B.  
Address  
 
 
 
 
 
Postcode: 
Tel.  
Mobile  
Email  
 
 
 
 
 Appendix II 
283 
 
 
 
 
 
Study No. 
 
 
 
MEDICAL HISTORY 
Age  
Gender  
Duration of Disease  
Risk Factors/Co morbid diseases  Diabetes 
 Hypertension 
 Hypercholesterolemia 
 Smoking 
 
Symptoms 
 
 
 
MEDICATIONS 
Drug Name Dosage Frequency 
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Study No. 
 
 
 
 
 
Baseline markers 
Date  
D.O.B.  
BP  
HbA1C  
 
 
Blood Markers 
 
 
White cell count 
 
 
C-reactive protein 
 
 
Urea 
 
 
Serum Creatinine 
 
 
INR 
 
 
Prothombin time  
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Serum Sodium 
 
 
Serum Potassium 
 
 
Total Cholesterol 
 
 
 
 
 
Triglyceride 
 
 
HDL 
 
 
LDL 
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Study No. 
 
 
Surgery Date: 
Type of Surgery: 
 
Below knee amputation             
 
Above knee amputation             
 
Has the stump healed/fit enough to take a prosthesis at 12 weeks? 
 
Healed                                   
 
Not healed                             
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Participant Information Sheet 
 
 
“Can biomedical markers play any role in predicting success of leg amputation in diabetic 
patients with advanced atherosclerosis?” 
 
My name is Suhel Ashraff and we would like to invite you to take part in a research study 
examining the role of biomedical markers and factors in predicting success of leg amputation 
in patients with atherosclerosis and Diabetes. 
 
Before you decide if you would like to participate, you need to understand why the research is 
being done and what it would involve for you.  Please take time to read the information 
carefully. Talk to others about the study if you wish.  
 
Please feel free to ask me if anything is not clear or if you would like more information. My 
contact details are at the end of this brochure. 
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What is the purpose of this study? 
 
The purpose of the study is to explore the relationship between the blood markers and factors 
(clotting factors, cholesterol and blood sugar) and success of leg amputation. It will examine 
the consistency of one assessor with the outcome measure as well as reliability between two 
different assessors. 
 
 Why have I been asked to take part? 
 
You have been asked to take part as you have previously been diagnosed with atherosclerosis 
and you are due to have a lower limb amputation.   
 
Do I have to take part? 
 
No, it is up to you to decide whether or not to take part and your participation in this research 
is entirely voluntary. If you do decide to take part you will be given this information sheet to 
keep and be asked to sign a consent form. If you decide to take part you are still free to withdraw 
at any time and without giving a reason. Deciding not to take part or withdrawing from the 
study will not affect the healthcare that you receive. 
 
What will happen if I take part? 
 
Once your consent is obtained you will be assessed on two separate occasions. Each visit for 
assessment will be approximately 20 minutes. Your visit plan will be as follows: 
 1) Visit 1:  Evaluation prior to surgery/pre-operative. This will happen when a decision has 
been made that you will have a lower limb amputation and you are admitted to the ward. 
Alternatively this could be your last clinic appointment prior to the date of lower limb 
amputation surgery.  
 2) Visit 2: 12 week’s later/post-operative. Your stump will be assessed. This will happen in 
you clinic appointment. 
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Both the assessors are familiar with the procedure, one being myself and the other vascular 
surgeon. 
 
At the time of your assessments, the following will happen: 
 
At each visit, you will have the chance to ask questions and raise any issues before, during or 
after each assessment. 
↓ 
Your blood sample (1) will be taken (only for the initial visit). This will take approximately 
20 minutes 
 
For the assessment, you will have to remove your jacket so that your clothing does not interfere 
with the procedure. The amount of blood taken will be 2 teaspoon full (about10 mls). Blood 
sample will be taken by NHS staff as a regular procedure for pre-operative tests only in the 
first visit. 
 
 
There are no known side-effects associated with either of these assessments. 
 
(1) For the biomedical markers analysis blood sample will be taken. From these test 
we will calculate your kidney function status, infection markers and lipid profile as 
mentioned above (these are routine tests done in the hospital). 
 
With your consent we will inform your GP that you are taking part in this study. 
 
The blood will be stored in the laboratory in the Royal Infirmary of Edinburgh in an 
anonymised form and the donor will not be identifiable to the researcher. 
 
Will there be any disadvantages of taking part? 
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It is not thought that there are many disadvantages; however, it is possible that you might 
develop a bruise from the site of blood withdrawal. If this was to happen you will be treated 
appropriately. Taking part in this study will not put you at risk of any bodily or mental harm. 
Your health status will not be altered in anyway by taking part. 
 
 Assessments will be carried out with respect for your privacy and your comfort will be ensured 
before and during the entire period of assessment to minimise any discomfort. 
 
What are the benefits of taking part in the study? 
 
You may learn about your body composition. 
 
What will happen to the results of the study? 
 
If you are interested in the overall results of the study, these will be emailed to you as well once 
the study is complete. 
 
The results may be published in a journal or presented at a conference or used as a part of a 
PhD thesis. Your anonymity will be preserved. 
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What happens when the study is finished? 
 
At the end of the research we will inform you about the results of the study through written 
feedback. The data will be kept in a safe in Queen Margaret University for no longer than 12 
months the access to which will be restricted to the Chief Investigator. 
 
Will my taking part in the study be kept confidential? 
 
All information about you collected during the course of the study will be kept securely and 
will be accessible only to the research team members and there are strict laws which safeguard 
your privacy at every stage.  
 
All information, which is collected, about you during the course of the research will be kept 
strictly confidential. 
 
All data will be anonymised and your name will be removed from the data so that you cannot 
be recognised from it. 
 
What will happen to the results of the study? 
 
The study will be written up as a PhD thesis and the results may be published in a journal or 
presented at a conference. 
  
Who is organising the research? 
 
This study has been organised by Queen Margaret University, Edinburgh and is self funded by 
the Chief Investigator. 
 
Who has reviewed the study? 
 
This study has been reviewed and given favourable ethical opinion by the Queen Margaret 
University Research Ethics Committee and South East Scotland Research Ethics Committee 2. 
NHS management approval has also been obtained. 
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What if there is a problem? 
 
Any complaint about the way you have been dealt with during the study or any possible harm 
you might suffer will be addressed. If you have a concern about any aspect of this study, you 
could ask to speak to me and I will do my best to answer your questions (Queen Margaret 
University telephone: 01314740000). Alternatively, you could also contact the NHS Lothian 
Complaints Team (contact details given), if you should wish to complain formally. 
 
What if I do not want to continue my participation? 
 
You are free to withdraw from the study at any given point without having to give a reason for 
doing so.  
If you have read and understood this information sheet, any questions you had have been 
answered, and you would like to be a participant in the study, please now see the consent form. 
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Further information and contact details  
 
Name of researcher: Suhel Ashraff 
 
Address:            Postgraduate Research Student, Podiatry 
                               School of Health Sciences 
                                   Queen Margaret University  
                                   Queen Margaret University Drive, 
                                   Musselburgh, 
                                   EH216UU 
 
Email / Telephone: drsuhelashraff@gmail.com / 0131 474 0000 (ext 4796) 
 
 
 
If you would like to discuss this study with someone independent of the study please 
contact: 
 
Name:    Mr J. Murie   
Post:       Consultant Vascular Surgeon   
               Royal Infirmary of Edinburgh 
               Little France, Old Dalkeith Road 
               Edinburgh 
               EH16 4SA 
Email / Telephone: jmurie@qmu.ac.uk / 0131 537 1000  
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If you wish to make a complaint about the study please contact NHS Lothian: 
 
NHS Lothian Complaints Team 
2nd Floor 
Waverley Gate 
2-4 Waterloo Place 
Edinburgh 
EH1 3EG 
Tel: 0131 465 5708 
 
 
 
Thank you for taking the time reading this information sheet. 
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APPENDIX IV: CONSENT FORM 
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CONSENT FORM 
 
Title of Project: 
“The Role of haematological markers and factors in predicting leg amputation success 
in diabetic patients with advanced atherosclerosis: An Exploratory Study” 
 
        Please initial box 
 
1. I confirm that I have read and understood the information sheet and this consent form.  
 I have had an opportunity to ask questions about my participation. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any time, 
  without giving any reason, without my medical care or legal rights being affected. 
 
3. I understand that sections of any of my medical notes may be looked at by responsible  
 Individuals (Research Team) or from regulatory authorities where it is relevant to my 
 taking part in research.  I give permission for these individuals to have access to my  
 records. 
 
4. I agree to take part in the above study.    
 
5.   I give consent to contact my G.P to inform him that I am taking part in this study.                  
________________________ ________________ ____________________ 
Name of Patient   Date Signature 
 
 
_________________________ ________________ ____________________ 
Researcher   Date  Signature 
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Contact details of the researcher  
Name of researcher: Dr Suhel Ashraff 
Address: PhD Student, Podiatry, School of Health Sciences 
Queen Margaret University 
Edinburgh, EH21 6UU  
Email / Telephone: drsuhelashraff@gmail.com / 0131 474 0000  
  
1 for patient; 1 for researcher; 1 to be kept with hospital notes
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APPENDIX V: G.P LETTER 
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Suhel Ashraff  
MBBS, MSc. Diabetes 
PhD Research Student 
School of Health Sciences 
Queen Margaret University  
Queen Margaret University Drive  
Musselburgh 
EH21 6UU 
Tel 0131 4740000 
 
         Date: 
 
 
Dear Dr ........................................................ 
 
Re:  ..............................................................     D.O.B.  ............................... 
Address:  ..................................................................................................... 
..................................................................................................................... 
.................................................................................................................... 
This patient has agreed to take part in the following research project: 
 
“The role of haematological markers and factors in predicting leg amputation success in 
diabetic patients with advanced atherosclerosis: An Exploratory Study” 
 
 
The study is being carried out at the New Royal Infirmary in Edinburgh and at Queen Margaret 
University in Musselburgh. 
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I enclose the summary of the protocol for your information. 
If you would like more information about this project, please don’t hesitate to contact us. 
 
Yours sincerely, 
 
Dr Suhel Ashraff, Research Student, QMU, Edinburgh 
 
Dr Thomas E Carline, Senior Lecturer & Course Director, QMU, Edinburgh 
 
Mr Zahid Raza, Consultant Vascular Surgeon, Royal Infirmary of Edinburgh 
 
Dr Derek Santos, Senior Lecturer, QMU, Edinburgh
Appendix VI 
 302  
 
 
 
 
 
 
 
 
 
 
 
APPENDIX VI: LABORATORY DETAILS 
OF THE BLOOD MARKERS 
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 Biochemistry 
.   
Analyte Methods used for 
measurement 
Analyzer 
used 
 
Range Calibration Measured 
at 
Serum 
Sodium 
Indirect ion-
selective electrode – 
all three electrolytes 
are measured 
simultaneously 
within a single 
‘chip’ 
Potentiometric Ion 
selective electrode 
(crown ether 
membrane) 
 
Abbott 
Architect 
c16000  
Ref range 
135-145 
mmol/L 
 
Calibration 
66320 ISE 
Buffer 
66319 ISE Mid 
Standard 
66318 ISE 
Reference 
66317 ISE Low 
serum Std 
66316 ISE 
High serum Std 
66314 Internal 
reference 
66313 ISE Na+ 
/ K+ 
Selectivity 
check 
 
Clinical 
Laboratory, 
Royal 
Infirmary 
of 
Edinburgh, 
Scotland, 
UK, 
Urea Enzymatic reaction 
involving 
urease.  The change 
in absorbance of the 
solution (caused by 
the oxidation of 
NADH) is measured 
photometrically at 
Abbott 
Architect 
c16000  
Ref Range 
2.5-
6.6mmol/L 
 
Calibrator 
Olympus 
system 
Calibrator 
66300 
Kinetiv UV, 
Cat No 
OSR6534 
Clinical 
Laboratory, 
Royal 
Infirmary 
of 
Edinburgh, 
Scotland, 
UK, 
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340nm  
Serum 
Creatinine 
Kinetic alkaline 
picrate reaction – 
rate of absorbance 
change measured 
photometrically at 
500nm. 
Standard kinetic 
Jaffe method 
Abbott 
Architect 
c16000  
Ref range 
60-120 
umol/L 
 
Calibrator 
Olympus 
system 
Calibrator 
66300 
Kinetic Jaffe, 
Cat No 
OSR6178 
 
 
Clinical 
Laboratory, 
Royal 
Infirmary 
of 
Edinburgh, 
Scotland, 
UK, 
CRP Latex immunoassay 
whereby 
agglutination of 
antigen-antibody 
complexes causes a 
change in 
absorbance at 
572nm  
Olympus System 
CRP Latex reagent  
 
Abbott 
Architect 
c16000  
Ref Range 
0-5 mg/L 
 
Calibrator 
(Normal set: 
ODC 00026) 
(Highly 
sensitive 
set:ODC00027) 
Cat No 
OSR6199 
 
Clinical 
Laboratory, 
Royal 
Infirmary 
of 
Edinburgh, 
Scotland, 
UK, 
Total 
Cholesterol 
Enzymatic reaction 
involving 
cholesterol 
esterase.  Formation 
of a coloured dye is 
measured 
photometrically at 
500nm  
Enzymatic colour 
test, Cat No 
Abbott 
Architect 
c16000  
No range 
given 
Calibrator - 
Olympus 
System Cal 
66300 
 
Clinical 
Laboratory, 
Royal 
Infirmary 
of 
Edinburgh, 
Scotland, 
UK, 
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OSR6116 
 
Triglycerides Enzymatic reaction 
involving glycerol 
phosphate 
oxidase.  Formation 
of a red dye is 
measured 
photometrically at 
500nm  
Enzymatic colour 
test: Cat No 
OSR6118 
 
Abbott 
Architect 
c16000  
Ref Range 
0.8-
2.1mmol/L 
 
Calibrator: 
66300 
 
Clinical 
Laboratory, 
Royal 
Infirmary 
of 
Edinburgh, 
Scotland, 
UK, 
 
HDL 
Uses a detergent to 
solubilise HDL, 
which then reacts 
with other 
compounds to form 
a coloured dye, 
measured 
photometrically at 
604nm  
Enzymatic colour 
test: Cat No 
OSR6187 
 
Abbott 
Architect 
c16000  
 
Ref Range 
1.1-1.7 
mmol/L 
 
Calibrator HDL 
cholesterol 
calibrator 
ODC0011 
 
Clinical 
Laboratory, 
Royal 
Infirmary 
of 
Edinburgh, 
Scotland, 
UK, 
Serum 
Potassium 
Indirect ion-
selective electrode – 
all three electrolytes 
are measured 
simultaneously 
Abbott 
Architect 
c16000 
 
Ref range 
3.6-5.0 
mmol/L 
 
Calibration 
66320 ISE 
Buffer 
66319 ISE Mid 
Standard 
Clinical 
Laboratory, 
Royal 
Infirmary 
of 
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within a single 
‘chip’ 
Potentiometric Ion 
selective electrode 
(crown ether 
membrane) 
 
66318 ISE 
Reference 
66317 ISE Low 
serum Std 
66316 ISE 
High serum Std 
66314 Internal 
reference 
66313 ISE Na+ 
/ K+ 
Selectivity 
check 
 
Edinburgh, 
Scotland, 
UK, 
LDL Calculated from the 
total cholesterol and 
the HDL cholesterol 
laboratory 
analyzer 
interface- 
AMS. 
No range 
given 
Calibrator - 
Olympus 
System Cal 
66300 
 
Clinical 
Laboratory, 
Royal 
Infirmary 
of 
Edinburgh, 
Scotland, 
UK, 
eGFR  
 
A calculated 
parameter, which 
takes into account 
serum creatinine, 
age and sex. 
laboratory 
analyzer 
interface- 
AMS. 
  Clinical 
Laboratory, 
Royal 
Infirmary 
of 
Edinburgh, 
Scotland, 
UK, 
 
 
 
HPLC (reversed-
phase cat ion 
exchange 
ADAMS HA-
8160 
(Menarini 
Ref Range 
(DCCT) % 
total Hb 4-
Calibrator: Cat 
No Ref 23385 
Low and High 
Clinical 
Laboratory, 
Royal 
Appendix VI 
 307  
 
HbA1C 
 
 
  
  
chromatography)  Diagnostics)
  
6 standard Infirmary 
of 
Edinburgh, 
Scotland, 
UK, 
Creatinine 
Kinase 
 
Kinetic UV (based 
on 
recommendations 
IFCC), Cat No 
OSR6179 
 
laboratory 
analyzer 
interface- 
AMS. 
Ref Range 
55-170 U/L 
 
Calibrator 
Olympus 
System Cal 
66300 
 
Clinical 
Laboratory, 
Royal 
Infirmary 
of 
Edinburgh, 
Scotland, 
UK, 
  
 
 
 
 
 
Analyzer  
 
 The Abbott Architect c16000 is a fully automated, fast throughput chemistry analyzer 
that can perform analyses by various photometric and potentiometric methods. 
 All lab analysis is tightly controlled by various protocols and procedures regarding 
quality.   
 There is a labs-wide quality manual, produced by the laboratories Quality Manager, 
which sets out what labs must do to conform to the Clinical Pathology Accreditation 
(CPA) standards that govern the labs. 
 The quality control inspection happens every two years.   
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Calibration and Validation 
 
 Calibration is performed using calibrator solutions provided by Abbott that are 
traceable to international reference standards.   
 All analytes have a manufacturer’s calibration interval programmed in the analyzer.   
 If the calibration interval is exceeded, it is not possible to use the assay until a 
calibration is performed.   
 Calibration intervals range from 24 hours to a few weeks, depending on the analyte, but 
calibration may also be required when quality control results start to drift. 
 
Quality control  
 
 Quality control is run for all of the above analytes every four hours and analyzed by 
Biomedical Scientist staff for any bias or imprecision that may require calibration or 
other analyzer troubleshooting to resolve.   
 If quality control for an analyte is outside the acceptable range or fails preset Westgard 
rules, all patient results are held back by the analyzer interface until the operator has 
resolved the problem. 
 The lab also participates in external quality assurance schemes for all analytes.   
 For those above, the provider of these schemes is UKNEQAS.  
 On a fortnightly basis (monthly for lipids and CRP), three samples of unknown 
concentration are sent out to the lab.   
 All three are analyzed and the results are returned to the UKNEQAS, who then run 
calculations based on the results of all participating labs (across the whole of the UK) 
and award each lab their own scores relating to accuracy and bias of their results 
compared with other labs.   
 In this way performance of each laboratory is ensured and is comparable to the rest of 
the UK, or at least to other labs using the same analyzers.   
 Any consistent poor performance is notified by the scheme providers by way of a letter, 
which must be investigated and resolved. 
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Haematology 
 
Analyte Analyzer used 
 
Range Calibration Measure at     
White cell count Sysmex XE 2100 
Full Blood Count 
analyzers  
(Supplier:  
Sysmex UK) 
 
Ref  Range 
4.0 - 11.0(x 
109/l)   
 
Calibrations: when 
Internal Quality 
control deviates 
from baseline, poor 
EQA or after 
significant service 
maintenance 
 
Clinical Laboratory, 
Royal Infirmary of 
Edinburgh, Scotland, 
UK, 
Prothrombin 
time 
Sysmex XE 2100 
Instrumentation 
Laboratory, UK  
The normal 
range: 10.5 
- 13.5 
seconds. 
 
Reagent: HemosIL 
Recomboplastin 2G 
IL UK). 
Clinical Laboratory, 
Royal Infirmary of 
Edinburgh, Scotland, 
UK, 
International 
Normalised 
Ration (INR) 
was 
(Instrumentation 
Laboratory, UK) 
(Reagent: 
HemosIL 
Recomboplastin 
2G IL UK). 
Specimens were 
stored at 24-36 
hours.  
Sysmex XE 2100 
Instrumentation 
Laboratory, UK  
 Reagent: HemosIL 
Recomboplastin 2G 
IL UK). 
Clinical Laboratory, 
Royal Infirmary of 
Edinburgh, Scotland, 
UK, 
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Calibration 
 
 Calibration is only required if the daily QC falls out with its range value.  
 The XE Analyzers are calibrated on Installation, using Factory set CS-1000 calibrator 
at source, but checked with Sysmex E-Check on site.  
 Internal QC is performed using e-Check in the morning.  
 The 3 modes of the analyzer (Auto/Manual/Capillary) are checked daily, and aspirate a 
fresh sample to check WBC and Differential.  
 Most of the other tests are calibrated using the IL (manufacturer of analyzer) calibration 
material.  
 This is traceable to WHO standards.  
 Calibrations are performed as and when required, for example when a lot of reagent/ 
material changes.  
 The calibration material has assigned values for tests, test protocols are written into the 
software of the analyzer.  
 The mean normal PT is established using healthy volunteers and then the ISI of the 
reagent is determined using WHO calibrant.  
 This is further validated by running Internal QC and previously performed External 
QC. 
 Routine operation of the analyzers involves IQC being performed post daily 
maintenance procedure and every 6 hours after this or when a vial of thromboplastin is 
changed.  
 Tests cannot be performed if the IQC fails.  
 IQC is performed using a normal and abnormal control. 
 All necessary reagents/ materials are placed onto the analyser and the calibration is 
performed.  
 The operator must then validate the calibration curve.  
 
 
 
Validation  
Appendix VI 
 311  
 
 External QC involves registration with UK NEQAS. Samples for these trials are 
analysed monthly.  
 Analyzer Validation was based upon the MHRA model: MHRA 03058 February 2003  
 For reference, the Operation of the Analyzers, and Maintenance of the Analyzers are 
listed in: HAEM-R-66 (Operation of the Sysmex XE HST System), and HAEM-R-177 
(Maintenance of the XE5000 Analyzer). 
 All documentation on this is held electronically in a database. 
 Each analyzer is validated for PTs/ INRs when a new lot of thromboplastin reagent is 
introduced, prior to the current batch running out. 
 
 
Quality control  
 
 Quality control is run for all of the above analytes every four hours and analyzed by 
Biomedical Scientist staff for any bias or imprecision that may require calibration or 
other analyzer troubleshooting to resolve.   
 If quality control for an analyte is outside the acceptable range or fails preset Westgard 
rules, all patient results are held back by the analyzer interface until the operator has 
resolved the problem. 
 The lab also participates in external quality assurance schemes for all analytes.   
 For those above, the provider of these schemes is UKNEQAS.  
 On a fortnightly basis (monthly for lipids and CRP), three samples of unknown 
concentration are sent out to the lab.   
 All three are analyzed and the results are returned to the UKNEQAS, who then run 
calculations based on the results of all participating labs (across the whole of the UK) 
and award each lab their own scores relating to accuracy and bias of their results 
compared with other labs.   
 In this way performance of each laboratory is ensured and is comparable to the rest of 
the UK, or at least to other labs using the same analyzers.   
 The precision method used for all the laboratory tests was the Westgard rules wherein 
the analytical method is first tested under ideal conditions. Following this the analytical 
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method was then put to use in routine practice as noted under the Westgard rules. Using 
the Levey Jennings chart.  
 Any consistent poor performance is notified by the scheme providers by way of a letter, 
which must be investigated and resolved. 
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APPENDIX VII: INDEMNITY 
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All participants were informed about procedure followed during the study. They were also 
informed about any possible harm they might suffer and how it would be addressed. If patients 
had any concern about any aspect of this study, they were given the contact details of the 
principal researcher. They were also provided with the chief investigators contact details if they 
had any questions. Alternatively, they could also contact the independent advisor who was 
aware about the project but was not directly involved in this research (contact details given) or 
the NHS complaints team, if they wished to complain formally. 
Compensation for QMU financed or co-financed medical research was covered by the Royal 
and Sun alliance insurance, which encompassed all participants in medical tests, together with 
their relatives, charges, executors, administrators or legal representatives. In general, referrals 
were not necessary as the insurance policy included wide-range medical research and tests. No 
complaint was received in this study.  
Royal and Sun Alliance insurance provides indemnity for QMU sponsored or co-sponsored 
clinical study (Appendix IV). This is a no-fault compensation policy and covers any person 
taking part in a clinical trial including their dependants, executors, heirs, administrators and 
legal representatives. Cover applies automatically to clinical trials and general clinical research 
within wide parameters without the need for referral although there are exclusions. In this study 
no complaints were received. 
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